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Claire Elizabeth Fraser, Ph.D.
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The regulation of protein synthesis is an important aspect of the control of gene
expression in neurons and is thought to contribute to neurologic diseases such as Fragile
X mental retardation syndrome. We demonstrate that several neuronal RNA-binding
proteins implicated in human disease are associated with brain polyribosomes, namely
the Nova and Hu paraneoplastic antigens and the Fragile X mental retardation protein.
We use microarray analysis of polyribosomal mRNAs in knockout mouse models of
these diseases to identify target mRNAs and analyze the translational profiles of mice
lacking Nova-1 or FMRP. The KH2 and RGG box RNA-binding domains of FMRP bind
specific RNA motifs that form kissing complex and G-quartet structures, respectively.
We find that the association of FMRP with polyribosomes in both mouse brain and
human neuroblastoma cells is abrogated by competition with kissing complex RNA, but
not by high-affinity G-quartet RNA.

In addition, the polyribosome associations of

FMRP-interacting proteins FXR1 and FXR2, are specifically abrogated by competition
with this kissing complex RNA. FXR1 and FXR2 also bind kissing complex RNA via
KH2, and they are competed off polyribosomes by kissing complex RNA even in the
absence of FMRP. Kissing complex RNA does not disrupt heterodimerization between
FMRP and FXR1 or FXR2. We conclude that the mental retardation associated with the
I304N mutation, and likely the Fragile-X syndrome more generally, may relate to a
crucial role for RNAs harbouring the kissing complex motif as targets for FMRP
translational regulation.
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CHAPTER I: INTRODUCTION

Translational control in neurons
Translation of messenger RNAs into functional proteins is the final step in the
gene expression pathway. As such, it represents a vital mechanism for control of protein
levels in the cell. Regulation of mRNA translation is relatively fast, lacking requirements
for RNA transcription, processing, and nuclear export. Instead, a previously established
pool of mRNAs can be held in a translationally inactive state, ready to produce encoded
proteins when necessary.

Furthermore, this mechanism may be restricted locally;

translation of a particular pool of mRNAs in a specific subcellular area undergoes
regulation unique to that subcellular location, such as an individual dendritic spine. Tight
control of translation is particularly necessary for neurons, since neuronal signaling
mechanisms rely on a delicate balance of synaptic components for effective
neurotransmission and memory formation. Translational control can be achieved by both
global and mRNA-specific mechanisms, and by interventions during translation initiation
and/or elongation steps. As such, translational regulation represents a real-time strategy
for cellular control of gene expression. (Gebauer and Hentze, 2004; Kindler et al., 2005;
Moore, 2005; Wang and Tiedge, 2004)
Global control of translation mainly involves modification of initiation factors. A
well-characterized example is that of cap-binding protein eIF4E availability. Interaction
of eIF4E with the scaffold protein eIF4G is required for cap-mediated recruitment of the
43S ribosomal complex to an mRNA during initiation. eIF4E-binding proteins (4E-BPs)
compete with eIF4G for interaction with eIF4E, preventing recruitment of the 43S
complex and resulting in translational inhibition. However, activation of the insulin,
1

PI3K/Akt/mTOR and MAPK signaling pathways can phosphorylate 4E-BPs to enable
interaction of eIF4E with eIF4G and initiation of translation (Gingras et al., 1999;
Kelleher et al., 2004a; Kelleher et al., 2004b; Pause et al., 1994; Raught et al., 2000;
Ruggero and Sonenberg, 2005; Treisman, 1996).

A second example of global

translational repression occurs during cell death. The apoptotic protein caspase-3 cleaves
initiation factor eIF4G and poly(A)-binding protein (PABP) resulting in inhibition of
initiation. (Bushell et al., 2000; Marissen et al., 2004)

A location-specific, global

mechanism of translational repression can be found in the small, untranslated BC1 and
BC200 RNAs, which are specifically targeted to dendrites in neurons. BC1 inhibits
translation of a reporter in Xenopus oocytes by interacting with both translation initiation
factor eIF4A and PABP (Wang et al., 2005).
Blockage of translational initiation factor recruitment is also a goal of some
mRNA-specific regulatory mechanisms. Sequence and structural elements in an mRNA
such as the presence of a hairpin, internal ribosome entry site (IRES), or binding site for
an RNA-binding protein can influence translational state. The iron regulatory proteins
IRP1 and IRP2 bind an iron-responsive element (IRE) in the 5’UTRs of the ferritin
heavy- and light-chain mRNAs. Protein binding to this stem-loop sequence hinders 43S
complex recruitment by the cap-binding complex, thereby preventing translation
initiation. (Gray and Hentze, 1994; Muckenthaler et al., 1998) Other regulatory proteins
can act as message-specific 4E-BPs. The cytoplasmic element-binding protein (CEBP)
binds a CPE sequence in the 3’UTR of target mRNAs. It inhibits translation initiation by
forming a complex with Maskin, a protein that binds to eIF4E and displaces eIF4G. On
phosphorylation by Aurora kinase, CEBP promotes polyadenylation of the mRNA and
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dissociation of Maskin from eIF4E. (Mendez and Richter, 2001) During development of
the Drosophila melanogaster embryo, Bicoid inhibits the translation of caudal mRNA by
directly binding to both eIF4E and an element in the 3’UTR (Niessing et al., 2002). In
response to interferon-γ, ribosomal protein L13a is phosphorylated and released from the
60S ribosomal subunit; it then binds to a sequence in the 3’UTR of ceruloplasmin mRNA
and subsequently inhibits the initiation of translation (Mazumder et al., 2003). The RNAbinding proteins hnRNP K (heterogenous nuclear ribonucleoprotein K) and hnRNP E1
bind to a CU-rich sequence known as the differentiation-control element (DICE) in the
3’UTR of 15-lipoxygenase (LOX) mRNA. hnRNP K and hnRNP E1 repress LOX
translation by preventing 60S ribosomal subunit binding. (Ostareck et al., 2001; Ostareck
et al., 1997; Ostareck-Lederer and Ostareck, 2004) Zipcode binding protein 1 (ZBP1)
binds to the 3’UTR of β-actin mRNA and is required for its translocation to sites of
active actin polymerization (Eom et al., 2003; Farina et al., 2003; Oleynikov and Singer,
2003; Tiruchinapalli et al., 2003). Like hnRNP K, ZBP1 inhibits translation initiation by
impairing the transition from a 48S complex to an 80S ribosome. Translation of β-actin
mRNA is activated by Src-dependent phosphorylation of ZBP1, which abrogates RNAbinding ability (Huttelmaier et al., 2005). As described above, most translational control
mechanisms yet described act on the translational initiation pathway, and result in the
inhibition of protein synthesis.
Translational control can also be achieved through regulation of elongation rather
than initiation.

NMDA receptor activation in rat brain synaptoneurosomes induces

phosphorylation of elongation factor eEF2, a process that reduces the rate of peptide
chain elongation. This promotes a general decrease in protein translation, but an increase
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in translation of abundant but poorly initiated mRNAs such as that encoding αCamK II.
(Scheetz et al., 1997; Scheetz et al., 2000) Translational regulation of the Drosophila
oskar (osk) and nanos mRNAs seem to involve inhibition of both initiation and
elongation. Initiation is inhibited by binding of Bruno to the 3’UTR of osk. Bruno
recruits a 4E-BP, Cup, which then prevents binding of eIF4E to eIF4G (Nakamura et al.,
2004) Cup is also involved in translational repression of nanos by interaction with
Smaug bound to the nanos 3’UTR (Nelson et al., 2004). However, both osk and nanos
mRNAs are associated with polyribosomes even when osk and nanos proteins do not
accumulate, suggesting that there may be more than one means of repressing the
translation of these mRNAs (Braat et al., 2004; Clark et al., 2000).

microRNAs

(miRNAs) inhibit translation by partial base-pairing to target mRNAs, usually in the
3’UTR (Hutvagner and Zamore, 2002). The mechanism of this repression is largely
unknown, but may involve inhibition of elongation, as translational repression of lin-14
mRNA by lin-4 miRNA does not alter its association with polyribosomes (Olsen and
Ambros, 1999).
Local control of translation is an important aspect of the regulation of gene
expression. Although originally studied in developmental processes in Xenopus and
Drosophila, mRNA targeting and localization has become a key aspect of the current
theory of activity-dependent synaptic modification. (Schuman et al., 2006; Wang and
Tiedge, 2004) In essence, for an mRNA to have a selective impact on a specific synapse,
its transport must be correctly targeted to the translational area of that synapse, and either
transport or translation of this mRNA must be regulated in a manner that can be altered
by activity at that synapse. It follows that locally translated messages should encode
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proteins that are in use at the synapse, modify other proteins at the synapse, or serve as
messengers to send signals back to other parts of the neuron. Many studies have shown
that protein synthesis is required for long-lasting forms of behavioral and synaptic
plasticity (Bailey et al., 1996; Mayford et al., 1996; Nguyen and Kandel, 1996).
Evidence for this hypothesis includes localization of polyribosomes and associated
membranous cisterns to sub-synaptic sites in dendrites (Gardiol et al., 1999; Steward,
1983; Steward and Fass, 1983; Steward and Levy, 1982), assessments of the mRNA
complement of dendritic processes (Eberwine, 1996; Eberwine et al., 2002; Eberwine et
al., 2001; Miyashiro et al., 1994), protein synthesis in isolated synaptosomal preparations
(Chicurel et al., 1993; Rao and Steward, 1991), translation of an mRNA construct
transfected into an isolated dendrite (Crino and Eberwine, 1996), studies of
polyadenylation-induced translation of the αCaMKII mRNA in synaptosome
preparations after NMDA receptor activation (Huang et al., 2002), and the observation
that polyribosomes redistribute to dendritic spines from dendritic shafts after induction of
long-term potentiation (LTP) (Ostroff et al., 2002). Investigation of the roles for neuronspecific RNA-binding proteins in translational control may yield valuable clues for both
synaptic physiology and human disease.

Neurological disease and RNA-binding proteins: autoimmune-mediated
Paraneoplastic

neurologic

degenerations

(PNDs)

are

cancer-associated

neurodegenerative disorders that are thought to arise when a neoplasm expresses a
normally neuron-restricted protein. Autoreactive antibodies and T cells are generated
against the protein as an antigen of the tumor cell. If the immune response is present in

5

the cerebrospinal fluid, the antigen may then be recognized in its normal location – a
neuron. The development of an immune response to the paraneoplastic antigen may
benefit the patient in suppressing tumor growth, but may ultimately lead to loss of
function of this protein in the neurons where it normally resides. Such loss of function
may result in neuronal death and/or severe neurologic impairment. (Albert et al., 2000;
Albert et al., 1998; Albert and Darnell, 2004; Buckanovich et al., 1996; Darnell, 1996;
Darnell and Posner, 2003; Musunuru and Darnell, 2001)
It is interesting that a number of RNA-binding proteins (RBPs) have been found
to be target antigens in a variety of autoimmune diseases. The Nova family of RNAbinding proteins (RBPs) was first discovered as target antigens of the neurodegenerative
disorder, paraneoplastic opsoclonus-myoclonus ataxia (POMA). POMA is most often
found in association with tumors of the lung, breast and fallopian tubes. Symptoms are
characterized by a loss of inhibitory control of motor neurons in the brainstem and spinal
cord, leading to rapid irregular eye movements (opsoclonus), muscle spasms
(myoclonus), and a failure of muscular coordination (ataxia).(Buckanovich et al., 1993)
The Hu family of proteins was identified as during the investigation of another PND,
paraneoplastic encephalomyelopathy/sensory neuropathy (Hu syndrome). Hu proteins
contain three RNA-recognition motifs (RRMs) and are thought to be involved in RNA
stability, export and translation. (Antic and Keene, 1998; Antic et al., 1999; Darnell and
Posner, 2006; Levine et al., 1993) A novel RBP, termed GW182, has been identified as a
target antigen using serum from a patient with ataxia and sensory polyneuropathy
(Eystathioy et al., 2002). GW182 is a cytoplasmic protein that is involved in miRNA
mediated mRNA degradation in cytoplasmic processing bodies (Behm-Ansmant et al.,
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2006; Jakymiw et al., 2005; Liu et al., 2005). hnRNP A1, another RBP, is cross-reactive
with the viral HTLV-tax protein in individuals with human T-lymphotrophic virus type 1associated myelopathy/tropical spastic paresis (HAM/TSP) (Levin et al., 2002). These
patients develop antibodies to neurons and have symptoms of progressive corticospinal
tract damage (weakness, spasticity and pathological reflexes). These autoantibodies
inhibit neuronal firing, and are targeted to epitopes within hnRNP A1 that include an
RGG type RNA-binding domain, suggesting that this domain is important for normal
function of hnRNP A1 (Lee et al., 2006). While human autoimmune disorders have
provided the means to identify many of these RBPs, and clues to their physiological
functions in neurons, model organisms are required for further understanding of the
pathophysiology of these diseases.

Neurological disease and RNA binding proteins: loss-of-function mouse models
Several RBPs have been knocked out in the mouse to create model systems for
the study of human diseases. The Nova family consists of two highly conserved genes,
Nova-1 and Nova-2. Expression of Nova-1 (commonly targeted in POMA, originally
termed the Ri antigen) is expressed in the ventral spinal cord, brainstem, and deep nuclei
of the cerebellum, as well as in discrete supratentorial regions such as the cingulum and
amygdala. Expression of Nova-2, an antigen targeted in POMA patients with dementia,
is largely complementary to Nova-1, and is most prominently expressed in regions such
as the cerebral and cerebellar cortices and dorsal spinal cord (Yang et al., 1998). Nova-1
null mice show action tremors and difficulty walking, symptoms similar to those of
POMA patients. Apoptotic death of motor neurons is seen in these mice and ultimately

7

the mice die at about 1-2 weeks of age.(Jensen et al., 2000a) Nova-2 null mice have a
lesser degree of ataxia and die at approximately 2-3 weeks of age. (Ule et al., 2003)
In contrast to the severe phenotypes of the Nova-null mice, while there is a
transient delay in neurite extension in mutant embryos, HuD-null pups are
indistinguishable from their wild type littermates for the first several postnatal weeks.
Adult animals, however, develop an abnormal hind-limb clasping reflex and show poor
motor ability. (Akamatsu et al., 2005) Thus, the importance of RBPs to neurologic
disease is clear.
Fragile X syndrome (FXS) represents another neuropathology in which the
mechanism of disease is thought to result from an alteration in translational regulation by
an RNA-binding protein. FXS is the most common heritable form of mental retardation
in children, with an incidence of about 1 in 4000 males, and 1 in 8000 females. The
phenotype of FXS includes mild to severe cognitive deficits, attention-deficit
hyperactivity disorder, autistic-like behavior, abnormal facial features such as a
prominent jaw and large ears, macroorchidism in postpubescent males, and some
connective tissue abnormalities. (Reviewed in Jin and Warren, 2003.) Most cases of
Fragile X syndrome are caused by an expansion in the CGG repeat tract located in the
5’UTR of fragile X mental retardation 1 (FMR1) on the X chromosome (Fu et al., 1991;
Oberle et al., 1991; Verkerk et al., 1991). The expansion from a normal length of 7-54
repeats to a length of over 230 repeats in affected individuals effectively silences the
expression of FMRP, since the CGG tract is associated with increased methylation and
chromatin deacetylation (Coffee et al., 1999; Hornstra et al., 1993; Oberle et al., 1986;
Pieretti et al., 1991; Sutcliffe et al., 1992). However, some fragile X patients have
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intragenic deletions or nonsense mutations in FMR1 instead of a trinucleotide repeat
expansion (Hirst et al., 1995; Lugenbeel et al., 1995; Meijer et al., 1994). A single
patient has been identified with a missense mutation, I304N, that results in a severe
fragile X phenotype (De Boulle et al., 1993).
FMRP shuttles between the nucleus and cytoplasm and has been localized to
polyribosomes at synapses in neurons (Devys et al., 1993; Eberhart et al., 1996; Feng et
al., 1997b; Sittler et al., 1996; Tamanini et al., 1999). The presence of FMRP and its
autosomal paralogs, FXR1 and FXR2, at the synapse has implications for its role in the
cognitive phenotype of fragile X syndrome. In fact, abnormally long dendritic spines
have been noted in autopsy sections of brains from fragile X patients, and in brains for
Fmr1 knockout mice (Comery et al., 1997; Greenough et al., 2001; Hinton et al., 1991;
Irwin et al., 2000; Nimchinsky et al., 2001; Rudelli et al., 1985). Fmr1 knockout mice
have subtle defects in behavior and learning, as well as showing increased sensitivity to
audiogenic epileptic seizures and increased anxiety (Musumeci et al., 2000; Oostra et al.,
1994; Peier et al., 2000).

Furthermore, metabotropic glutamate receptor (mGluR)

activation in Fmr1 knockout mouse synaptoneurosomes does not produce the increase in
protein synthesis that is seen in synaptoneurosomes from wild type mice (Greenough et
al., 2001). Finally, group I mGluR-dependent long-term depression (LTD) is increased in
hippocampal slices of Fmr1 knockout mice and is dependent on the transient degradation
of FMRP in wild type mice (Hou et al., 2006; Huber et al., 2002). In Drosophila, a single
ortholog, dfmr1 (also called dfxr), exists for all three mammalian FMRP family members.
Dfmr1-mutant flies exhibit increased synaptic growth and branching at the neuromuscular
junction, impaired coordinated behavior, arrhythmic circadian activity and reduced
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courtship (Dockendorff et al., 2002; Inoue et al., 2002; Morales et al., 2002; Zhang et al.,
2001).

Activity-dependent synaptic modification depends in part on local protein

synthesis in the dendrite (Steward and Schuman, 2003). Since FMRP is associated with
polyribosomes at synapses, and since the FMRP null phenotype includes cognitive
impairment and synaptic abnormalities, FMRP may be involved in the regulation of local
translation in neurons.

KH domain proteins in RNA processing and regulation
The Nova-1 and Nova-2 genes encode proteins that contain two tandem hnRNP
K-homology (KH) RNA-binding domains followed by a spacer region of variable length
and a third KH domain. Nova-1 and Nova-2 are highly homologous, differing in the
length of the spacer region. The larger family of KH domain-containing RNA-binding
proteins (RBPs) includes hnRNP K, which, like the Nova proteins, contains three KH
domains in the same configuration. FMRP, implicated in Fragile-X syndrome, contains
two tandem KH domains and a third RNA-binding domain known as an RGG box (De
Boulle et al., 1993; Pieretti et al., 1991). Both hnRNP K and FMRP are thought to
function in translational control: hnRNP K by binding a pyrimidine-rich element in the
3’UTR and inhibiting translation initiation (Ostareck et al., 2001), and FMRP by
associating with mRNAs on actively translating polyribosomes (Corbin et al., 1997;
Khandjian et al., 1996; Khandjian et al., 2004; Laggerbauer et al., 2001; Stefani et al.,
2004).

Additional members of this family function in various aspects of RNA

metabolism and regulation, including RNA stability and translational control (hnRNP
E1/E2 and hnRNP K) (Kiledjian et al., 1995; Ostareck et al., 1997), subcellular
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localization and translational inhibition (ZBP-1) (Farina et al., 2003; Huttelmaier et al.,
2005), and splicing (hnRNP K, KSRP and splicing factor 1) (Arning et al., 1996; ExpertBezancon et al., 2002).
Our laboratory has shown that Nova-1 and Nova-2 influence alternative splice site
choice by binding YCAY-rich sites in both intronic and exonic RNA. Nova proteins
regulate pre-mRNA splicing for a network of synaptic proteins, suggesting that this
regulatory mechanism is critical for synaptic development and maintenance. (Dredge and
Darnell, 2003; Dredge et al., 2005; Jensen et al., 2000a; Jensen et al., 2000b; Musunuru
and Darnell, 2004; Ule et al., 2003; Ule et al., 2005b) Nova-1 and Nova-2, like FMRP
and hnRNP K, are found both in the nucleus and the cytoplasm (Eberhart et al., 1996;
Michael et al., 1997). Although the Nova proteins are predominantly nuclear, they are
present in significant quantities in the cytoplasm, and Nova-1 has been co-localized with
GlyRα2 mRNA in post-synaptic regions of the dendrite (Racca et al., submitted). Since
Nova proteins bind both coding and non-coding RNA sequences, it is reasonable to
suggest that the Nova proteins may be multifunctional, perhaps regulating downstream
events for messages that have undergone Nova-influenced alternative splicing.

For

example, after influencing an alternative splicing decision in the nucleus, Nova may
regulate the subcellular localization and/or the association with polyribosomes of a target
mRNA. Alternately, the cytoplasmic role(s) of the Nova proteins may affect an entirely
separate set of mRNAs than those affected by Nova’s splicing function. Nova may bind
to the 3’ UTR of a message in an analogous fashion to hnRNP K to regulate translation of
a message during transport and until such a time when translation of that message is
activated. Conversely, Nova may promote association with polyribosomes and activation
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of translation at the synapse upon receiving a hypothetical “activity-dependent” signal. A
third possibility is that Nova may be associated with an complex that inhibits translation
in mRNA trafficking, but also remains bound to the 3’UTR of mRNAs associated with
actively translating polyribosomes, perhaps serving as a scaffolding protein in this
translational complex.
While there is little evidence that Nova proteins are involved in translational
control, a related protein, FMRP, is thought to have a primary role in post-synaptic
regulation of translation. FMR1 is a 38kb long gene composed of 17 exons, which are
subject to alternative splicing and produce 20 predicted isoforms (4-5 protein bands are
detected in various tissues) (Devys et al., 1993; Eichler et al., 1993; Khandjian et al.,
1995; Sittler et al., 1996; Verheij et al., 1993; Verheij et al., 1995).

FMRP has three

conserved RNA-binding domains, two KH domains and one RGG box, and has been
shown to exhibit a high affinity for polyG and polyU homoribopolymers in vitro
(Adinolfi et al., 2003; Ashley et al., 1993; Denman and Sung, 2002; Dolzhanskaya et al.,
2003; Mazroui et al., 2003; Siomi et al., 1993) In addition to the RNA-binding domains,
FMRP also contains an N-terminal protein-protein interaction domain (NDF), a second
protein-protein interaction domain (PPId), a phosphorylation domain (Phd), a nuclear
localization signal (NLS) and a nuclear export signal (NES) (Adinolfi et al., 2003;
Ceman et al., 2003; Eberhart et al., 1996; Fridell et al., 1996; Siomi et al., 2002; Sittler et
al., 1996). FMRP has two autosomal paralogs, FXR1P and FXR2P, which share >60%
amino acid identity (Siomi et al., 1995; Zhang et al., 1995). FMRP is normally expressed
in most tissues at variable levels, although the highest expression is observed in brain and
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testis (Abitbol et al., 1993; Devys et al., 1993; Hergersberg et al., 1995; Hinds et al.,
1993).
Several laboratories have made efforts to identify the mRNA targets of FMRP.
FMRP has been shown to negatively regulate the translation of several mRNAs, both in
an in vitro rabbit reticulocyte lysate system and in vivo in cell culture (Laggerbauer et al.,
2001; Li et al., 2001b; Mazroui et al., 2002; Schaeffer et al., 2001). Target RNA
structural motifs have been identified for the RGG box domain (G-quartet RNA) and the
second KH domain (kissing complex RNA) (Darnell et al., 2005a; Darnell et al., 2001;
Darnell et al., 2005b). FMRP has also been shown to bind its own mRNA (Ashley et al.,
1993; Brown et al., 1998; Ceman et al., 1999; Schaeffer et al., 2001). Fmr1 mRNA
contains a G quartet FMRP binding site in the coding region which, when placed 50nt
downstream of the 5’ cap structure of a luciferase reporter, confers translational
repression in the presence of FMRP. Of note, all attempts to reproduce a 3’UTR G
quartet site have failed to confer translational repression (Schaeffer et al., 2001; JC
Darnell, unpublished data). Other target mRNAs for which there is some evidence of
translational regulation by FMRP include elongation factor 1A (EF-1A) (Sung et al.,
2003), MAP1B (Brown et al., 2001; Darnell et al., 2001; Zalfa et al., 2003), and PSD-95
(Todd et al., 2003).

Transcriptome-wide screening for FMRP target mRNAs has

identified mRNAs that preferentially co-IP with FMRP in the presence of EDTA (Brown
et al., 2001). Some of these mRNAs also display an altered polyribosomal profile in cells
from Fragile X patients. However, this study may have been biased toward identification
of RGG box-binding mRNAs, since the co-immunoprecipitation buffer contained 30mM
EDTA, which is known to disrupt ribosomes and KH2 binding to RNA (Darnell et al.,
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2005a). In addition, mRNA targets differentially associated with polyribosomes in the
presence or absence of FMRP were identified from lymphoblastoid cells, not brain.
Other potential FMRP targets have been identified by antibody-positioned RNA
amplification (Miyashiro et al., 2003) and in vitro RNA selection from transcribed
sequences in brain (Chen et al., 2003). However, little data at the protein level exist to
confirm translational regulation of these mRNAs by FMRP.

Methodologies to elucidate a role for FMRP and Nova proteins in translational control
In order to address potential functions for Nova-1, Nova-2 and/or FMRP in the
regulation of translation in neurons, we have devised several approaches. First, we have
developed a method to purify and analyze polyribosomes from mouse brain and spinal
cord lysates. Subjecting these lysates to various treatments can provide more knowledge
on whether these proteins are associated with polyribosomes or with other large
complexes.

Second, mRNA isolated from purified polyribosomes of wild type and

knockout mice can be interrogated by microarrays in order to screen for steady state
changes in mRNA translation that are associated with these proteins. Finally, we can use
known RNA ligands to these KH domain-containing proteins to investigate whether
binding to a particular RNA target has an impact on other protein-protein or protein-RNA
interactions. These experiments provide a foundation to address important aspects of
translational control in neurons, and the relationship to human neurological disease.
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CHAPTER II: MATERIALS AND METHODS

Polyribosome analysis
Polyribosomes from cortex or spinal cord were analyzed as follows. CD1 or FVB
mice at various ages were killed by decapitation after anesthesia with chloroform. The
brain or spinal cord was removed from the skull and placed in ice-cold buffer (10mM
HEPES-KOH, pH 7.4, 150mM KCl, and 5 mM MgCl2) containing 100 µg/ml of
cycloheximide. From this point on, the material was kept ice-cold or at 4°C throughout
the preparation. From brain, the cerebral cortex was dissected free of cerebellum,
brainstem, mesencephalon, diencephalon, basal ganglia, and much of the underlying
white matter. For spinal cord, meninges were carefully removed.

Tissue was

homogenized in 1 ml of homogenization buffer per cortex or per 4 spinal cords (except as
noted) (homogenization buffer: 10 mM HEPES-KOH, pH 7.4, 150 mM KCl, 5 mM
MgCl2, and 0.5 mM DTT) containing protease and RNase inhibitors (complete EDTAfree from Roche and Rnasin from Promega). Tissues were homogenized with 12 strokes
at 900 rpm in a motor-driven glass-Teflon homogenizer. The homogenized material was
spun at 2000 x g, 10 min, and NP-40 was added to the supernatant (S1) to a final
concentration of 0.3% or 1% v/v. After 5 min of incubation on ice, the material was spun
at 20,000 x g for 10 min, and the supernatant (S2) was loaded onto 20-50% w/w linear
density gradient of sucrose in 10 mM HEPES-KOH, pH 7.4, 150 mM KCl, 5 mM
MgCl2, or 30 mM EDTA where indicated. In the indicated samples, EDTA was added to
S2 to a final 30 mM concentration before loading on the gradient. Material obtained
from one cortex or one-half cortex was loaded onto each gradient. The gradients were
centrifuged at 40,000 x g for 2 hr at 4°C in a Beckman Instruments SW 41 rotor.
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Fractions of 0.5, 0.75, or 1 ml volume were collected with continuous monitoring at 254
nm using an ISCO UA-6 UV detector. For the RNase experiments, before centrifugation,
the S2 fraction was incubated with 1000 U/ml RNase T1 (Ambion) and 44 U/ml RNase
A (United States Biochemical) for 10 min at room temperature.
The same procedure was used for the analysis of polyribosomes extracted from
cells in culture. A postmitochondrial extract was obtained by lysis of 1 x 107 N2a,
IMR32, 293 or 293T cells (American Type Culture Collection) or primary cortical
neurons from seven 10-cm-diameter dishes in 1 ml of the following buffer: 20 mM
HEPES-KOH, pH 7.4, 10 mM KCl, 5 mM MgCl2, 0.3% NP-40, 0.5 mM dithiothreitol,
40 U/ml Rnasin (Promega), and complete protease cocktail (Roche). The salt
concentration was adjusted to 150 mM with 1 M KCl, and the lysate was spun 12,000 x
g, 10 min at 4°C. The resulting supernatant was loaded on sucrose gradients as described
above.
The proteins contained in each fraction of the sucrose gradients were TCAprecipitated and analyzed by Western blot.

Western blotting
Anti-FMRP (1C3, Chemicon; 2F5, hybridoma from J. Fallon), anti-S6 ribosomal
protein (Cell Signaling Technology), anti-L7 ribosomal protein (GeneTex), anti-P0
ribosomal protein (a kind gift from Dr. Tan, Scripps Institute; Biodesign International),
and anti-poly(A) binding protein (PABP) (10E10; Immunoquest), anti-Nova (rabbit
polyclonal and human patient sera), anti-Hu (human patient sera), anti-FXR1(830, gift of
E. Khandjian and B. Bardoni), anti-FXR2 (1G2, Iowa Hybridoma Bank), anti-CYFIP1,
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anti-CYFIP2, anti-NUFIP, anti-83FIP (all gifts of B. Bardoni), anti-hAgo1 and antihAgo2 (gifts of T. Tuschl), anti-myoVa (Sigma), anti-puralpha (Abnova), anti-mStaufen
(Chemicon), anti-YB1 (Abcam), anti-eIF4E (Santa Cruz), anti-EF1alpha (Novus), antiSam68 (Upstate), anti-aPKCzeta (Sigma), and the appropriate HRP-conjugated secondary
antibodies (Jackson Immunochemicals) were used for Western blotting. Signal was
detected by chemiluminescence. The membranes were exposed on Biomax MR film
(Eastman Kodak) and to the digital camera of a Versadoc Imaging System (Bio-Rad).

Pharmacological treatments of cells
Cells in culture were treated with 0.35 mM cycloheximide (Sigma) for 10 min or
with 1 mM puromycin (Sigma) for 3 hr before lysis, as described. Cycloheximide was
dissolved in methanol, and puromycin was dissolved in water.

In vitro transcription
In vitro transcription of RNA for binding curves was performed with 13 µL of
PCR-generated DNA template, 0.4 µM NTPs, 1 µL RNAsin (Promega), 40 µCi {alpha}32P-UTP, 1x transcription buffer (Stratagene), and 1 µL T7 RNA polymerase
(Stratagene). RNA was treated with 3 units of RQ1 DNase for 45 min at 37°C and
followed by gel purification on 8% denaturing polyacrylamide gels.

Nitrocellulose filter binding assays
Ten-thousand counts per minute (1-5 fmol) of internally labeled RNA (preheated
to 75°C and cooled at room temperature for 5 min) was incubated with the indicated
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concentrations of protein in a total volume of 50 µL in SBB, 10 min at room temperature.
Binding solutions were passed through MF-membrane filters (0.45 HA, Millipore) and
washed with 4 mL SBB. Filters were air dried and counted in 5-mL ReadiSafe scintillant.
Data were plotted as percentage of total RNA bound versus log of the protein
concentration and Kd's determined using Kaleidograph software (Synergy Software).

RNA treatment of polyribosome preparations
In vitro transcribed RNAs were prepared as described above, incubated in 100 µL
of 1x SBB for 10 min at 75°C, then incubated for 15 min at room temperature. The
supernatant (S1) from the homogenized material was collected and adjusted to 1% NP40, v/v. Two microliters of rRNasin, and 100 µL of in vitro transcribed RNA (or yeast
tRNA, Roche) in 1x SBB were added to 1.1 mL of S1 and mixed by inversion. After
incubation for 15 min at room temperature, S1 lysate was spun at 20,000 x g for 10 min
at 4°C and the supernatant (S2) was loaded onto sucrose gradients as described above.

Immunoprecipitation
A post-mitochondrial supernatant (S2) from cerebral cortex was prepared as for
polyribosome analysis and pre-cleared with 50µl protein A-sepharose (Sigma) for 30min
at 4°C. Mixed monoclonal anti-FMRP IP matrix was prepared as follows: 120µl Protein
A-sepharose was incubated with 12µl rabbit anti-mouse Fcgamma (2.4mg/ml, Jackson
Immunochemicals) for 30 min. at room temperature, then washed three times with 0.1M
NaPO4 buffer (pH 8.0) before incubation with 8µl 7G1-1 and 25µl 2F5 monoclonal
antibodies overnight at 4°C. Final IP matrix was washed three times with 0.1M NaPO4
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buffer before addition to pre-cleared supernatant. Immunoprecipitations were performed
at 4°C for 2 hours, after which they were washed twice with brain lysis buffer lacking
NP40.

Microarray analysis
Total cytoplasmic or polyribosomal RNA was isolated with TRIzol LS (Invitrogen)
extraction followed by RNeasy (Qiagen) purification with DNase treatment on column.
Ten µg of RNA was used as input for cRNA generation according to Affymetrix
guidelines. Biotin-labeled, fragmented cRNA was hybridized to either MGU74v2 ABC
or MG430 2.0 GeneChips (Affymetrix). Data analysis was accomplished as described in
Chapter 4 using MicroArray Suite 5.0 (Affymetrix), GeneTraffic (Stratagene), and/or
GeneSpring (Agilent).

Lentivirus production
All lentiviral constructs and packaging reagents were obtained from D. Trono (Geneva,
Switzerland). Packaging plasmids psPAX2 (15µg) and pMD2.G (6µg) were introduced
with 20µg pLVTt into 1x107 80% confluent 293T cells (ATCC) by calcium phosphate
transfection (Invitrogen).

Virus-containing media was collected 48 hours after

transfection and filtered through a 0.4µm membrane.
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CHAPTER III: NEURONAL RNA-BINDING PROTEINS AND THEIR
ASSOCIATION WITH POLYRIBOSOMES IN MOUSE BRAIN

Introduction
Translation of mRNA messages into functional proteins can be regulated in
various ways by RNA-binding proteins in cells. Once transcribed and spliced in the
nucleus, mRNAs must be exported to the cytoplasm, transported to their subcellular
destinations, protected from or encouraged to undergo translation, and degraded under
the appropriate circumstances. (Reviewed in (Moore, 2005)) However, these events in
the lifetime of an mRNA do not exist in isolation, as supported by recent advances in the
fields of transcription, pre-mRNA splicing, mRNA export, nonsense-mediated
degradation (NMD) and translation. Instead, they are coupled to the events that precede
and follow. Many proteins that bind a specific RNA at a given step in processing remain
bound and function in downstream events. It is through this network of regulatory
mechanisms that additional layers of complexity are added to our genomic program for
tissue-specific cellular function in a temporal and spatial fashion.
Local control of translation is an important aspect of the regulation of gene
expression, especially in neurons, which can extend processes and create synapses
enormous distances from the cell body. Although originally studied in developmental
processes in Xenopus and Drosophila, mRNA targeting, localization, and translation have
become a key aspects of the current theory of activity-dependent synaptic modification.
(Richter and Lorenz, 2002; Steward and Schuman, 2003; Sutton and Schuman, 2005) In
essence, for an mRNA to have a selective impact on a specific synapse, its transport must
be correctly targeted to the translational area of that synapse. It follows that locally
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translated messages should encode proteins that are in use at that synapse, modify other
proteins at the synapse, or serve as messengers to send signals back to other parts of the
neuron. Finally, transport and/or translation of this mRNA must be regulated in a manner
that can be altered by activity at that synapse.
Many studies have shown that protein synthesis is required for long-lasting forms
of behavioral and synaptic plasticity. (Govindarajan et al., 2006; Kang and Schuman,
1996; Kelleher et al., 2004a; Mayford et al., 1996; Nguyen and Kandel, 1996) Evidence
for this hypothesis to date includes: localization of polyribosomes and associated
membranous cisternae to sub-synaptic sites in dendrites, assessments of the mRNA
complement of dendritic processes, protein synthesis in isolated synaptosomal
preparations, translation of an mRNA construct transfected into an isolated dendrite, and
studies of polyadenylation-induced translation of the αCaMKII mRNA in synaptosome
preparations after NMDA receptor activation. (Crino and Eberwine, 1996; Eberwine et
al., 2001; Gardiol et al., 2001; Huang et al., 2002; Miyashiro et al., 1994; Steward and
Levy, 1982)
Analysis of the subcellular distribution of a given RNA-binding protein by
gradient centrifugation may offer clues to its function in vivo. In particular, if the protein
in question cosediments with polyribosomes, it may be involved in the regulation of
translation of its target mRNAs. Three target antigens for paraneoplastic neurologic
disease (PND), Hu (family members HuB, HuC and HuD), Nova (family members
Nova1 and Nova2), and Trim9 are neuronal RNA-binding proteins that may function in
this manner. Fragile-X mental retardation protein (FMRP) is a related RNA-binding
protein that is also implicated in neurologic disease. We show that the while only 10-
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25% of cytoplasmic Nova proteins are bound to polyribosomes, the majority of FMRP
and the neuronal Hu proteins are associated with actively translating polyribosomes in
brain and neuronal cells in culture.

Results
Polyribosomal protein analysis by gradient centrifugation
Velocity sedimentation of cytoplasmic components by centrifugation through a
sucrose gradient allows subsequent fractionation and simultaneous measurement of
absorbance at 254nm.

This method was first used in 1961 to work out the basic

mechanisms of protein synthesis, describing complexes that included multiple ribosomes
and messenger RNAs, and thereby generating a polyribosomal profile for a given cell
population (Becker et al., 1963; Gierer, 1963; Marks et al., 1962; Penman et al., 1963;
Rich et al., 1963; Risebrough et al., 1962; Scherrer et al., 1963; Slayter et al., 1963;
Spyrides and Lipmann, 1962; Staehelin et al., 1963a; Staehelin et al., 1963b; Warner et
al., 1963a; Warner and Knopf, 2002; Warner et al., 1963b; Wettstein et al., 1963). The
UV absorbance tracing of post-mitochondrial supernatant sedimented through a
continuous 20-50% (w/w) sucrose gradient displays clearly distinguishable peaks for the
40S and 60S subunits, 80S ribosomal monomer, and subsequent increases in the number
of ribosomes associated with mRNA. Protein analysis of polyribosome gradients by
Western blotting is one tool to understand whether a given RNA-binding protein is
associated with ribosome-loaded mRNAs; such an association may indicate a role for that
protein in the regulation of mRNA translation. For example, FMRP co-sediments with
polyribosomes from tissue culture cells (Corbin et al., 1997; Khandjian et al., 1996).

22

There are data to show that FMRP can negatively regulate the translation of several
mRNAs, both in an in vitro rabbit reticulocyte lysate system and in vivo in cell culture
(Laggerbauer et al., 2001; Li et al., 2001b; Mazroui et al., 2002; Schaeffer et al., 2001)
In our studies of neuronal RNA-binding proteins, we have developed a method to
fractionate polyribosomes from mouse cerebral cortex in order to ascertain the
polyribosomal distributions of these proteins.

Several RNA-binding PND antigens

demonstrate partial polyribosomal association in vivo. There are several commonly used
assays to demonstrate true polyribosome association and distinguish it from co-migration
on a sucrose gradient. Treatment with EDTA, translational initiation inhibitors that allow
run-off of translating ribosomes, or RNase result in disruption of the polyribosomal
profile and a change in the sedimentation rate of ribosomal proteins. If a protein is
indeed associated with polyribosomes, its sedimentation rate should mirror that of
ribosomal proteins under these conditions. Since EDTA chelates the magnesium ions
necessary for 80S ribosome formation and stabilization, an EDTA-treated lysate will
produce a profile showing two large peaks for ribosomal subunits (often off-chart and
merged into a single peak) but no peaks corresponding to 80S ribosomes or
polyribosomal complexes. A polyribosome-associated protein may be bound to actively
translating or stalled complexes. To distinguish between these types of polyribosomes,
sodium fluoride (NaF) and sodium azide (NaN3) can be used to inhibit ribosome reinitiation in a cell lysate, allowing previously bound ribosomes to run-off the mRNA and
complete translation. The resultant UV profiles are shown in Figure 3.1A. Protein from
each fraction of each gradient was precipitated with tricloroacetic acid and analyzed by
western blotting. The S6 ribosomal protein shows the position of the small (40S)
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Figure 3.1 Polyribosomal profiles and protein distributions: comparison of
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ribosomal subunit throughout the gradients (Figure 3.1B). 49% of total S6 protein is
found in fractions 12-20, which correspond to polyribosomal complexes with more than
five ribosomes. A 25% shift in the distribution of S6 is seen with EDTA treatment.
Smaller shifts (16%) are evident in the NaF- and NaN3- treated samples. These data
confirm that 30mM EDTA disrupts polyribosomes, and that ribosome re-initiation
inhibitors do have an impact on the number of ribosomes per message under these
conditions. Despite the incomplete translational run-off achieved here, partial sensitivity
to NaF and NaN3 is still informative for our analysis of polyribosomal proteins.

HuB, HuC and HuD
The neuronal ELAV-related RNA-binding proteins HuB, HuC and HuD were
visualized using sera from a patient with anti-Hu PND.

Although the ubiquitously

expressed family member HuR (HuA) has been shown to associate with polyribosomes in
cell culture and other tissues (Sheflin et al., 2001), this association had not been
demonstrated for the CNS-specific HuB, HuC and HuD proteins. HuB and HuC have
been shown to be important for neuronal development in both the CNS and PNS.
(Akamatsu et al., 1999) The Hu proteins contain RRM-type RNA-binding domains. HuR
has been shown to increase the stability of its target mRNAs, as well as increasing the
translation of these messages into protein. (Antic and Keene, 1997; Antic and Keene,
1998; Antic et al., 1999; Gallouzi et al., 2000; Levine et al., 1993) Figure 3.1C shows
that 52% of neuronal Hu proteins are associated with polyribosomes containing more
than 5 ribosomes (fractions 12-20) in mouse cerebral cortex. When treated with EDTA,
Hu proteins shift to the upper region of the gradient, mirroring the dissociation of
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ribosomes into subunits shown by ribosomal protein S6. Furthermore, when treated with
NaF or NaN3 in a run-off translation assay, Hu proteins show a 30% shift from their
control peak at fractions 12-16 to several peaks between fractions 3 and 10.

This

evidence supports a role for neuronal Hu proteins in actively translating polyribosomal
complexes.

Trim9
Another PND antigen, tripartite motif (RING, B-box and coiled-coil domains) 9,
or Trim9, shows partial association with polyribosomes. While the amount of Trim9
peaks in fractions 3-9 in both control and EDTA-treated samples, there is 25% less signal
in fractions 12-22 of the EDTA-treated sample (Figure 3.1D). However, Trim9 does not
seem to be associated with actively translating polyribosomes, since a shift is not seen in
the NaF- and NaN3-treated samples. It is possible that Trim9 could be associated with
stalled polyribosomes or other large complexes that are magnesium dependent.

Trim9

has been shown to bind RNA (W. Y. Park, unpublished data). In addition, recent work
indicates that it binds microtubules and is localized to the synapse. (Li et al., 2001a;
Short and Cox, 2006)

Onconeural ventral antigens Nova1 and Nova2
Nova1 and Nova2 are closely related target antigens of paraneoplastic opsoclonus
myoclonus ataxia (POMA). Both Nova proteins contain three KH-type RNA-binding
domains, and have been shown to bind YCAY-rich sequences. (Buckanovich et al.,
1993; Jensen et al., 2000a) The roles of Nova1 and Nova2 in the regulation of alternative
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splicing in neurons have been extensively documented by our laboratory (Dredge and
Darnell, 2003; Jensen et al., 2000a; Ule et al., 2003; Ule et al., 2005b). However, while
RNA splicing is almost always a nuclear process, approximately 40-60% of Nova is
present in the cytoplasm (J. Ule, doctoral thesis). Since RNA-binding proteins are often
involved in more than one processing event, it is a reasonable hypothesis that Nova could
be involved in the translational regulation of target mRNAs. To test this hypothesis, the
polyribosomal distribution of both Nova1 and Nova2 was visualized using high-titer
POMA patient sera. Figure 3.2A shows that the majority of Nova is found in the first
two (lightest) fractions of the gradient, likely in small protein-only or mRNP complexes.
UV absorbance profiles were not obtained for this experiment since fractions were
collected through a pinhole at the bottom of the gradient tube. This technique prevents
accidental contamination of the heaviest fractions by proteins present in other regions of
the gradient. For control purposes, unchelated and EDTA-treated gradients were assayed
for a number of proteins, as shown in Figure 3.2A, including non-polyribosomal proteins
gamma-tubulin, PTEN and MAPK. In order to better quantify the percentage of cytosolic
Nova that is associated with large magnesium-dependent complexes, Western blot
chemiluminescence was quantified using the Versadoc Imaging System (Bio-Rad) for
control and EDTA-treated polyribosome gradients. Figure 3.2B illustrates that there is a
sharp visual difference between the amount of Nova present in fractions 12-19 of control
versus EDTA-treated polyribosome profiles, and 11.8% of cytosolic Nova shifts out of
these fractions per gradient (one brain). Conversely, 22.4% of total Nova signal is shifted
to fractions 4-11 of the EDTA-treated gradient. A repetition of this experiment yields an
EDTA-dependent shift of 18.6% of total cytosolic Nova to fractions 4-11 (data not
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Figure 3.2 10-25% of non-nuclear Nova proteins associate with polyribosomes in
mouse cerebral cortex. (A) Western blots of polyribosomal distributions in the absence
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shown). Thus, we can estimate that approximately 10-25% of brain cytosolic Nova is
associated with large complexes in a magnesium-dependent manner that may in fact
contain polyribosomes.

Fragile-X Mental Retardation Protein
Converging lines of evidence support a role for FMRP in translational control.
FMRP is found associated with polyribosomes in various non-neuronal cell lines. (Corbin
et al., 1997; Eberhart et al., 1996; Feng et al., 1997a; Khandjian et al., 1996) In addition,
the abundance of a set of mRNAs in the polyribosomal fraction is altered in human cell
lines derived from Fragile X syndrome patients. (Brown et al., 2001) The Drosophila
ortholog of FMRP, dFXR, has been shown to repress the expression of futsch at the
translational level. (Zhang et al., 2001)

Finally, the ability of FMRP to act as a

translational repressor of reporter constructs has been demonstrated in vitro and in
transfected cells. (Laggerbauer et al., 2001; Li et al., 2001b; Mazroui et al., 2002) It has
been suggested that the loss of proper regulation of translation of FMRP target mRNAs
underlies the morphological and functional abnormalities observed at some synapses of
Fmr1-null mice. (Huber et al., 2002; O'Donnell and Warren, 2002)
These observations introduce the question of whether they are relevant to FMRP
function in the mammalian brain. Technical difficulties in sedimentation studies using
CNS tissue have, until recently, prevented researchers from being able to definitively
show that FMRP is present on polyribosomes from brain. The most promising evidence
showed that FMRP may co-sediment with polyribosomes in synaptosomal preparations
from rat cortex, however, this data included neither an RNA absorbance profile nor

29

sufficient biochemical controls for synaptosomal preparation purity (Feng et al., 1997b).
In addition, a recent study reported that FMRP is in fact not associated with
polyribosomes in brain extracts, but rather that it cosediments with the 80S ribosome and
with heterogeneous complexes of smaller size. (Zalfa et al., 2003)
We devoted a significant effort to improving existing methodologies for the
purification of polyribosomes from mouse brain.

The essential differences in our

technique are the dissection and removal of underlying white matter tracts from the
cerebral cortex, and the use of 0.3% to 1% NP40 as a detergent instead of sodium
deoxycholate. Our method of polyribosome fractionation allows us to demonstrate that,
indeed, FMRP is present on polyribosomes in brain in both juvenile (postnatal day 9,
Figure 3.3A) and adult (5 months old, Figure 3.3B) mice. OD254 absorption profiles and
Western blots are shown for polyribosome gradients treated with either 5mM magnesium
chloride or 30mM EDTA. EDTA treatment entirely disrupts polyribosomal complexes
into the small and large ribosomal subunits, as shown by the shift in rpS6 distribution. It
also results in a significant and similar shift in FMRP distribution, from association with
the largest polyribosomes to co-sedimentation with, or slightly larger than, the 60S
ribosomal subunit.

To examine whether the cosedimentation of FMRP with

polyribosomes in the brain was RNA-dependent, extracts were treated with RNases A
and/or T1, and analyzed by gradient centrifugation. This treatment resulted in complete
disruption of polyribosomes, as shown by the shift of ribosomal protein P0, and also
shifted FMRP to the lighter fractions of the gradient (Figure 3.3C). (Stefani et al., 2004)
In addition, when extracts are treated with both RNase and EDTA, there is a small
additional shift to the lightest fractions of the gradient (Figure 3.3D). This suggests that
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Figure 3.3 FMRP is associated with polyribosomes in mouse cerebral cortex. UV
absorbance profiles and Western blots for FMRP and ribosomal protein S6 (rS6) of
polyribosome fractionations from cerebral cortices of juvenile (postnatal day 9, A) and
adult (five months of age, B) mice. A comparison between control conditions (MgCl2)
and EDTA treatment shows that both FMRP and polyribosomes (profiles, rS6) are
disrupted by chelation of magnesium for both juvenile and adult mice. (C) Treatment of
juvenile (postnatal day 9) mouse cortical lysate with RNase A also causes FMRP and
ribosomal protein P0 (P0) to shift into the upper fractions of the gradient. (D) Treatment
with both RNase A and EDTA (bottom panel) results in a supershift of EDTA-released
FMRP complexes. Western blots for FMRP of polyribosome gradients from mouse
cortical lysate with the indicated treatments.
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FMRP may exist in complexes of multiple sizes, which are differentially dependent on
both magnesium and RNA. These results are in agreement with previous observations in
non-neuronal cell lines. (Ceman et al., 2003; Eberhart et al., 1996)
One variable used in previous polyribosome profiles from brain has been the
presence or absence of ionic detergent such as deoxycholate. (Bagni et al., 2000; Zalfa et
al., 2003) To rule out the possibility that the observed sedimentation pattern of FMRP
might relate to the presence or absence of detergents, we analyzed gradients of brain
extracts prepared in the presence of deoxycholate, Nonidet P-40, or in the absence of any
detergent. After elimination of the insoluble material with a 20,000 x g centrifugation
step, we obtained clearly discernible polyribosome peaks in sucrose gradients (Figure
3.4A). In agreement with our previous results, FMRP cosediments with polyribosomes in
this preparation, eliminating the possibility of technical artifacts caused by the presence
of detergents in the extract. Conversely, we find that FMRP association with
polyribosomes is completely disrupted by the presence of deoxycholate (Figure 3.4B).
(Stefani et al., 2004)

These results demonstrate that FMRP is associated with

polyribosomes in the brain. Khandjian and colleagues have reported similar findings on
the impact of deoxycholate on FMRP distribution. (Khandjian et al., 2004)
The molecular mechanism through which FMRP might modulate the expression
of its target mRNAs is unknown. Even tissue-culture studies have failed to convincingly
show whether FMRP associates with actively translating polyribosomes or with
translationally arrested ribosome-associated messenger ribonucleoprotein complexes
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Figure 3.4 FMRP associates with polyribosomes in the absence of detergent. Postmitochondrial supernatants from juvenile mouse cortices were prepared without detergent
(A) and subjected to control (left panel) and EDTA (right panel) treatments, or in the
presence of 1% Nonidet P40 (NP40) (B, left panel) or NP40 plus 0.5% sodium
deoxycholate (DOC, right panel). Western blots of polyribosome gradient fractions are
shown for FMRP and the ribosomal proteins S6 (rS6) and L7.
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(RNPs). It has been suggested that the phosphorylation state of FMRP may regulate
whether it is associated with active or stalled polyribosomes. (Ceman et al., 2003)
In tissue-culture studies, the FMRP-polyribosome association has been disrupted
by treatment with pleotropic inhibitors of translation reinitiation such as sodium fluoride
and sodium azide (Ceman et al., 2003; Feng et al., 1997a), but it is unknown whether the
FMRP-polyribosome association can be disrupted with these agents in a cytoplasmic
lysate from mouse cerebral cortex. Figure 3.5 shows the distribution of FMRP in control,
EDTA-treated and translation re-initiation-inhibited conditions. These data demonstrate
that, when ribosomes are allowed to undergo run-off translation, 14% of polyribosomal
FMRP shifts from fractions 12-21 into fractions 5-10. Further evidence for the
association of FMRP with actively translating polyribosomes is shown in Figure 3.6.
(Stefani et al., 2004) To assess whether FMRP is associated with actively translating
polyribosomes in cells of neuronal lineage, we treated Neuro-2a cells, a murine
neuroblastoma cell line, with the translational inhibitor puromycin. Puromycin is an
analog of amino-acyl transfer RNA that binds to the acceptor site of the ribosome,
blocking elongation and causing premature release of the growing polypeptide chain.
(Davis et al., 1974)

Therefore, the drug specifically targets actively translating

polyribosomes. We attempted to assay FMRP sensitivity to puromycin treatment in vivo
by injecting puromycin into the intraperitoneal space of mice. We were not able to obtain
usable polyribosome gradients from the brains of these mice due to the lipid insolubility
of puromycin. As a relatively hydrophilic molecule, puromycin has difficulty crossing
the blood-brain barrier. We were unable to achieve sufficient puromycin concentrations
in the brain before the mice died due to systemic toxicity (data not shown.) For these
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Figure 3.5 FMRP cosediments with translating polyribosomes in mouse cortex.
Western blots for FMRP from polyribosome gradient fractions in Figure 3.1 show that
65% of FMRP is bound to polyribosomal complexes containing at least 5 ribosomes (top
panel, fractions 12-20. 14% of this population of FMRP shifts under run-off conditions
when translation initiation is inhibited by NaF or NaN3.

reasons we have used a neuroblastoma cell line (Neuro2a) to test whether FMRP is bound
to actively translating polyribosomes.
FMRP cosediments with the larger polyribosomes in Neuro-2A cells treated with
cycloheximide (Figure 3.6 top panel), as observed in the brain. After treatment of Neuro2A cells with 1mM puromycin for 3 hr, virtually all polyribosomes containing multiple
(i.e., >4-6) ribosomes were fully disrupted, whereas the peak corresponding to the 80S
ribosome monomer was markedly increased, as judged by the OD254 profile and the
Western blot for ribosomal protein S6 (middle panel). Under these conditions, the
sedimentation of FMRP shifts from fractions harboring large polyribosomes (more than
six ribosomes) to less dense fractions. These FMRP-containing fractions present after
puromycin treatment correspond either to non-translating monosome-size particles or to
residual polyribosomes containing 2-4 ribosomes bound to mRNA. Ribosomal protein
S6 and Poly-A Binding Protein (PABP) shift to smaller fractions, mostly corresponding
to 80S ribosomal monomers and 60S large subunits. Taken together, these results

35

Figure 3.6 FMRP associates with functional polyribosomes in neuronal cells. Neuro2A cells treated with 100ug/ml cycloheximide (top), puromycin (middle) or 30mM
EDTA and analyzed by sucrose gradient centrifugation. Western blots are shown for
FMRP, ribosomal protein S6 (rS6), and poly(A)-binding protein (PABP).
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demonstrate that FMRP is associated with functional polyribosomes in neuronal cells.
(Stefani et al., 2004)

Discussion
We have optimized a reliable procedure for the analysis of polyribosomes from
differentiated neural tissues, based on the careful dissection of cerebral cortex with
removal of underlying white matter, followed by homogenization and lysis in mild
conditions that preserve the interaction between various neuronal RNA-binding proteins
and polyribosomes. Data from these experiments demonstrate that neuronal proteins can
exhibit varying degrees of polyribosomal association when analyzed by gradient
centrifugation. Here we have looked at several proteins identified as target antigens for
autoimmune responses initiated by the ectopic expression of these antigens in somatic
cancer cells. The results of these paraneoplastic autoimmune activations are neurologic
syndromes whose constellation of characteristics can inform studies on the normal
function of these proteins in neurons. Trim9, identified as a target antigen of sera from a
patient with paraneoplastic cerebellar symptoms (W. Y. Park, unpublished results), is
partially located in heavy gradient fractions in a magnesium-dependent manner. This
association is resistant to treatment with translation reinitiation inhibitors, suggesting that
Trim9 may be a component of a large complex that may include stalled polyribosomes.
The Hu antigens, first described as targets of paraneoplastic subacute sensory neuropathy,
encephalomyelopathy, and/or cerebellar dysfunction, are entirely associated with actively
translating ribosomal complexes when present in the post-mitochondrial supernatant.
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Approximately 15-20% of non-nuclear paraneoplastic opsoclonus-myoclonus ataxia
(POMA) targets Nova1 and Nova2 are associated with polyribosomes in cerebral cortex.
Although not a known target antigen for a paraneoplastic neurologic disorder,
FMRP is related to Nova by means of their KH-type RNA-binding domains. FMRP is
widely expressed, with highest expression observed in brain and testis. (Abitbol et al.,
1993; Devys et al., 1993) Despite the essentially ubiquitous distribution, the human
syndrome caused by the absence of FMRP is most notably characterized by cognitive
impairments. (O'Donnell and Warren, 2002) Therefore, a detailed understanding of
FMRP biology in the cerebral cortex is of great interest. In addition, the clinical and
biochemical data from Fragile-X patients suggest that a defect in mRNA processing may
be a critical component of this syndrome. We provide definitive evidence that FMRP is
associated with polyribosomes in mammalian brain. We reproducibly observed EDTA
and RNase-sensitive association of FMRP with polyribosomes in extracts from cerebral
cortex from young and adult animals. Furthermore, we demonstrate that the complexes
formed by FMRP with polyribosomes are translationally active in neuronal cells, because
treatment with puromycin, sodium fluoride or sodium azide sufficient for disruption of
polyribosomes decreases the rate of sedimentation of FMRP. Association of FMRP with
polyribosomes has been described in non-neuronal cell lines, but contradictory reports
exist in the literature about the existence of such interaction in neural tissues. One
previous report has suggested a possible association of FMRP with polyribosomes in
neural tissue. (Feng et al., 1997a) However, the evidence presented was not conclusive,
in part because the absence of an absorbance profile makes the integrity and purity of the
polyribosomes difficult to assess. In contrast, a recent report suggests that FMRP is not
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associated with polyribosomes specifically in mouse brain, but instead cosediments with
RNPs smaller than a single ribosome, (Zalfa et al., 2003) The results presented in this
study definitively demonstrate that FMRP cosediments with polyribosomes purified from
cerebral cortex. The purity of the polyribosomes from cortex is comparable to
preparations from cultured cells, as judged by absorbance profiles.
Although the observed migration of FMRP on sucrose gradients and its sensitivity
to EDTA and RNase are highly suggestive of an interaction between FMRP and
translating polyribosomes, other interpretations cannot be ruled out a priori. Krichevsky
and Kosik (Krichevsky and Kosik, 2001) have reported evidence for large molecular
weight RNP granules in neurons. However, these data were obtained from primary
neuronal cultures, and no such granules were seen in cells grown for 3 d in vitro (only
after 7 d in vitro), suggesting a phenomenon closely related to culture conditions. In our
work, we see no evidence for such RNP granules on OD254 profiles of either young or
adult mouse brain. In other studies, FMRP has been reported in large cytoplasmic
complexes similar to stress granules in tissue culture after various treatments (Mazroui et
al., 2002).

Again, we have not observed a measurable amount of FMRP in such

complexes in untreated mouse brain.
The association of FMRP with actively translating polyribosomes suggests that
the protein may itself play a role in translational regulation. Previous studies have
suggested that FMRP may promote mRNA translation. (Brown et al., 2001; Miyashiro et
al., 2003; Todd et al., 2003)

Although in principle an association with actively

translating polyribosomes might be consistent with a positive role on translation, a
number of reports also suggest that FMRP may inhibit the translation of its target RNAs.

39

(Laggerbauer et al., 2001; Li et al., 2001b; Mazroui et al., 2002; Zhang et al., 2001)
Interestingly, whereas puromycin clearly disrupts large FMRP-polyribosome complexes,
FMRP still cosediments with the largest remaining polyribosomes containing three to
four ribosomes rather than with the much more prominent peak of monomeric ribosomes
(Figure 3.6). The less than complete shift of FMRP may be consistent with relative
translational inhibition of some FMRP-associated transcripts. Alternatively, since FMRP
is generally associated with larger polyribosomal complexes (compared to the
distribution of ribosomal proteins, see Figures 3.3-3.6), its continued association with the
largest remaining complexes may simply reflect incomplete treatment with puromycin,
leaving a percentage of translating ribosomes intact. A third possibility is that FMRP is
bound to mRNAs that are longer than average, and can therefore carry a greater number
of ribosomes. Finally, FMRP binding may inhibit the rate of translation elongation,
rather than initiation. This causes the number of ribosomes on a transcript to increase,
since the ribosomes are packed more closely together. The association of FMRP with
"stalled" polyribosomes has been shown previously to correlate with phosphorylation in
non-neuronal cells treated with sodium azide. (Ceman et al., 2003) Although unusual,
examples of translational repression of mRNAs associated with polyribosomes have been
reported.

Hac1 mRNA expression in yeast is regulated on translationally stalled

polyribosomes by means of an RNA-RNA interaction between the 5’ UTR and a retained
intron in the 3’ region of the message. (Chapman and Walter, 1997; Ruegsegger et al.,
2001) Translationally suppressed nanos mRNA is associated with puromycin-sensitive
polyribosomes in Drosophila, and is subject to translational runoff in vitro. (Clark et al.,
2000) Moreover, it has been reported that lin-14 and lin-28 mRNAs, whose translation is
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blocked by miRNA lin-4, are nonetheless found in the polyribosomal fraction.
(Krichevsky and Kosik, 2001; Olsen and Ambros, 1999; Seggerson et al., 2002) Our
puromycin results suggest that translation is occurring on FMRP-bound mRNAs;
however, taken together, all of our data is consistent with a slow elongation rate. By
modulating the efficiency of translation of mRNAs that are fully engaged in
polyribosomal complexes, FMRP might be suitable to mediate particularly rapid and
reversible regulatory events, consistent with its proposed role in the regulation of protein
synthesis-dependent synaptic plasticity. (Huber et al., 2002)
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CHAPTER IV: MICROARRAY ANALYSIS OF POLYRIBOMAL MESSENGER
RNAS

Introduction
Identification of affected mRNA targets is critical to an investigation of the role
of an RNA-binding protein in translational regulation. While target mRNAs have been
identified by co-immunoprecipitation and/or bioinformatics screen for a known binding
sequence (Brown et al., 2001; Darnell et al., 2001), one can also look at the general
contribution of an RNA-binding protein on the translational status of expressed mRNAs.
As for the transcriptional state of a tissue, microarrays can be used to examine whether
the absence of an RNA-binding protein changes the mRNAs engaged by multiple
ribosomes.

This scheme for high-throughput expression screening based on mRNA

translation states was first employed by Zong et al to compare translational profiles of
resting and mitogenically-activated fibroblasts (Zong et al., 1999).

Briefly, mRNAs

isolated from polyribosome fractions corresponding either to association with less than
two or to association with two or more ribosomes were used to interrogate cDNA arrays.
Polyribosomal profile patterns of mRNAs were compared between resting and activated
cells. A number of groups have used similar methods to assay the mRNA content of
polyribosomes purified from conditions including poliovirus-infected HeLa cells
(Johannes et al., 1999), human Fragile X lymphoblastoid cell lines (Brown et al., 2001),
rapamycin-treated T cells (Grolleau et al., 2002), rapidly growing and rapamycin-treated
Saccharomyces cerevisiae (Arava et al., 2003; Preiss et al., 2003), renal carcinoma cells
expressing von Hippel-Lindau tumor suppressor protein (Galban et al., 2003), mouse
glial progenitor cells with activation of the Ras and/or Akt signaling pathways (Holland
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et al., 2004; Rajasekhar and Holland, 2004), cultured embryonic rat cortical neurons
treated with BDNF +/- rapamycin (Schratt et al., 2004), Arabidopsis thaliana leaves
under normal conditions and mild dehydration stress (Kawaguchi and Bailey-Serres,
2005), and prepuberal and adult mouse testis extracts (Iguchi et al., 2006). We have
combined our method for polyribosome preparation with knockout animals for two RNAbinding proteins, Nova-1 and FMRP.
The identification of mRNA targets of FMRP is a goal of many laboratories in the
field. FMRP has been shown to negatively regulate the translation of several mRNAs,
both in an in vitro rabbit reticulocyte lysate system and in vivo in cell culture
(Laggerbauer et al., 2001; Li et al., 2001b; Mazroui et al., 2002; Schaeffer et al., 2001).
However, in our hands, these data seem to result from a global inhibitory effect of FMRP
on translation, rather than specific inhibition of a target mRNA (JC Darnell, unpublished
data.) FMRP has been shown to bind its own mRNA through a G quartet motif (Ashley
et al., 1993; Brown et al., 1998; Ceman et al., 1999; Schaeffer et al., 2001). Other target
mRNAs for which there is some evidence of translational regulation by FMRP include
elongation factor 1A (EF-1A) (Sung et al., 2003), MAP1B (Brown et al., 2001; Darnell et
al., 2001; Zalfa et al., 2003), and PSD-95 (Todd et al., 2003). Many possible targets of
FMRP have been identified through a number of screening methods.

Using co-

immunoprecipitation of FMRP-RNA complexes from mouse brain followed by
oligonucleotide microarray screening, 432 mRNAs were identified with the ability to
preferentially co-IP with FMRP (Brown et al., 2001). 251 mRNAs differing in the
polyribosomal fractions of human normal and fragile X lymphoblastoid cell lines were
also identified by microarrays. Of these, 136 were increased in fragile X polyribosomes
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and 115 were decreased.

14 of the co-IP-identified mRNAs were present in the

polyribosome-identified group.
mRNAs.

A G quartet sequence was identified in 8 of these

MAP1B was present in both groups, and was shown to be increased in

polyribosomes from fragile X cells. However, this study may have been biased toward
identification of RGG box-binding mRNAs, since the co-immunoprecipitation buffer
contained 30mM EDTA.

It is possible that mRNA targets bound in a magnesium

dependent manner by the KH2 domain of FMRP have not been identified by this study.
In addition, mRNA targets differentially associated with polyribosomes in the presence or
absence of FMRP were identified from lymphoblastoid cells, not brain.

The

lymphoblastoid cell lines used for these experiments were derived from 5 human subjects
in each group, introducing more biological variation than is present in inbred mice.
Finally, there is evidence that RNA-protein complexes can be falsely coimmunoprecipitated when the two components have been expressed in separate cell lines,
then lysed and pooled, suggesting that there may be a significant number of false
positives in the co-IP data (Mili and Steitz, 2004). Thus, screens for differentially
polyribosome-associated mRNAs in the brain of the Fmr1 KO mouse may reveal further
information.
Antibody Positioned RNA Amplification (ARPA) has identified another set of
possible FMRP targets from primary rat hippocampal neuronal cultures (Miyashiro et al.,
2003). Of the 83 cDNA clones identified by this method, 25% contain G quartets,
although it is not stated what percentage of all neuronal mRNAs contain G quartets using
the sequence definition particular to this paper. In vitro RNA selection from transcribed
sequences in brain (cDNA-SELEX) was used to identify 57 cDNAs, of which 2 contain
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G quartets (Chen et al., 2003). MAP1B was identified by this method and shown to have
23% decreased expression in Fmr1 KO cerebellum.

Finally, total RNA from pooled

whole brains from adult wild type and Fmr1 KO mice were used to probe a cDNA
microarray (D'Agata et al., 2002). 73 genes were identified with greater than 2-fold
differences between WT and KO signal. However, real-time PCR validation did not
support the magnitude of the differences observed on the array. Others have indicated
that there are few deviations from normal steady-state expression levels for most genes in
fragile X patient cells or Fmr1 knockout mouse brain (Jin and Warren, 2003).
While the role of FMRP in translational regulation is being extensively studied,
that for the Nova proteins has not yet been considered. Although Nova-1 and Nova-2 are
present in the cytoplasm of neurons, and do bind some mRNA targets in exonic regions
(Dredge et al., 2005; Ule et al., 2003; Ule et al., 2005b), no translational targets of either
Nova protein have yet been validated. Like the related RNA-binding proteins hnRNP K
and hnRNP E1/E2 (Ostareck-Lederer and Ostareck, 2004), the Nova proteins may have a
significant role in translational regulation. It is generally thought that mRNAs associated
with polyribosomes are being actively translated. Our lab has preliminary data to suggest
that 11.8-22% of Nova may be associated with polyribosomes in the mouse CNS at
approximately one month of age (Racca et al., submitted). Thus, it is an open question
whether Nova inhibits translation of mRNAs in Nova-associated mRNPs, or whether
Nova may promote or inhibit translation by binding directly to polyribosomes. If Nova
acts in a similar manner to that which has been suggested for hnRNP K (OstareckLederer and Ostareck, 2004), we expect to see an increase in association with
polyribosomes of target mRNAs in Nova-1 null mouse spinal cord. Or, we may see a
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more complex set of data, with some mRNAs increased and others decreased in Nova-1
knockout polyribosomal RNA, as has been seen for the lymphoblastoid cell lines from
patients with Fragile X mental retardation syndrome (Brown et al., 2001). Thus both
Nova and FMRP are candidate model systems to assay changes in translational status for
mRNAs.

Results
Nova-1 wild type versus knockout mouse spinal cord
Nova RNA-binding proteins, Nova-1 and Nova-2, are target antigens of
paraneoplastic opsoclonus-myoclonus ataxia (POMA), a neurodegenerative disorder of
autoimmune etiology (reviewed in Darnell, 1996). Nova-1 is expressed in the ventral
spinal cord, brainstem, deep nuclei of the cerebellum, and midbrain (Buckanovich et al.,
1993). Nova proteins contain three hnRNP K-homology (KH) domains with RNAbinding activity. Although the Nova proteins are predominantly nuclear, they are present
in significant quantities in the cytoplasm and Nova-1 has been co-localized with GlyRα2
mRNA in post-synaptic regions of the dendrite (Racca et al., submitted). While there is
evidence that Nova proteins act to influence alternative splicing in neurons (Jensen et al.,
2000a; Ule et al., 2003; Ule et al., 2005b), they may also have a role in the local
regulation of protein synthesis in neurons. Both Nova-1 and Nova-2 are associated with
polyribosomes in mouse brain and spinal cord in a magnesium-dependent manner (See
Figures 3.1-3).

For this reason we have used gradient density centrifugation,

fractionation and microarray (Affymetrix MGU74v2ABC GeneChips) hybridization to
identify mRNAs that have an altered distribution on polyribosomes in Nova-1 knockout

46

spinal cord from four day-old mice. To control for transcriptional differences between
Nova-1 knockout and wild type spinal cord we have also assayed total RNA from the
same samples. Three biological replicates of four pooled spinal cords each were used for
each genotype. A representative polyribosome profile and Western blots are shown in
Figure 4.1. Signal values for each probeset were calculated using Microarray Suite 5.0
(Affymetrix). Further data analysis was accomplished using Genespring 5.0 (Silicon
Genetics). To analyze the differences between total mRNA and polyribosomal RNA
populations, these signals were compared irrespective of Nova-1 genotype.

The

probesets that exhibited a change between total RNA and polyribosomal RNA (p<0.001)
are shown in Figure 4.2. Of note, these probesets include mRNAs for 21 ribosomal
proteins (Table 4.1) containing oligopyrimidine tracts (TOP) in their 5’UTR regions and
known to be translationally repressed in post-mitotic cells (Meyuhas, 2000). mRNAs
showing an increased representation in polyribosomes include GAPDH and actin.

47

A254

% Sucrose (w/w)

0

20

50

40S 60S 80S

Polyribosomes

WT,
anti-NOVA
WT,
anti-P0
Nova-1 KO,
anti-NOVA
Nova-1 KO,
anti-P0

Figure 4.1 Polyribosome Fractionation from Nova-1 wild type and knockout mouse
spinal cord. Four spinal cords from postnatal day 4 mice were used for each 20-50%
sucrose gradient centrifugation. A representative OD254 profile is shown in the top
panel. Positions of the ribosomal subunits and polyribosomes are indicated. Gradients
were fractionated and aliquots assayed for protein by Western blot.

Polyribosomal

distributions of Nova-1 and Nova-2 proteins (anti-Nova) and ribosomal protein P0 (antiP0) are shown for wild type (WT) and Nova-1 knockout (KO) spinal cords. Fractions 911 (red box) from each gradient were pooled to isolate polyribosomal RNA.
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Figure 4.2 mRNAs that differ between Total and Polyribosomal RNA, p≤0.001.
Normalized intensities (log scale) of probeset signals were compared by t-test between
total RNA and polyribosomal RNA, irrespective of genotype.
displayed for all four conditions on a discontinuous graph.
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Probeset signals are

mRNA

p-value

ribosomal protein S12

3.48E-05

ribosomal protein L13*

4.97E-05

ribosomal protein S26

4.97E-05

ribosomal protein L41

1.01E-04

acidic ribosomal phosphoprotein PO*

1.22E-04

ribosomal protein, large, P1

1.22E-04

ribosomal protein L27a (x2)

1.31E-04

ribosomal protein S28 (x2)

1.55E-04

ribosomal protein S8*

2.24E-04

ribosomal protein L28

2.57E-04

mitochondrial ribosomal protein L52

2.71E-04

ribosomal protein P23*

3.60E-04

ribosomal protein S2

3.60E-04

ribosomal protein L23a,

3.60E-04

ribosomal protein P40*

3.79E-04

ribosomal protein L30*

4.24E-04

ribosomal protein L27A

5.17E-04

ribosomal protein L21

5.55E-04

ribosomal protein L31

5.69E-04

ribosomal protein S17*

6.34E-04

ribosomal protein S11*

8.11E-04

Table 4.1 Genes encoding ribosomal proteins are translationally repressed.
*Indicates a TOP mRNA; mRNAs interrogated by multiple Affymetrix probesets are
indicated in parentheses
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Figure 4.3 shows a graphical representation of RNAs that showed a difference
between wild type and Nova-1 knockout polyribosomes with p<0.05. Signals for each
gene on the polyribosomal chips were normalized to the corresponding signal from total
RNA by genotype and sample, thus all signals equal one for both wild type and Nova-1
knockout total RNA data points. Table 4.2 lists the mRNAs that exhibit a greater than
twofold difference between wild type and Nova-1 knockout polyribosomal RNA. We
were unable to confirm these data by real-time quantitative PCR and Western blotting for
changes in steady state protein levels between Nova-1 wild type and knockout spinal
cords (data not shown.) Of note, Nova-2 is also expressed in mouse spinal cord, albeit in
dorsal rather than ventral areas. Since Nova-1 and Nova-2 have similar RNA binding
specificities, slight changes in the polyribosomal distributions of a Nova target mRNA
could be further obscured by the presence of Nova-2 in Nova-1 knockout spinal cord.

10
Intensity
1

0.1

KOPoly WTPoly

KOTotal WTTotal

Figure 4.3 Comparison of mRNAs sedimenting with wild type versus Nova-1
knockout polyribosomes. Probeset signals are normalized to Total RNA signal for each
gene by genotype, thus all probesets have a normalized intensity of 1 in KO Total and
WT Total conditions. KO Polyribosome compared to WT Polyribosomes by t-test, p≤
0.05.
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Increased in KO Polysomes
Fold
Change9.92
5.87

selenium binding protein 2
polynucleotide kinase 3'- phosphatase (PNKP)
VACM (vasopressin activated calcium mobilizing)
epithelial membrane protein 3
homeodomain interacting protein kinase 1
RIKEN cDNA 2300004H16 gene
similar to PDZ protein interacting with TC10
18S rRNA.
Filamin
ESTs
ESTs
putative membrane protein
chloride channel regulator Icln (pseudogene)
EST, Weakly similar to RIKEN cDNA 2510008H07 [Mus musculus]
similar to testis expressed sequence 27, clone IMAGE:4950648, mRNA
BALC (brain and acute leukemia, cytoplasmic)
RIKEN cDNA 4933426K21 gene
RIKEN cDNA 2510005D08 gene
Cluster Incl U62674: histone H2a.2-615 , and histone H3.2-615 genes
neural stem cell derived neuronal survival protein
RIKEN cDNA C330026P08 gene
clone IMAGE:4507459, mRNA, partial cds
ESTs
vw95f07.r1 Stratagene mouse skin cDNA clone IMAGE:1262725 5', mRNA
exostoses -like 1
RIKEN cDNA 5830417I10 gene
EST, Weakly similar to NED4_MOUSE NEDD-4 protein [M.musculus]
ESTs, Moderately similar to COTE_HUMAN COTE1 PROTEIN [H.sapiens]

4.73
4.51
3.91
3.89
3.44
3.19
3.12
2.95
2.92
2.76
2.64
2.43
2.42
2.40
2.40
2.36
2.35
2.30
2.29
2.27
2.14
2.09
2.08
2.07
2.07
2.02

Functions in synaptic densities
Metalloproteinases
Transcription factors

Decreased in KO Polysomes
Fold
Change 6.13
5.29

ESTs
EST (transcription factor?)
Mouse CNK (connector enhancer of ksr)
RIKEN cDNA 4933439F18 gene
Damage-induced neuronal endopeptidase (DINE)
RIKEN cDNA 5830415F09 gene
cell division cycle 45 homolog -like
Rho GTPase activating protein 6
ESTs
RIKEN cDNA 1110038G02 gene
ESTs sim to JC5629 mullerian-inhibiting substance type II receptor
Janus kinase 3
endothelin converting enzyme 2
RIKEN cDNA 1810031K17 gene
expressed sequence AI448652
ESTs
Ngfi-A binding protein 1 (NAB1)
Helicase-like transcription factor
ADAMTS15
ras homolog gene family, member J
ESTs
ESTs
melastatin 1
ESTs
Fas-activated serine/threonine kinase
acid phosphatase 2, lysosomal
RIKEN cDNA 2010002L15 gene
expressed sequence AI315192
RIKEN cDNA 1110012J22 gene
ESTs
RIKEN cDNA 1110021E09 gene
neuronal PAS domain protein 1 (nPAS 1)
RIKEN cDNA 2410018G23 gene
phospholipase A2, group IID
ESTs
RIKEN cDNA 5830401B18 gene
similar to cleavage stimulation factor subunit 3
Structural protein of Rauscher oncovirus p10
DAP-1

4.79
4.3
4.16
4.01
3.92
3.53
3.42
3.38
3.35
3.19
3.12
3.07
2.95
2.63
2.63
2.56
2.55
2.5
2.49
2.44
2.43
2.43
2.41
2.4
2.36
2.32
2.3
2.28
2.26
2.19
2.19
2.19
2.19
2.18
1.15
2.05
2.04

Table 4.2. Nova1-dependent changes in polyribosomal mRNAs. mRNA targets
increased or decreased in Nova-1 KO polyribosomes relative to wild type polyribosomes
and normalized to total RNA signal for each gene and genotype. Genes are boxed by
color according to function.
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More recently, our lab has identified and validated an extensive network of Nova1 and Nova-2 RNA targets through two novel methods, cross-linked immunoprecipitation
(CLIP, (Ule et al., 2005a)) and a custom Affymetrix splicing microarray (Ule et al.,
2005b).

For 1143 validated Nova targets, 1480 unique Affymetrix probesets were

identified on the MGU74v2ABC GeneChips. While this list of validated Nova target
RNAs does not overlap with those in Table 4.2, using this validated target list, the
complements of Nova-1 wild type and knockout polyribosomal mRNAs were compared
anew. Figure 4.4 illustrates the mean signal values each gene in Nova-1 knockout and
wild type polyribosomes for each of the three GeneChips (A, B, and C) for the
MGU74v2 mouse genome set. For each chip type, gene signals from polyribosomal and
total RNA samples are shown for wild type and Nova-1 knockout (left panels), and after
normalization to the corresponding signal from total RNA by genotype (right panel).
These gene expression patterns are clustered by similarity. It is interesting to note that
while the majority of these RNAs show a great change between polyribosomal and total
RNA distributions, none show a wild type vs. Nova-1 knockout fold-change of 2.0 or
greater using either normalization scheme (Figure 4.4).

Validation of possible

translational targets of Nova-1 identified in Table 4.2 bears further investigation with
methods designed to maximize the signal: noise ratio.
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Polyribosomal profiles of Nova CLIP and splicing target mRNAs.

Validated RNA targets identified by CLIP or splicing microarray methods (Ule et al.,
2003; Ule et al., 2005b) were interrogated by MGU74v2 A, B, and C GeneChips (A, B,
and C panels, respectively.)

Left panels show dendrograms of probeset signals

normalized by the standard GCRMA algorithm.

Right panels show the same

polyribosomal RNA probesets normalized to total RNA signal by genotype after
GCRMA processing.
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Fmr1 wild type versus knockout cerebral cortex
The identification of mRNA targets of FMRP is a goal of many laboratories in the
field. Several laboratories have identified putative G-quartet-containing mRNA targets of
FMRP. Because additional KH2-binding mRNA targets may not have been identified by
these studies, we have performed a microarray screen to identify mRNAs that are
differentially associated with polyribosomes in the cerebral cortex of P7 Fmr1 null mice
(KO) compared to their wild type littermates (WT). To control for sex differences, only
male mice were used.

Briefly, cytoplasmic lysates from cerebral cortices (two per

gradient) were prepared in buffer containing 1% NP40 and 5mM MgCl2. 20% of total
lysate was taken for total RNA. The remaining sample was fractionated by gradient
centrifugation on a 20-50% sucrose gradient. Fractions were collected and 15% of each
fraction analyzed by Western blot. RNA was extracted from the remaining 85% of each
fraction.

RNA from fractions 10-13, corresponding to association with 6 or more

ribosomes, was pooled as polyribosomal RNA. Both total and polyribosomal RNAs were
labeled by standard methods and used to interrogate Affymetrix Mouse 430 2.0
GeneChips. Six biological replicates from each genotype were prepared (12 mice from
each genotype, 24 microarrays encompassing four groups with six replicates each). A
representative profile and Western blots are shown in Figure 4.5. Data was analyzed
using the Robust Multi-Array Average (GCRMA) method (Irizarry et al., 2003),
GeneTraffic (Iobion/Stratagene), and GeneSpring 7.3 (Agilent). Comparisons between
WT and Fmr1 KO polyribosomal mRNA levels directly (Figure 4.6A), or after
normalization of each probeset to its mean signal in Total RNA by genotype (Figure
4.6B), show that few probesets lie outside the two-fold difference cutoff (black lines).
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Figure 4.5 Polyribosomal fractionation of wild type and FMRP KO mouse brain.
Two cerebral cortices from postnatal day 7 mice were used for each 20-50% (w/w)
gradient. Fraction 1 corresponds to the 0% sucrose brain lysate loaded on top of the 2050% gradient. Fraction 16 is the heaviest 0.75ml fraction from each 12ml gradient. A
representative RNA absorbance profile is shown at top. Western blots are shown for
anti-FMRP (1C3, Chemicon) and ribosomal protein S6. Fractions 10-13 (boxed) were
pooled from each gradient for extraction of polyribosomal RNA. Signal for FMRP in the
FMRP KO sample is due to 1C3 cross-reaction with FXR1. (+: positive control for
FMRP and S6 proteins)
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Notably, Fmr1 is the only gene with a signal difference of greater than 2-fold (3
probesets show 6.4-fold, 4.1-fold, and 1.7-fold increases in WT polyribosomal RNA.)
Genes with signal differences greater than 1.27 are listed in Figure 4.6C and Table 4.3 (of
these, the highest fold change is a 1.42-fold decrease). Of these 39 genes, only three are
increased in KO polyribosomes, while 36 are decreased.

In addition, three genes,

gelsolin, proteolipid protein (Plp), and tuberin-like protein 1 were exhibited similar
changes in two probesets on the chips. Of note, FMRP has previously been shown to
bind Plp mRNA (Wang et al., 2004). A comparison of total RNA from WT and KO
animals (Figure 4.7) reveals decreases of 4.9-fold, 3.25-fold, and 1.45-fold for the three
Fmr1 probesets in KO total RNA. Again Fmr1 is the only gene with a fold change above
2. No genes show an increase greater than 1.27-fold in KO total RNA. 38 genes exhibit
signal decreases between 1.27-fold and 1.8-fold in KO total RNA, and are listed in Table
4.4. Of these, receptor (calcitonin) activity modifying protein 2 (Ramp2) exhibits a
greater than 1.27 fold decrease in 3 probesets, and calbindin 1 and cartilage link protein 1
show decreases in 2 probesets each. Calbindin 1 and RGS13 have been previously
identified as FMRP targets by APRA (Miyashiro et al., 2003).
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A

C

WT Polyribosome
Vacuolar protein sorting 35
Stearoyl-Coenzyme A desaturase 2
Spectrin beta 2
Adenomatosis polyposis coli
NA
L1 cell adhesion molecule
Fmr1
RIKEN cDNA 11100020L19
RIKEN cDNA 17000298D6
Proteolipid protein
Fmr1
Serologically defined colon cancer antigen
33
RIKEN cDNA 4833415N24
Splicing factor 3b, subunit 2
RIKEN cDNA 8430415B05
Phosphofructokinase, platelet
Retinoblastoma binding protein 1-like 1
RIKEN cDNA 2810017B07
Amyloid beta (A4) precursor-like protein 2
RIKEN cDNA 4930438O05
Creatine kinase, mitochondrial 1, ubiquitous
Janus kinase 1
RIKEN cDNA 9930028C20
Solute carrier family 18, member 2
Gelsolin
Zinc finger protein 291
RIKEN cDNA 2350035C23
RIKEN cDNA 9630020E24
Abelson helper integration site
RIKEN cDNA 2810482G21
Carboxypeptidase D
Topoisomerase II beta
Protein kinase C epsilon
Proteolipid protein
RIKEN cDNA 2900054D09
Fmr1
Dynamin 1-like
Gelsolin
Tuberin-like protein 1
Erythrocyte protein band 4.1-like 2
RIKEN cDNA 9930033H14
RIKEN cDNA 4833415N24
Leucine-rich repeat LGI family, member 3

KO Polyribosome

B
WT Polyribosome

KO Polyribosome

Figure 4.6 Wild type versus FMRP knockout polyribosomal mRNAs. (A) Mean
signals from wild type polyribosome chips are compared to signals from FMRP knockout
polyribosome chips for all probesets interrogated (MG430 2.0 GeneChip). Black lines
indicate a two-fold change. (B) Comparison as in (A), except mean polyribosomal
signals have been normalized to total mRNA levels by genotype for each probeset. (C)
Probesets exhibiting a fold-change greater than 1.27 between wild type and knockout
polyribosomes. Mean signals shown as a comparison to a baseline WT Total signal for
each probeset.
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mRNAs changed in Fmr1 knockout polyribosomal RNA

Table 4.3 Probesets with fold-change ≥ 1.27 between wild type and FMRP knockout
polyribosomes.

WT Total

KO Total
Figure 4.7 Wild type versus knockout total RNAs. Mean signals from wild type and
FMRP knockout total RNA chips are compared for all probesets. Black lines indicate a
two-fold change.
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mRNAs changed in Fmr1 knockout total RNA

Table 4.4 Probesets with fold-change ≥ 1.27 between wild type and FMRP knockout
total RNAs.

To assess the quality of this microarray data, we can look at several positive
controls incorporated into the experimental design. The significant decrease in Fmr1 on
all KO chips confirms the genotypes of the mice used and the ability of these arrays to
detect a change of this magnitude. The quality of the polyribosome preparations can be
assessed by comparing polyribosomal RNA to total RNA for wild type mouse cortex.
This comparison identifies 18 probesets that increase greater than 2-fold in polyribosomal
RNA, and 878 probesets that decrease greater than two-fold (Figure 4.8), none of which
show significant changes in FMRP knockout mouse brain. Of the 878 probesets that
decrease, at least 32 assay for ribosomal protein mRNAs and identify a minimum of 24
different ribosomal proteins. This is consistent with work showing that many mRNAs
encoding ribosomal proteins also contain a 5’ terminal oligopyrimidine tract (TOP
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WT
Total

KO
Total

WT
Poly

KO
Poly

18 probesets
increased in
polyribosomes

878 probesets decreased
in polyribosomes
32 are mRNAs for
ribosomal proteins

Figure 4.8 mRNAs that differ between wild type polyribosome and wild type total
with fold change ≥ 2.

GCRMA-normalized intensities of probeset signals were

compared by t-test between WT total RNA and WT polyribosomal RNA (knockout
groups were not included for this comparison.) Probesets are grouped by signal pattern
similarity and are displayed for all four conditions.
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mRNAs), and that such mRNAs are translationally repressed in non-dividing cells
(Meyuhas, 2000).
Recent work by Julie Zang has identified mRNAs that UV cross-link to FMRP in
vivo. To look specifically at these FMRP target mRNAs, 1451 Affymetrix probesets were
identified for 1254 FMRP CLIP tag sequences. A direct comparison of WT and KO
polyribosomal signals for these mRNAs is shown in Figure 4.9A. None exhibit greater
than two-fold differences between groups. Likewise, none exhibit greater than two-fold
difference between WT and KO total samples (Figure 4.9B). FMRP target mRNAs are
grouped by polyribosomal profile pattern between WT and KO mice in Figure 4.9C. To
correct for transcriptional changes between WT and KO mice, these analyses were
repeated after normalization of polyribosomal signals to total signals by genotype and
probeset (Figures 4.9D,E). Our polyribosomal pattern profile data does not indicate that
there is an obvious, reproducible change in polyribosomal association of target mRNAs
in the absence of FMRP.
Given the lack of robust FMRP-dependent polyribosomal association of target
mRNAs, together with the confirmation of expected results for Fmr1 and TOP mRNAs,
we can hypothesize that perhaps the presence of FMRP shifts a target mRNA in a subtle
fashion between polyribosome fractions (for example, a shift from 15 ribosomes to 8
ribosomes). Thus it may be worthwhile to use real-time PCR to compare the distribution
of the identified mRNAs (from the polyribosomal RNA comparison between WT and
KO) over all individual fractions of the polyribosomal gradients of WT and KO cortices,
thereby confirming, for example, a decrease in polyribosome association by a
corresponding increase in mRNP representation for a given target. This method may
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Figure 4.9 Polyribosomal distributions of FMRP CLIP target mRNAs. mRNAs that
UV-crosslink with FMRP in vivo are interrogated by probesets on MG430 2.0
GeneChips. (A, B) Scatter plots of probeset signals compared between WT and FMRP
KO polyribosomal (A), and total RNA (B), standard GCRMA normalization, black lines
indicate two-fold change. (C) Dendrogram of probesets normalized by the standard
GCRMA algorithm. (D) Scatter plot of probeset signals for WT vs. KO polyribosomes
normalized to respective total signals. (E) Dendrogram of probesets: polyribosomal
signals normalized to total RNA signal by genotype after GCRMA processing.
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further elucidate the mechanism of FMRP, since data from previous studies is
inconsistent as to whether FMRP increases or decreases translation of target mRNAs
(Brown et al., 2001; Chen et al., 2003; Darnell et al., 2001).

Confirmation of

translational regulation at the protein level by Western blot remains a more definitive
method of validation, but presents its own difficulties in achieving an adequate signal to
noise ratio. Other possible issues in this work include the influence of neurotransmitter
stimulation for FMRP action, and/or FMRP function at a small subset of polyribosomes
in the cerebral cortex. Only a handful of mRNA targets have validated FMRP-dependent
changes in protein level (Chen et al., 2003; Hou et al., 2006; Lu et al., 2004; Miyashiro et
al., 2003; Wang et al., 2004; Zhang et al., 2001).
Since FMRP is consistently associated with the most rapidly sedimenting
polyribosomes in neurons, these data present three possibilities for a role of FMRP in
translational regulation. First, FMRP may be associated with population of RNAs that are
particularly lengthy. This is not the case in this data set, since the mRNAs in Table 4.3
average 2570nt in length, with a distribution of 626 – 5995nt. Second, FMRP may be
associated with a population of mRNAs that are translated at a slower rate. Finally,
mRNAs associated with FMRP may be stalled in translation, with many ribosomes bound
but little translation occurring.

Discussion
These data present a picture of the steady-state translational profiles of mRNAs in
the central nervous systems of two mouse models of human disease. What is most
remarkable is the very lack of robust changes in polyribosomal associations of mRNA
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targets of these disease-related RNA-binding proteins. The expected number of false
positive results exceeds the number of probesets with significant changes identified in
each experiment. For example, of the 36,000 probesets included on the MGU74v2
GeneChips, 1,800 probesets are expected to show a false positive change between
conditions at p<0.05 (without multiple testing correction.) In the comparison between
Nova-1 wild type and knockout polyribosomal RNA, using three biological replicates per
condition, only 67 probesets show a fold change greater than 2 with p<0.05 (Table 4.2).
Furthermore, these differences are not reproducible by real-time PCR in our hands.
However, expected results for TOP mRNAs are seen with high significance (p<0.001,
Figures 4.2, Table 4.1). This contrast between a comparison by genotype (wild type
versus knockout) and by fractionation (total RNA versus polyribosomal RNA) is even
more striking when six biological replicates are used for each condition. When FMRP
wild type total RNA is compared to wild type polyribosomal RNA, 896 probesets are
identified with a fold change greater than two. Yet, when wild type mouse cortex is
compared to FMRP knockout cortex for either total or polyribosomal mRNA populations,
the only probesets showing a difference greater than two-fold hybridize to the Fmr1
mRNA itself. These data stand in stark contrast to the 426 mRNAs identified previously
as increasing or decreasing greater than two-fold in fragile X lymphoblastoid cell lines
(Brown et al., 2001). There are a number of reasons for this contrast. Our experiments
used inbred mouse cerebral cortices with six biological replicates per condition,
compared to the five independently transformed lymphoblastoid cell lines from nongenetically identical humans for each condition. Furthermore, we were able to use later
generation microarray technology and analytic software, which may further decrease the
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statistical impact of outlier data points. Taken together, these data indicate that the
steady-state transcriptional and translational profiles do not exhibit significant changes in
the absence of Nova-1 or FMRP.
Efforts to maximize the signal to noise ratio in polyribosomal profile pattern
analysis by microarray are ongoing in our laboratory. For the Nova proteins, double
Nova-1 and Nova-2 knockout mouse brains show increased splicing affects for target
RNAs (M. Ruggiu, J. Ule, H. Wang, and A. Mele, unpublished data.) It is likely that any
affect of Nova on polyribosomal association of target mRNAs will be amplified in double
knockout mice.
Similarly, two neuronal proteins closely related to FMRP, FXR1 and FXR2, may
share redundant functions with FMRP. A mouse model that eliminates the contributions
of all three of these proteins in neurons would be an ideally suited for polyribosomal
mRNA interrogation of microarrays. Furthermore, recent evidence indicates that FMRP
can contribute to activity-dependent, rapid fluctuations in protein levels in hippocampal
neurons (Hou et al., 2006). The magnitude of these DHPG-induced protein changes is at
most a 50% change, as assayed by Western blot. Thus, real changes in polyribosomal
association that occur in response to activity in specific neurons are likely to be
overwhelmed by the steady state levels of mRNA translation that exist in the unaffected
neurons and glia in mouse cerebral cortex. Other methods could include chemical or
electrical stimulation of neuronal activity to increase the FMRP-dependent change in
polyribosomal mRNAs. A more rigorous dissection of polyribosomal profile patterns for
FMRP target mRNAs under a variety of conditions including synaptic activity and/or
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abrogation of redundant function of FMRP-related proteins may provide a foundation for
future research evaluating the mechanism of translational regulation by FMRP.
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CHAPTER V: KISSING COMPLEX RNA MEDIATES INTERACTION
BETWEEN FMRP AND BRAIN POLYRIBOSOMES

Introduction
Fragile-X Mental Retardation Protein (FMRP), the product of the FMR1 gene, is
characterized by a number of protein-protein interaction domains, and three RNAbinding domains, specifically two tandem KH-type RNA-binding domains and a third
RGG-type RNA-binding domain (RGG box). Although transcriptional silencing of
FMR1 due to trinucleotide repeat expansion and hypermethylation is the most frequent
cause of the disorder, patients expressing mutations or deletions within FMR1 have been
described (Jin and Warren, 2003), emphasizing that loss of FMRP function leads to the
Fragile-X syndrome. Given that the loss of FMRP activity leads to complex behavioral
and cognitive deficits, understanding FMRP function has the potential to provide a link
between molecular neurobiology and higher brain function.
FMRP is believed to regulate mRNA translation in the brain, although the
mechanism for this action, and the RNA targets of this regulation, are unknown. We and
others have demonstrated that FMRP is present on polyribosome fractions from both
brain and tissue culture cells. (Corbin et al., 1997; Feng et al., 1997a; Feng et al., 1997b;
Khandjian et al., 1996; Khandjian et al., 2004; Stefani et al., 2004) Additional data
suggests that there may be a link between FMRP function and microRNA (miRNA)
regulation of translation, since miRNAs are associated with polyribosomes (Bartel,
2004), and FMRP co-purifies with components of the RNA-induced silencing complex
(RISC) (Caudy et al., 2003; Caudy et al., 2002; Ishizuka et al., 2002; Jin et al., 2004).
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Previous studies in cell lines have examined the requirement of various domains
of FMRP for association with polyribosomes. EBV-transformed lymphoblastoid cell
lines from a patient with a missense mutation (I304N) in FMRP have been used to study
the impact of this mutation on the association of FMRP with polyribosomes. Located in
KH2, the I304N mutation does not impair capture of FMRP via association with poly(A)
RNA, so mRNA binding is still possible for this mutant. However, association of FMRP
with polyribosomes is abolished by I304N, and mRNPs containing I304N are abnormally
small. (Siomi et al., 1994) FXR2P, an FMRP ortholog and interacting protein, remains
associated with polyribosomes in the presence of I304N FMRP. (Feng et al., 1997a)
Transfections of FMRP deletion constructs into an FMRP-null cell line reveal that the
protein-protein interaction (PPId), KH1 and KH2 domains are all required for association
with polyribosomes. Point mutations in either KH1 (I241N) or KH2 (I304N) abrogate
binding of FMRP to polyribosomes and show a diffuse cytoplasmic distribution. In
contrast, deletion of the RGG box results in a wild type distribution of FMRP on
polyribosomes and punctate cytoplasmic distribution. (Darnell et al., 2005b)
Interestingly PPId and KH1, but not KH2, are required for FMRP interaction with
FXR1P, in an RNA-independent manner. Finally, the RGG box seems to be required for
incorporation of FMRP into temperature-sensitive stress granules in the cytoplasm of
cells. (Mazroui et al., 2003) In the phosphorylation domain (Phd) of FMRP, Ser499 can
be phosphorylated by casein kinase II (CKII). Phosphorylation of FMRP at this site has
been shown to be associated with stalled polyribosomes in cell culture, while Ser499Ala
FMRP is associated with actively translating polyribosomes. Phosphorylation seems to
have no effect on the magnesium- and RNA- dependence of FMRP association with
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polyribosomes, and hasn’t shown an effect on FMRP binding to known targets in vivo
(although an effect of phosphorylation on dFMR binding to ribohomopolymers has been
demonstrated.) (Ceman et al., 2003; Siomi et al., 2002) Thus it seems that the KH2
and/or KH1 domains of FMRP, but not the RGG box, are required for association with
actively translating polyribosomes.
The finding that the I304N mutation can reduce FMRP binding to
ribohomopolymers offers a clue to the function of the KH2 domain. (Siomi et al., 1994)
Structure-studies of KH domains from analogous proteins indicate that the FMRP I304N
mutation maps to the RNA binding pocket and is critical for stabilizing sequence-specific
RNA-protein interactions. (Lewis et al., 2000; Ramos et al., 2003b) RNA selection with
full-length FMRP has led to the identification of high-affinity FMRP RNA ligands that
harbor a signature structural motif termed a G-quartet. (Brown et al., 2001; Darnell et al.,
2001) G-quartets are stacked coplanar arrays of 4 guanine bases each, stabilized by
cyclic Hoogsteen bonding between guanines. Of the three RNA-binding domains in
FMRP, G-quartet RNA binding maps to the RGG box. (Darnell et al., 2001) Evaluation
for G-quartets has been widely used to screen candidate FMRP RNA targets, identified
through a variety of approaches, including bioinformatics, immunoprecipitation and
DNA chip analysis, antibody-positioned RNA amplification, and biochemical
approaches. (Brown et al., 2001; Darnell et al., 2001; Miyashiro et al., 2003; Schaeffer et
al., 2001; Todd et al., 2003) Biochemical studies have suggested that FMRP may
associate with specific mRNAs on polyribosomes; several mRNAs were found to have
altered polyribosome distributions in lymphoblastoid cells obtained from Fragile X
patient cells and to harbor G-quartet motifs. (Brown et al., 2001; Darnell et al., 2001)
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Subsequent analysis of one of these targets, MAP1B, suggests that the Drosophila
homolog of this protein (futsch) may be regulated at the translational level by the
Drosophila FMRP homolog, dFMR. (Zhang et al., 2001)
Subsequent RNA selection with the KH1 and KH2 domains of FMRP identified a
loop-loop pseudoknot, or “kissing complex” motif as a high affinity ligand for KH2.
(Darnell et al., 2005a) The nature of the kissing complex structure, containing two stemloops that form a third stem and an additional inter-loop base pair, has prevented easy
identification of endogenous kissing complex RNAs that may be regulated by FMRP.
Detailed analysis of the FMRP KH domain-RNA interaction revealed that binding to the
kissing complex is KH2-specific, and is abrogated by the I304N mutation. Binding is
dependent in part on the RNA structure and on several specific nucleotides, as indicated
by Mg+2-dependence, chemical modification, and mutational analysis. (Darnell et al.,
2005a)
Identification of the kissing complex as a KH2 target allowed us to re-examine
the nature of FMRP association with polyribosomes. We find that the association of
FMRP with brain polyribosomes is entirely and specifically competed by kissing
complex RNAs. These results suggest that mental retardation associated with the I304N
mutation, and likely the Fragile-X syndrome more generally, may relate to a crucial role
for RNAs harboring kissing complex motifs as targets or mediators of FMRP
translational regulation.
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Results
FMRP RNA-binding domains bind different high affinity RNA ligands
We have tested the hypothesis that the RNA-binding ability of KH2 may mediate
polyribosome association with a novel method that forces endogenous FMRP in mouse
brain lysate to choose between binding a high affinity RNA ligand and binding its
endogenous RNA targets, in a domain-specific manner. Our lab has identified high
affinity RNA target ligands through in vitro RNA selection (SELEX) of a pool of random
96-mers for FMRP binding. (Darnell et al., 2005a; Darnell et al., 2001) Two groups of
target sequences have been identified. Those that bind preferentially to the RGG box of
FMRP contain a G quartet structure that is required for binding (gqRNAs), and those that
bind to KH2 exhibit a loop-loop pseudoknot “kissing complex” structure. This binding is
sequence- and structure- specific, as mutations in the RNAs and or protein domains can
abrogate binding. (For a thorough treatment, see details in (Darnell et al., 2005a; Darnell
et al., 2001)). Figure 5.1 shows the an experimentally derived structure for high affinity
RNA ligands of the G-quartet type (sc1; Figure 5.1A; adapted from (Darnell et al., 2001))
an M-Fold predicted structure for an RNA of the kissing complex type (kc2; Figure 5.1B;
(Zuker, 2003)). A mutation that abrogates binding to FMRP is indicated for each. A
consensus structure from experimental data for kcRNA folding is shown in Figure 5.1C
and illustrates the requirement for an inter-loop stem and a Watson-Crick base pair “kiss”
between the opposite sides of the loops (Darnell et al., 2005a).

72

C.

A.

*
*

B.
B.

G34
C

*G23
C

*
Figure 5.1 Experimental and predicted structures of FMRP RNA ligands. (A)
Experimentally derived G-quartet RNA structure of sc1 RNA (Darnell et al., 2001),
arrow indicates a mutation that abrogates binding to FMRP.

(B) Mfold-predicted

structure of kc2 RNA folding (Zuker, 2003). Green dots indicate nucleotides that form a
stem between loops. Pink asterisks indicate the base-pair “kiss” between opposing sides
of the loops.

The G23C mutation prevents this “kiss” and binding by FMRP. (C) An

experimentally derived model of the consensus kissing complex RNA motif (Darnell et
al., 2005a).
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kcRNA can shift FMRP off polyribosomes in brain lysate
The first suggestion that FMRP might be involved in translational regulation was
based on findings that it associated with polyribosomes in tissue culture cell lines, and
that this association was abrogated by the I304N mutation. We have used both kcRNAs
and gqRNAs to compete with endogenous RNAs for FMRP binding as a tool to analyze
the importance of KH2 and RGG RNA-binding domains on FMRP association with
polyribosomes. As an initial experiment, post-mitochondrial supernatant from postnatal
day 9 mouse cerebral cortex was prepared using standard conditions for polyribosome
analysis. This lysate was incubated with either 500nM in vitro transcribed kc1 RNA or
an equal volume of RNA folding buffer (1X SBB) for 15 minutes at room temperature.
Samples were then loaded on 20-50% (w/w) sucrose gradients and analyzed using
standard methods. The resulting Western blots are shown in Figure 5.2. While the
distributions of ribosomal protein S6 (rpS6) and gamma tubulin remain consistent
between samples, the distribution of FMRP changes dramatically in the sample treated
with kc1 RNA. While FMRP signal peaks in fractions 13-20 in the control sample, all
FMRP in the kc1 RNA-treated gradient is located in fractions 3-6, a complete shift to the
lighter area of the gradient.

Thus, it appears that in the presence of kcRNA, FMRP

dissociates from a fast-sedimenting complex into a smaller particle. Since kcRNA does
not disrupt the distribution of the small ribosomal subunit (as shown by rpS6), and since
FMRP has been shown to associate with actively translating polyribosomes (Stefani et
al., 2004), it is a reasonable hypothesis that the presence of kcRNA results in the specific
dissociation of FMRP from polyribosomes in brain lysate, leaving previously FMRPbound polyribosomes intact. This is consistent with previously published data showing
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that the KH2 domain is required for FMRP cosedimentation with polyribosomes.
(Darnell et al., 2005b; Mazroui et al., 2003)
To look for a dose-dependent effect on competition of kcRNA with endogenous
targets that mediate the FMRP:polyribosome complex, and to define the approximate
affinity of this interaction, we tested increasing concentrations of kcRNA. When brain
polyribosomes were incubated with 3-500nM kc2 RNA, we observed a dramatic dosedependent shift in FMRP sedimentation from the polyribosomal fractions to light
fractions corresponding to a size smaller than the 40S ribosomal subunit (Figure 5.3B).
As seen with kc1 RNA, FMRP shifts from fractions 10-14 (of 16) to fractions 2-4 when
in the presence of 500 nM kc2 RNA. The global polyribosomal profile was unchanged, as
shown by UV absorbance tracings for 0nM and 500nM kc2 RNA (Figure 5.3A).
Quantitation reveals that the half-maximal FMRP shift off polyribosomes occurred at an
RNA concentration of approximately 100nM (Figure 5.3C), similar to the KD for FMRP
binding kc2 RNA in vitro (~66nM). The ability of kissing complex RNA ligands to
compete endogenous FMRP off polyribosomes suggests that this ligand mimics the site
FMRP uses to regulate translation in neurons.

FMRP:polyribosomes are specifically dissociated by kcRNA
To assess the specificity of these results, and to further probe the role of RGG
box-mediated RNA binding in FMRP polyribosome association, the experiment was
repeated with sc1 RNA, a G-quartet ligand (gqRNA) for the RGG box. Sc1 RNA binds
purified FMRP with an affinity of approximately 8nM in vitro. (Darnell et al., 2001) As
a critical control, we tested mut kc2, a point mutant in kc2 that destroys a critical base

76

Figure 5.3 Exogenous kc2 RNA dissociates FMRP from polyribosomes in a
dose-dependent manner. (A) P8 mouse cerebral cortical extracts were separated
by sucrose density gradient (20%-50%) centrifugation; positions of the 80S
monosome and polyribosomes are indicated. Indicated amounts of kc2 RNA were
added to brain lysates and incubated for 15 min at room temperature prior to
centrifugation. A254 profile of sucrose density gradients for the lowest and
highest kc2 RNA concentrations are shown; A254 profiles for all kc2
concentrations were indistinguishable (data not shown). (B) Western blots of
indicated fractions from sucrose density gradients incubated with the indicated
kc2 concentration were probed with the FMRP monoclonal antibody 1C3.
Fractions corresponding to 40S, 60S, and 80S ribosomal peaks are indicated.
Ribosomal protein S6 was unshifted at all kc2 concentrations (data not shown).
(C) Quantitation by chemiluminescence of the Western blot data in B (Versadoc
imaging); the percentage of FMRP present in each fraction as a function of the
total FMRP signal in that gradient is indicated. Inset shows a plot of the percent of
FMRP shifted off the polyribosomes plotted against kc2 concentration
(nanomolar). The half-maximal concentration of kc2 able to compete FMRP off
of polyribosome fractions is ~100 nM kc2 RNA.
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pair in the loop-loop interaction (G23C, see Figure 5.1, (Darnell et al., 2005a)), and mut
sc1, a point mutant in sc1 that destroys the G-quartet (G34C, (Darnell et al., 2001)). In
each case, the association of FMRP with polyribosomes was unaffected (Figure 5.4). As
an additional control, we evaluated sedimentation of the neuronal Hu RNA-binding
proteins, since the nonneuronal Hu isoform is known to be polyribosome associated.
(Gallouzi et al., 2000; Okano and Darnell, 1997) We found that the neuronal Hu proteins
are polyribosome associated in mouse brain, but that neither kcRNA nor gqRNA was
able to disrupt this association (Figure 5.4). These results demonstrate that kcRNA
specifically disrupts FMRP polyribosome association. Taken together, these experiments
suggest that the binding of KH2 to kissing complex RNA ligands may mediate
polyribosomal association in the brain, while association of the RGG box with G-quartets
is not required for stability of the complex.
The ability of kcRNA to fold correctly and bind KH2 is dependent on the
presence of a magnesium ion coordinated between the two loops of the pseudoknot. As a
result, KH2 is unable to bind kcRNA in the presence of EDTA. (Darnell et al., 2005a)
However, the interaction between the RGG box and gqRNA is unaffected by EDTA.
(Darnell et al., 2001) To confirm that even an increased concentration of gqRNA is not
able to change the sedimentation rate of polyribosome-associated FMRP complexes,
brain lysate was incubated with 5µM sc1 RNA (Figure 5.5). Although there is some
variation between the FMRP distributions of 500nM sc1 and mut sc1, 5µM sc1 RNA and
control samples, there is no consistent effect of gqRNA, even at a concentration
approximately 500 times that of its in vitro affinity for FMRP. To analyze whether
competition with gqRNA is able to change the sedimentation rate of smaller FMRP
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Polyribosomes

Figure 5.4 Kissing complex, but not G-quartet RNA, competes FMRP off
polyribosomes. Western blot as in Figure 5.3 of sucrose density gradients in which
indicated RNAs were used to compete FMRP polyribosomal association; mut kc2
harbors a single point mutation in kc2 RNA, and mut sc1 harbors a single point mutation
that destroys G-quartet formation and FMRP binding (indicated in Figure 5.1). Western
blots were probed with antibodies to the indicated proteins, including FMRP, ribosomal
protein S6, and the Hu family of RNA-binding proteins.
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mRNPs that have been dissociated from polyribosomes (see Figure 3.4D), brain lysate
was incubated with 500nM sc1 or mut sc1 RNA plus 30mM EDTA. UV absorbance
profiles for RNA+EDTA-treated samples do not differ from a profile of a sample treated
with EDTA alone (Figure 5.5A). Western blots for these gradients reveal that FMRP is
located in fractions 2-7, as expected since EDTA disrupts polyribosomes. (See Chapter 3;
(Stefani et al., 2004))

However, as shown in Figure 5.5B, there is no significant

difference between the FMRP distributions for sc1 + EDTA and mut sc1 + EDTA. In
addition, incubation of lysate with both kcRNA and gqRNA produces an FMRP
distribution that is identical to that of treatment with kcRNA alone (Figure 5.4, bottom
panel). While these data suggest that gqRNA targets are not involved in regulating
whether FMRP is associated with large complexes, this result does not rule out the
possibility that FMRP mRNPs (that have been dissociated from polyribosomes by
EDTA) contain G-quartet mRNAs. This question warrants further investigation using 525% sucrose gradients for a finer assessment of FMRP sedimentation rates under these
conditions, and is being pursued by another PhD candidate in the lab.
We

also

examined

whether

an

irrelevant

RNA

could

disrupt

the

FMRP:polyribosome interaction. Nova proteins contain KH-type RNA-binding domains
that bind in vitro selected RNAs harboring a stem-loop structure and a YCAY motif.
“10021” RNA binds Nova KH domains with an affinity of ~500nM. (Jensen et al.,
2000b) Competition for KH-mediated RNA binding by 30uM 10021 RNA does not
disrupt the interaction of Nova with large complexes (Figure 5.6A). Furthermore, 10021
RNA does not affect FMRP distribution, as shown in Figure 5.6B. Thus, a high affinity
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Figure 5.5 sc1 RNA does not change FMRP distribution on polyribosomes or in
EDTA-liberated mRNPs. A254 profiles (A) and Western blots (B) for mouse cerebral
cortex treated with sc1 RNA, mutant sc1 RNA and/or EDTA before sucrose
centrifugation.

The in vitro binding affinity of the FMRP RGG box for sc1 is

approximately 8nM (Darnell et al., 2001).
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Figure 5.6 Sucrose gradient distributions of Nova-1, Nova-2 and FMRP are
unaffected by the presence of 10021, an RNA ligand for the Nova KH domains.
Western blots for Nova (A) and FMRP (B) from TCA-precipitated sucrose gradient
fractions analyzing mouse cerebral cortex lysate under treatment with exogenous 10021
RNA and/or EDTA.
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RNA ligand that binds a KH domain of another RBP is not able to disrupt the interaction
of FMRP with polyribosomes.

BC1 RNA and tRNA do not compete for KH2 binding
It has recently been reported that FMRP binding to BC1, a neuron-specific,
dendritically localized nontranslatable RNA (Brosius and Tiedge, 2001), may play a role
in modulating mRNA translation (Zalfa et al., 2003). It has also been reported that
FMRP binds to highly structured RNAs such as tRNA. (Gabus et al., 2004) We tested
whether an excess of BC1 RNA or tRNA was able to compete FMRP off polyribosomes
(Figure 5.7). Addition of up to 5 µM BC1 (Figure 5.7A) or tRNA (Figure 5.7B) to
cortical lysates fails to compete with the in vivo binding site of FMRP on polyribosomes
and displace it. Moreover, although BC1 has been shown to be involved in the global
regulation of translation (Wang et al., 2005), the polyribosome profile and rpS6
distribution do not change in the presence of a vast excess of this RNA.

Other

researchers have found no significant interaction between FMRP and BC1 (Wang et al.,
2005).

Our results demonstrate that FMRP is specifically associated with brain

polyribosomes, and that this interaction is effectively competed by kissing complex
RNAs.
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Figure 5.7 BC1 RNA and yeast tRNA do not disrupt FMRP interaction with
polyribosomes. A254 traces (A) and Western blot analysis for FMRP or ribosomal S6
protein (B), as in Figure 6. No RNA was added to the control lysates (control). BC1 RNA
(produced by in vitro transcription and gel purified) and yeast tRNA at the indicated
concentrations fail to compete with FMRP binding to polyribosomes.
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kcRNA cross-links directly to FMRP in brain lysate
Despite the fact that FMRP binds kcRNA with high affinity in vitro, the
possibility remains that kcRNA disrupts FMRP:polyribosome complexes by some
mechanism that does not involve stable binding to FMRP. For example, in brain lysate,
kcRNA could act as a “toxic” aptamer, transiently binding FMRP and releasing a
denatured protein. Alternatively, kcRNA could interfere with the FMRP binding site in
translating mRNAs.

In order to address this question and confirm FMRP:kcRNA

complex formation in brain lysate, we used cross-linking immunoprecipitation (CLIP) to
assess whether there is a direct interaction between protein and RNA. CLIP has been
developed and optimized by our lab as a method for rapid identification of in vivo targets
of RNA-binding proteins. (Ule et al., 2005a)

FMRP-specific modifications to this

protocol have been developed by J. Zang and J. C. Darnell (unpublished data.) For this
experiment, a post-mitochondrial supernatant was prepared from wild type or FMR1
knockout mouse cerebral cortex, and divided into two tubes. One set of wild type and
knockout lysates was incubated with 500nM kc7 RNA for 15 minutes at room
temperature. Each sample was then loaded on a 20-50% sucrose gradient, centrifuged and
collected into 16 fractions using standard polyribosome protocols.

After fraction

collection, the first 6 fractions of each gradient were divided equally, and protein from an
aliquot precipitated for Western blot analysis. One half of each fraction was brought to
30mM EDTA, mixed, and placed on ice. Both sets of gradient fractions (intact and
EDTA-treated) were exposed to UV cross-linking (6 X 4000J) while kept on ice and
swirled before each UV exposure. Fractions 1-3 from each gradient and condition were
pooled and FMRP:RNA complexes were immunoprecipitated using mixed monoclonal
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and bridging antibodies with Protein A Dynabeads (see Chapter II for details). After
1:100 digestion with RNase A and a series of stringent washes, radio-labeled RNA
linkers were ligated to RNAs that remained cross-linked to FMRP. These RNAs were
isolated by SDS-PAGE and nitrocellulose blotting (Figure 5.8B), eluted, subjected to
PCR (Figure 5.8C) and cloned. Figure 5.8A shows the FMRP distribution in fractions 16 of the wild type (WT) and kc7 RNA treated-wild type (WTkc7) gradients.

As

expected, there is no signal for FMRP in the knockout (KO) and kc7 RNA treatedknockout (KOkc7) gradients. Of the eight sets of fractions (each gradient +/- EDTA), we
have immunoprecipitated from four: WT+EDTA, WTkc7, WTkc7+EDTA, and
KOkc7+EDTA. After immunoprecipitation and RNA ligation, FMRP-RNA complexes
electrophorese more slowly than non-cross-linked FMRP. Specifically, we can expect
FMRP cross-linked to a RNA of ~100 nucleotides to migrate at about 33 kilo Daltons
larger than that of FMRP alone (68-80kDa) ((Ule et al., 2005a); J. Zang, J. Ule, and A.
Mele, unpublished data.) Figure 5.8B is an autoradiograph from labeled FMRP:RNA
complexes that have been transferred to nitrocellulose after electrophoresis. Specific
bands are visible which correspond to specific RNA species.

A band between

approximately 120kDa and 140kDa (asterisk) is just visible in the WT+EDTA and
KOkc7+EDTA lanes.
dependent.

This is a non-specific band that is neither kc7- nor FMRP-

(It represents contaminating immunoprecipitation of Ago2:miRNA

complexes by the 7G1-1 monoclonal antibody against FMRP that cross-reacts with Ago2
(J. Zang, unpublished data.))
A dark band of ~90-100kDa (§) is visible in the WTkc7 and WT kc7+EDTA
lanes. When cloned and sequenced, 17 of 26 tags from the WTkc7 band are pieces of
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Figure 5.8 kc7 RNA cross-links to FMRP in sucrose gradients. (A) Western blots
against FMRP of fractions 1-6 (of 16) of FMRP wild type and knockout mouse cortex
polyribosomal gradients.

Fractions 1-3 from each gradient are pooled for

immunoprecipitation in (B), an autoradiogram of a nitrocellulose membrane showing
radiolabeled RNA crosslinked to immunoprecipitating proteins. Arrowhead indicates the
expected migration of non-crosslinked FMRP.
membrane, amplified by PCR and gel-purified (C).
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Lettered bands were cut out of the

kc7 RNA. In fact, a closer look at these sequences reveals that every sequence includes
either of the two “kissing” nucleotides (G23 and C64 in kc7, the equivalent of G23 and
C66 in kc2 and G20 and C45 in Δkc2), as shown in Table 5.1. This data from an unbiased
screen supports previous biochemical data describing the sequence and structure
specificities of kissing complex RNA folding and interaction with FMRP. (Darnell et al.,
2005a) The remaining nine sequences from this band are six ribosomal RNAs, one
miRNA, one intronic sequence, and one clone of repeat sequence from genomic DNA.
Notably, kc7 sequences were not found among the KOkc7+EDTA and WTkc7+EDTA
CLIP tags. This indicates that magnesium can be chelated by addition of EDTA when
FMRP has first been incubated with kc7 RNA, and that this chelation disrupts the
FMRP:kc7 interaction, preventing subsequent cross-linking.
The WTkc7+EDTA autoradiograph in Figure 5.8B while very dark, seems to
contain many bands of different sizes, all of which were cloned and sequenced. 18 of 23
CLIP tags from this lane were identified as ribosomal RNAs. These sequences map to
many regions of the full-length 18S and 28S rRNAs. It is possible that FMRP may
interact with ribosomal RNA in vivo. Indeed there is a report that FMRP associates with
the large subunit of the ribosome (Siomi et al., 1996), and there are 6 rRNA CLIP tags
identified from the intact WTkc7 CLIP. However, it is more likely that as a “sticky”
RNA-binding protein newly dissociated from its RNA cargoes by the combination of kc7
followed by EDTA, it is now able to bind to rRNAs, present in great abundance in the
cell. Moreover, EDTA treatment also disrupts the ribosome, exposing surfaces of rRNAs
that are normally inaccessible to FMRP. In addition, rRNAs are the most frequent nonspecific “contaminating” RNAs identified by CLIP for several RNA-binding proteins (J.
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Zang, A. Mele, and J. Ule, unpublished data.) Thus, in the absence of a particular overenriched sequence from either the 18S or 28S species in the resulting CLIP tags, this
interaction may be an artifact and not biologically relevant. Taken together, these data
indicate that FMRP interacts directly with the kcRNA pseudoknot in brain lysate, that
this interaction is stable enough to persist through a two-hour centrifugation and fraction
collection, and that EDTA disrupts this interaction.

kc7 sequence
3’ hairpin (includes C64)
5’ hairpin (includes G23)
rRNA
18S rRNA
28S rRNA
mRNA
miRNA
snRNA
other*
# sequenced
Total CLIP tags

WT
EDTA
-

KOkc7
EDTA
-

6
0
6
2†
1
2
32
11

-

1
1
4
2

WTkc7
17
16
1
6
2
4
1
2
46
26

WTkc7
EDTA
-

18
16
2
4†
1
53
23

Table 5.1 Classification of kc7-shifted FMRP CLIP tags.
Sequences cloned from bands in Figure 5.8C were identified by BLAT (UCSC) and
NCBI BLAST.

Of the total number of clones sequenced, many represented vector

religation or primer-primer ligation events. As such the total number of identifiable
sequences is given as Total CLIP tags. *other sequences include: mitochondrial DNA
(1), genomic DNA (3), intron RNA (1). †mRNAs: cat eye syndrome chromosome region
candidate 6 (Cecr6), cytidine monophospho-N-acetylneuraminic acid synthetase (Cmas),
Fucosyl transferase 10, UDP-Galβ galactosyl transferase 6, RIKEN cDNAs 4930500O05
and G730014J15
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Recombinant KH2 as a competitor for polyribosome association
FMRP:polyribosome complexes can be dissociated by an RNA competitor for
KH2 binding. Therefore, the converse question is relevant: can increased concentrations
of recombinant KH2 compete for endogenous kissing complex-type binding sites on
polyribosomes and thereby displace endogenous FMRP? If so, KH2 could act as a
dominant negative protein that could potentially serve as a tool to inhibit FMRP function
in vivo. To test this hypothesis, we purified two types of recombinant FMRP KH2, a
construct encoding the minimal sequence necessary to bind kcRNA that lacks exons 11
and 12 (KH2 –e11, 12), and a protein that includes the variable loop of exon 11 within
the KH2 domain (KH2 –e12).

Incubation of either of these KH2 isoforms at

concentrations from 500nM to 18µM does not alter the distribution of FMRP (Figure
5.9B, C). As a control, these protein preparations were tested for in vitro kcRNA-binding
ability by filter binding assay. The affinity of KH2 for kc7 RNA has previously been
measured as approximately 35nM (Darnell et al., 2005a). From the binding curves in
Figure 5.9A, the Kd for KH2 (-e11,12) is ~27nM, and the Kd for KH2 (-e12) is ~45nM.
Thus, these preparations of both KH2 isoforms are able to bind kc7 with the expected
affinity, and the presence of exon11 does not affect this binding. While this experiment
shows that using recombinant KH2 as a spiked-in competitor for endogenous KH2 target
RNAs does not disrupt FMRP:polyribosome complexes, there are many caveats to this
result. First, kcRNA is an in vitro selected aptamer that, by definition, will have the
highest possible affinity for KH2.

Therefore, it is a reasonable possibility that

endogenous targets of KH2 have lower affinities and are easily displaced by kcRNA in
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Figure 5.9 Recombinant KH2 does not shift endogenous FMRP off polyribosomes.
(A) Filter binding assays of two preparations of recombinant KH2 (-e11, 12) and (-e12)
show that these preparations bind kc7 RNA with the expected affinity in vitro (~30nM).
(B, C) Western blots for FMRP from mouse cortex polyribosome gradients that have
been treated with various concentrations of recombinant KH2 isoforms.
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our assay. However, recombinant KH2 and full-length FMRP have the same in vitro
affinity for kcRNA. Thus, when competing with endogenous FMRP in brain lysate,
recombinant KH2 does not have the advantage of a higher affinity for RNA targets.
Second, there are as yet no data describing the mechanism by which FMRP binds in vivo
mRNA targets. This process may very well involve other domains in FMRP as discussed
earlier, perhaps in a helicase-type manner that allows another domain to bind an
otherwise hidden site. Or, multiple domains may be required for enhanced stability of the
FMRP:mRNA interaction, perhaps involving several binding sites on a single mRNA.
As a single RNA-binding domain spiked into a cytoplasmic lysate, recombinant KH2
does not see the same opportunities for binding mRNAs during the course of normal
processing events. Finally, KH2 has been shown to be important for heterodimerization
of FMRP with FXR2. (Feng et al., 1997a) This suggests that spiked-in KH2 may be
sequestered by protein-protein interactions and therefore fail to bind endogenous mRNA
targets. An alternative scenario hinges on the likelihood that FMRP may bind its mRNA
targets in the nucleus and participate in their export, transport, and translation. All of
these issues bear investigation. Further study is warranted to more precisely elucidate the
role of the KH2 domain in FMRP function.

Discussion
Fragile-X mental retardation results from mutations that lead to loss of FMRP
function. In particular, the substitution of an arginine for a conserved isoleucine in the
second KH domain results in a severe form of Fragile-X mental retardation syndrome,
and abrogates polyribosome association (De Boulle et al., 1993; Feng et al., 1997a).
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However, there have been various interpretations of the latter observation, including
suggestions that the I304N mutation interferes with protein homodimerization
(Laggerbauer et al., 2001), disrupts heterodimerization with FXR2 (Feng et al., 1997a),
causes protein instability (Musco et al., 1996), or abrogates sequence-specific RNA
binding (Lewis et al., 2000; Ramos et al., 2003a). To specifically target the contributions
of KH2 to normal FMRP function in neurons, we have used high affinity RNA ligands to
compete for binding to either the KH2 or RGG RNA-binding domain. The kissing
complex ligand for KH2 is a unique structure motif that offers clues to the mechanism of
FMRP interaction with polyribosomes. The I304N mutant FMRP is associated with
abnormally small mRNPs rather than polyribosomes (Feng et al., 1997a), and does not
bind kissing complex RNAs in vitro (Darnell et al., 2005a). We find that the association
of FMRP with brain polyribosomes is specifically competed by the KH2 kissing complex
RNA, but not by G-quartet RNAs that bind to the FMRP RGG domain. Therefore, the
FMRP:kissing complex RNA interaction links the neurologic disease of Fragile-X
syndrome and the potential role of FMRP in translational regulation.
Biologically relevant kissing loop-loop interactions were first described in tRNA.
(Kim et al., 1974; Moras et al., 1980) This subset of loop-loop pseudoknots can be
intramolecular, as for tRNA, or intermolecular, such as the HIV RNA genome, which
dimerizes via the stem loop of the DIS region. (Paillart et al., 1996) The bicoid mRNA
homodimerizes via loop-loop interactions between 3’ UTRs of two bicoid messages.
This dimerization is required for interaction with Staufen and localization to the anterior
pole of the Drosophila embryo. (Ferrandon et al., 1997) It is possible that FMRP could
bind to two stem-loops on different RNA molecules present in high enough local
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concentration. However, our data indicate that an intramolecular kissing complex is
required for interaction with KH2.
There are several examples of loop-loop interactions that suppress translation in
vivo. In the yeast Hac1 mRNA, a site in the 3’UTR forms a duplex with a stem loop in a
retained intron, causing translating polyribosomes to stall. (Chapman and Walter, 1997;
Ruegsegger et al., 2001) In prokaryotes, two small non-translated RNAs, OxyS and
CopA, are complementary to 5' noncoding sequences of target mRNAs, and form
intermolecular kissing complexes that suppress translation. (Argaman and Altuvia, 2000;
Kolb et al., 2000) The FMRP:kissing complex may stabilize the interaction of two stemloops in a single mRNA or in distinct messages. It is also possible FMRP is involved in
the mechanism of translation inhibition by miRNAs by means of this type of structure.
These results predict that the in vivo RNA target(s) of FMRP KH domains harbor
kissing complex motifs.

Ongoing efforts in our lab and others aim to develop a

bioinformatic screen for this complex structure- and sequence- specific motif.

In

addition, it is possible that previously identified FMRP targets may contain one or both
stem-loops of a functional kissing complex.
FMRP interacts with a number of RNA-binding proteins, some of which are also
associated with polyribosomes (see Chapter 6 for discussion and references.) As such, it
has been suggested that FMRP may bind to polyribosomes indirectly, perhaps through
another protein:RNA complex or through interaction with components of the RISC
complex and/or miRNAs. However, our data support the direct association of FMRP
with RNAs that contain a kissing complex motif, and that are bound by ribosomes.
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FMRP may independently bind RNAs harboring G-quartets or kissing complex
motifs, or may interact with both motifs at the same time. Such interactions could be in
trans, such that FMRP binds both motifs in independent RNA molecules, facilitating
interaction between different RNA-protein complexes. Alternatively, FMRP may bind
single transcripts harboring both G-quartet and kissing complex RNA targets.
Furthermore the combination of these distinct binding sites may be key to the overall
function of FMRP. While KH2 binding to kissing complex RNA allows FMRP to
interact with polyribosomes, the RGG:G-quartet complex may influence translational
regulation by an additional or complementary mechanism. Moreover, G-quartet RNA
binding by FMRP may also be involved in other aspects of the export and localization of
target mRNAs.
We have found that kissing complex RNA is able to displace FMRP from
polyribosomes at ~100-nM concentration. This disruption is very specific for the kcRNA
ligand, since FMRP polyribosome association is not affected by kcRNA harboring a
single point mutation, nor by 50-fold higher concentrations of G-quartet RNA, tRNA, or
BC1 RNA. These observations clearly indicate that the ability of the KH2 domain to
specifically bind kcRNA is critical for the association of FMRP with brain polyribosomes
and may be central to the molecular pathophysiology of Fragile X syndrome.
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CHAPTER VI: FXR1 AND FXR2 BIND POLYRIBOSOMES VIA KISSING
COMPLEX RNA

Introduction
Local control of protein synthesis in specific sub-cellular domains is an important
aspect of the regulation of gene expression in neurons.

In particular, regulation of

translation at post-synaptic sites plays a role in activity-dependent synaptic changes. A
number of RNA-binding proteins have been shown to regulate the translation of their
target mRNAs. One family of candidate RNA-binding proteins for this regulatory role in
neurons is the Fragile X related (FXR) family of FMRP, and the Fragile X mental
retardation-related proteins 1 and 2 (FXR1 and FXR2). The absence of FMRP or FXR2
produces a neurologic phenotype in mouse models, and these proteins have been
localized to sub-synaptic areas of dendrites.
The phenotype of fragile X syndrome includes mild to severe cognitive deficits,
attention-deficit hyperactivity disorder, autistic-like behavior, abnormal facial features
such as a prominent jaw and large ears, macroorchidism in postpubescent males, and
some connective tissue abnormalities. Fmr1 knockout mice have subtle defects in
behavior, learning and motor coordination, as well as an increased sensitivity to
audiogenic epileptic seizures, and increased anxiety. FMRP is normally expressed in
most tissues at variable levels, although the highest expression is observed in brain and
testis.

Despite the presence of an NLS, the majority of FMRP is located in the

cytoplasm. FMRP has been shown to shuttle between the nucleus and cytoplasm and has
been localized to polyribosomes at synapses in neurons. Since FMRP is associated with
polyribosomes at synapses, and since the FMRP null phenotype includes cognitive
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impairment and synaptic abnormalities, FMRP may be involved in the regulation of local
translation in neurons. (Reviewed in (O'Donnell and Warren, 2002; Willemsen et al.,
2004).)
FMRP has two autosomal paralogs, FXR1 and FXR2, which share >60% amino
acid identity. Like FMRP, both FXR1 and FXR2 include two N-terminal tandem KHtype RNA-binding domains, as well as an RG-rich region in the C-terminal region.
However, if one considers only the two KH domains, the percentage of conserved similar
residues rises to 90% (Figure 6.1). (The extended variable loop for FMRP is dispensible
for RNA binding by KH2 and has been excluded from this comparison (Darnell et al.,
2005a).) In contrast, the RG-rich regions of FXR1 and FXR2 are less than 40% identical
to that of FMRP (Figure 6.2). Both FXR1 and FXR2 have been shown to associate with
polyribosomes in the presence or absence of FMRP. (Corbin et al., 1997; Feng et al.,
1997a) In addition, FMRP can heterodimerize with FXR1 and FXR2, an interaction that
is not RNA-dependent, but may involve the KH domains of both partners. (Siomi et al.,
1994)
Like FMRP, FXR2 is expressed in the brain and testes, with the majority of
protein in the cytoplasm. Fxr2-null mice display increased hyperactivity, impaired motor
coordination, impaired fear conditioning, and decreased ability to locate the platform in
the Morris water maze. (Bontekoe et al., 2002)

In contrast, FXR1 is the only family

member with a critical role in skeletal and cardiac muscle development and function.
FXR1 is localized to costameres within muscle fibers, and is important for proper
localization of vinculin, dystrophin and alpha-actinin. It has been suggested that FXR1
may have a primary role in the regulation of transport and translation of costameric
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Figure 6.1 Alignment of minimal KH domains of mammalian FXR family members
FMRP, FXR1 and FXR2.
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mRNAs. In addition to skeletal and cardiac muscle, FXR1 is highly expressed in the
central nervous system and gonads. Fxr1-knockout mice die shortly after birth, likely
due to cardiac or respiratory failure. Mice homozygous for a hypomorphic allele of Fxr1,
Fxr1+neo, show reduced expression of FXR1 protein, and live for several months after
birth. Due to severely impaired muscle development, behavioral analysis of these mice
has not been attempted. (Mientjes et al., 2004) An investigation of the CNS role of
FXR1 requires a tissue-specific conditional knockout.

There are no known human

diseases due to mutations in either Fxr2 or Fxr1.
It has been suggested that the FXR family members may display significant
functional redundancy in the cells where they are co-expressed. This is supported by the
subtle neurologic phenotypes observed in mice that lack FMRP or FXR2. Thus, a double
knockout may reveal a more obvious phenotype, and provide additional clues to the roles
of both proteins. Fmr1/Fxr2 double-knockout mice have been generated by the Nelson
and Oostra laboratories. Compared to single knockout littermates, these mice exhibit
increased hyperactivity in the open field test, decreased habituation to a novel
environment, decreased prepulse inhibition to an acoustic startle, and impaired fear
conditioning. (Spencer et al., 2006)
The Drosophila genome contains a single homolog of the FXR family, dfmr. This
protein does not contain a functional RGG box (J. C. Darnell, manuscript in preparation);
however, the two KH-type RNA-binding domains of dFmr are highly conserved through
mouse and human homologs. dfmr mutant flies exhibit defects in neurite extension,
branching and guidance. (Michel et al., 2004; Morales et al., 2002) In addition, they
display arrhythmic circadian activity (Dockendorff et al., 2002; Inoue et al., 2002) and an
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inability to maintain courtship interest. (Dockendorff et al., 2002) The alterations in
circadian rhythm of dfmr mutant flies echo the sleep disturbances characteristic of some
patients with Fragile-X syndrome (Gould et al., 2000). Thus, there is evidence that, in
addition to a highly conserved sequence, the three FXR family members in mammals
may share similar functions in neurons.
We have recently shown that FMRP binds to kissing complex RNA (kcRNA) via
KH2, and that the FMRP:polyribosome complex can be disrupted by excess amounts of
kcRNA.

Since the KH domains of all three FXR family members are so highly

conserved, it is of interest to test whether FXR1 and FXR2 behave in the same manner.
FXR1 and FXR2 heterodimerize with FMRP, and may be dissociated from
polyribosomes by kcRNA for three reasons. First, they may be shifted off polyribosomes
when their protein-protein binding partner, FMRP, loses its association with an mRNA
undergoing translation. In this case, the heterodimer would remain intact, but RNA
binding by FMRP KH2 would be disrupted. Second, kcRNA may disrupt the proteinprotein interaction between FMRP and FXR1 or FXR2. Here, both proteins would shift
off polyribosomes, but their ability to interact would be abrogated. Third, if the KH2
domain of FXR1 and/or FXR2 is able to bind kcRNA directly, kcRNA will disrupt the
association of these proteins with polyribosomes. More importantly, this effect will be
observed in brain lysates of both wild type and Fmr1 knockout mice. Our data support
the third possibility, and suggest that the KH2 domains of FMRP, FXR1 and FXR2
associate with polyribosomes via kissing complex RNA motifs.
In addition to FXR1 and FXR2, FMRP has been identified as a binding partner
for many proteins, some of which also bind RNA and/or are associated with
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polyribosomes. Notable interactors include: NUFIP1 (Bardoni et al., 1999; Bardoni et
al., 2003b); CYFIP1 and CYFIP2 (Schenck et al., 2001); 82-FIP (Bardoni et al., 2003a);
Nucleolin (Ceman et al., 1999); YB1 (Ceman et al., 2000); Pur α, mStaufen and Myosin
Va (Ohashi et al., 2002); microspherule protein 58 (Davidovic et al., 2006); PAR6, mLgl
and aPKCζ (Zarnescu et al., 2005); ribosomal proteins L5 and L11; Dmp68 (Ishizuka et
al., 2002); and the Argonaute protein Ago2 (eIF2C2) (Caudy et al., 2002; Ishizuka et al.,
2002; Jin et al., 2004). Our high-affinity RNA ligands for the KH2 and RGG domains of
FMRP are useful tools to study the whether these domains are required for interaction
with the above proteins, and whether any of these interacting proteins remain associated
with FMRP even after it has been dissociated from polyribosomes by kcRNA.
Finally, our domain-specific high-affinity RNA ligands, kcRNA and gqRNA,
represent unique tools to address the contributions of each RNA-binding domain for the
FXR protein family. By selectively targeting the RNA-binding ability of KH2, in vivo
expression of these ligands as “RNA decoys” can overcome the overlapping roles of
FMRP, FXR1 and FXR2, creating a KH2-domain functional hypomorph for all three
genes.

Results
kcRNA dissociates FXR1 and FXR2 from polyribosomes
The KH domains of FMRP, FXR1 and FXR2 are highly conserved, as shown in
Figure 6.1, whereas the RG-rich C-terminal regions of these proteins display little
similarity (Figure 6.2). In addition FMRP has been shown to interact with both FXR1
and FXR2. We have previously shown that FMRP dissociates from polyribosomes when
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treated with 30mM EDTA or 500nM kcRNA, but not 500nM gqRNA (Chapter 5 and
(Darnell et al., 2005a)). For these reasons, we probed Western blots from Figure 5.4 with
an antibody to FXR2 (1G2).

As shown in Figure 6.3, when a post-mitochondrial

supernatant from wild type mouse brain is fractionated on a 20-50% sucrose gradient,
FXR2 cosediments with polyribosomes. Treatment with EDTA shifts FXR2 to fractions
3-8 (of 16). When brain lysate is incubated with kcRNA (500nM kc2), but not gqRNA
(500nM sc1), FXR2 no longer cosediments with intact polyribosomes. Thus, the effect
of an excess of kissing complex RNA is not specific to FMRP, but may extend to other
FMRP-interacting proteins and/or other proteins able to bind kcRNA.
The KH domains of FXR family members are highly conserved from Drosophila
melanogaster through Homo sapiens. (Morales et al., 2002) As such, we investigated
whether human FXR family members also were susceptible to competition by kcRNA.
IMR-32 cells, originally derived from a human neuroblastoma were lysed with 0.3%
NP40 in a hypotonic buffer. A post-mitochondrial supernatant was incubated with
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Figure 6.3 FXR2 is shifted off polyribosomes by EDTA and kissing complex RNA.
Polyribosome gradient separations were performed from wild type mouse cerebral cortex
and subjected to incubation with 30mM EDTA, 500nM kc2 RNA or 500nM sc1 RNA.
Western blots of TCA-precipitated gradient fractions are shown for FXR2.

500nM RNA or an equal volume of RNA-folding buffer, and loaded onto a 20-50%
sucrose gradient. Figure 6.4 shows polyribosome profiles (A) and Western blots (B)
from samples treated with kc2 RNA, mutant kc2 RNA or sc1 RNA. Both FMRP and
FXR1 fail to cosediment with polyribosomes in the presence of 500nM kcRNA, but not
mutant kcRNA or gqRNA. Therefore, the ability to interact with polyribosomes via
kcRNA is conserved in mouse and human FXR family members.

FXR1 and FXR2 associate with kcRNA and polyribosomes independently of FMRP
Additional experiments by J. C. Darnell show that recombinant KH2 domains of
FXR1 and FXR2 bind kcRNA in vitro, and that this interaction is abrogated by mutations
in FXR1 and FXR2 that are analogous to the FMRP I304N mutation in KH2 (data not
shown). Moreover, the dfmr KH2 domain also binds kcRNA with a similar affinity. The
KH1 domains of all three family members do not bind kcRNA. Interestingly, while
FMRP binds gqRNA with high affinity (Darnell et al., 2001), the C-termini of FXR1 and
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Figure 6.4 FMRP and FXR1 are competed off polyribosomes by kissing complex
RNA in human neuroblastoma cells. UV absorbance profiles (A) and Western blots
(B) against FMRP and FXR1 for polyribosome gradient fractionations of IMR32 cell
cytoplasmic extracts. After cell lysis with hypotonic buffer containing 0.3% NP40, postmitochondrial supernatants were incubated with 500nM kc2, mutant kc2, or sc1 RNAs,
or an equal volume of RNA binding buffer (Control), before 20-50% sucrose gradient
centrifugation.
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FXR2 do not bind gqRNA, a result that is supported by the low conservation of these
domains (Figure 6.2).
In order to differentiate between the possibilities that FXR1 and FXR2 might be
sensitive to kcRNA by direct binding or through their heterodimerization with FMRP,
kcRNA incubation experiments were performed using cerebral cortices from FMRP
knockout mice. Polyribosomal profiles are intact in FMRP knockout mice, with or
without incubation with 500nM RNA (Figure 6.5A, and ribosomal protein L7 in Figure
6.5B). FXR1 and FXR2 cosediment with polyribosomes in the absence of FMRP (Figure
6.5B). Incubation of FMRP KO brain lysate with 500nM kc2 RNA results in a shift of
both FXR1 and FXR2 from bimodal peaks in fractions 3-6 and 9-11 (of 16) to a single
peak in fractions 1-7. Interestingly, nine percent each of FXR1 and FXR2 may indeed
interact with polyribosomes via FMRP, since there is a reproducible shift of these
proteins when the distributions are compared between samples from FMRP WT and KO
mice. However, it is evident in Figure 6.5 that both FXR1 and FXR2 are able to
associate with polyribosomes by binding kissing complex RNA, irrespective of whether
FMRP is present.

Unrelated polyribosome-bound proteins do not dissociate with kcRNA
To test whether the ability of excess kcRNA to disrupt interaction with
polyribosomes is specific for the FXR family of RNA-binding proteins, gradient fractions
from Figure 6.5 were probed for a several neuronal non-FXR RNA-binding proteins.
Elongation factor 1alpha (EF1α, Figure 6.6A), the neuronal ELAV-related proteins HuB,
HuC, and HuD (Hu, Figure 6.6B), and eukaryotic translation initiation factor 4E (eIF4E,
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Figure 6.5 FXR1 and FXR2 are shifted off polyribosomes by kissing complex RNA
independently of FMRP. A254 traces (A) and Western blots (B) from polyribosome
separations of wild type and FMRP knockout mouse cerebral cortices.

Post-

mitochondrial supernatants were incubated with 500nM kc2 (kc2) or mutant kc2 (mut
kc2) RNAs or RNA binding buffer (Control) before sucrose gradient centrifugation.
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Figure 6.6 Control polyribosome-associated proteins do not shift with kissing
complex RNA. Western blots of TCA-precipitated gradient fractions shown in Figure
6.5 (A-C) or a replicate experiment (D) were probed for polyribosome-associated
proteins that are not known to interact with FMRP: elongation factor 1alpha (A), the
neuronal Hu proteins HuB, HuC and HuD (B), translation initiation factor 4E (C), and
Sam68 (Src-associated in mitosis, 68kDa, D).
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Figure 6.6C) are all unaffected by the absence of FMRP and incubation with kcRNA.
Fractions from a similar experiment were probed for the RNA splicing and export factor
Sam68 (Figure 6.6D), which remains bound to polyribosomes in the presence of kcRNA.

Polyribosomal distributions of FMRP-interacting proteins
FMRP has been shown to co-precipitate with a large number of neuronal proteins,
which include nuclear FMRP-interacting protein 1 (NUFIP1) and 82-FIP (Bardoni et al.,
1999; Bardoni et al., 2003b); cytoplasmic FMRP-interacting proteins 1 and 2 (CYFIP1
and CYFIP2) (Schenck et al., 2001); Nucleolin (Ceman et al., 1999); Y box-binding
protein 1 (YB1) (Ceman et al., 2000); Pur α, mStaufen and Myosin Va (Ohashi et al.,
2002); the mouse homolog of Drosophila lethal giant larvae (mLgl) and atypical Protein
Kinase C zeta (aPKCζ) (Zarnescu et al., 2005); ribosomal proteins L5 and L11; Dmp68
(Ishizuka et al., 2002); poly(ADP-ribose) glycohydrolase (PARG) (Gagne et al., 2005);
the Argonaute protein Ago2 (eIF2C2) (Caudy et al., 2002; Ishizuka et al., 2002; Jin et al.,
2004); Ran-binding protein 9 (RanBP9/RanBPM) (Menon et al., 2004); and nuclear
export receptor NXF2 (Lai et al., 2006). Using antibodies against some of these proteins,
we have screened Western blots from polyribosome gradients of fractionated wild type or
FMRP knockout brain lysate treated with kcRNA or gqRNA (Figure 6.7). Figure 6.7A
demonstrates that FMRP is shifted off polyribosomes when treated with kcRNA,
compared to control (-) and gqRNA-treated samples. (Signal evident in lanes one and
two of the FMRP knockout samples is non-specific background chemiluminescence due
to the large amount of protein loaded in these lanes. These samples are from FMRP
knockout brain lysate.) Confirming results shown in Figures 6.3, 6.4 and 6.5, FXR1
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Figure 6.7 Polyribosome distributions of FMRP-interacting proteins in
mouse brain.
Western blots of TCA-precipitated sucrose gradient fractions from wild type or
FMRP knockout mouse cerebral cortex polyribosomes.

Post-mitochondrial

cortex supernatants were treated with kc7 RNA (kcRNA), sc1 RNA (gqRNA) or
RNA binding buffer (-). The gradient positions of the 80S single ribosome and
polyribosomes are indicated. Blots were probed with antibodies to FMRP (A,
2F5), FXR1 (B, 830), FXR2 (C, 1G2), ribosomal protein P0 (D, Biodesign), Pur
alpha (E, Abnova), mouse Staufen (F, Chemicon), the neuronal myosin Va (G,
Sigma), cytoplasmic FMRP-interacting protein 2 (H, courtesy of B. Bardoni),
nuclear FMRP-interacting protein (I, courtesy of B. Bardoni), Y-box binding
factor 1 (J, Abcam), and the atypical Protein Kinase C zeta (K, Sigma).
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(Figure 6.7B) and FXR2 (Figure 6.7C) cosediment with polyribosomes in the presence
and absence of FMRP. This interaction is disrupted by kcRNA, but not gqRNA, in both
wild type and FMRP knockout cerebral cortex. The distribution of ribosomal protein P0,
a component of the 60S subunit, is not altered by a lack of FMRP or incubation with
kcRNA or gqRNA (Figure 6.7D).
Ohashi and colleagues identified an mRNP containing FMRP, Purα, mStaufen
and myosin Va (Ohashi et al., 2002). This complex is released from polyribosomes by
EDTA, and is abolished by treatment with RNase. Purα binds both single-stranded DNA
and RNA, and is reported to control the expression of BC1 RNA, as well as that of a
number of other genes. (Kobayashi et al., 2000; Ohashi et al., 2000; Zhang et al., 2005)
It also cosediments with polyribosomes, and Purα-null mice exhibit impaired neural
development. (Gallia et al., 2000; Khalili et al., 2003) Therefore, it has been proposed
that Purα may assist mRNP assembly in an RNA-dependent manner and be involved in
targeting mRNPs to polyribosomes in cooperation with other RNA-binding proteins
(Ohashi et al., 2002). We find that the majority of cytoplasmic Purα does not cosediment
with polyribosomes, but is in fact found in the upper region of the gradient, likely in a
non-polyribosomal mRNP (Figure 6.7E). However, there is a portion of Purα that is
found in fractions 4-9 that may be bound to polyribosomes. This interaction is not
affected by the loss of FMRP (FMRP KO -), but does exhibit a slight shift in the presence
of kcRNA, and a more significant shift in the gqRNA-treated gradients. These shifts do
not require FMRP, since the kcRNA and gqRNA shifts are comparable between wild
type and knockout gradients. This finding clearly demonstrates that cytoplasmic Purα
interacts with large complexes via RNA, but that this interaction may not be sequence-
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specific. Further study of the literature reveals that Purα binds G-rich sequences in both
RNA and single-stranded DNA. (Gallia et al., 2000) Since both kcRNA and gqRNA
contain stretches of multiple G residues (gqRNA more so than kcRNA), it is likely that
these spiked-in RNAs compete with endogenous targets for binding by Purα. This may
be related to FMRP biology in that Purα could be bound to mRNA cargoes that also
carry FMRP. It is likely that specific interaction of Purα with an mRNA does not depend
on the RNA binding abilities of FXR KH domains or the FMRP RGG box.
mStaufen, the mouse homolog of Drosophila staufen, is an RNA-binding protein
thought to be involved in mRNA transport and localization.

In addition to the

coimmunoprecipitation of mStaufen with Purα and FMRP (Ohashi et al., 2002), the Ortin
laboratory reported that FMRP copurifies with granules containing hStaufen, ribosomes,
cytoskeletal control proteins, and motor proteins (Villace et al., 2004). We find that the
majority of mStaufen is found in fraction 2 (of 12), a region of the 20-50% sucrose
gradient that contains mRNPs, and possibly 40S ribosomal subunits (Figure 6.7F). Faint
bands can be seen in fractions 3-8, indicating that mStaufen may be present on
polyribosomes, as has been previously reported (Ohashi et al., 2002). Incubation with
kcRNA or gqRNA does not appear to alter the distribution of mStaufen in either wild
type or FMRP knockout cerebral cortex.
A fourth component of the mRNP containing FMRP, Purα and mStaufen is
myosin Va, a non-muscle myosin that is expressed in brain and involved in the transport
of vesicles and mRNAs (Evans et al., 1998). When centrifuged through a 20-50%
sucrose gradient, myosin Va exhibits an unusual distribution. There are two peaks
present: the first in fraction three, corresponding to mRNPs and the 40S ribosomal
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subunit, and the second in fractions 10-12, possibly containing large granules and/or
cytoskeletal networks (Figure 6.7G). Of note, while others have described an association
of FMRP with cytoplasmic granules (De Diego Otero et al., 2002; Krichevsky and Kosik,
2001; Mazroui et al., 2002; Villace et al., 2004), in our hands, this is the first evidence of
a complex of that size, as assayed by gradient centrifugation. We do not see a granule
“peak” in polyribosome profiles from brain and tissue culture cells. FMRP, FXR1 and
FXR2 are present in fractions 10-11, but do not display the same peak of protein
concentration that is seen for myosin Va. Myosin Va is present in the intervening
fractions 4-9. The distribution in fractions 3-9 does not change with the absence of
FMRP or treatment with kcRNA or gqRNA. The myosin Va peak in fractions 10-11
does seem to shift from fraction ten in wild type brain, to fraction eleven in FMRP
knockout brain. However, this change in distribution is only one fraction, which could be
due to technical artifact in gradient fraction collection. Further analysis requires better
resolution of these fractions (e.g. a 35-60% sucrose gradient divided into more fractions
of smaller volume.) From these data, myosin Va does not display a gross change in
polyribosome distribution when treated with kcRNA or gqRNA.
CYFIP1 and CYFIP2 share 88% sequence identity, and contain no known
functional motifs. They were first identified as FMRP-interacting proteins through a
yeast two-hybrid screen (Schenck et al., 2001). In addition, the Drosophila proteome
contains a single homolog, CYFIP/Sra-1, that interacts with dFmr1 (Schenck et al.,
2003). Interestingly, CYFIP1 interacts only with FMRP, while CYFIP2 interacts with all
three of the FXR family members via the same N-terminal domain that mediates
heterodimerization between FXR proteins. CYFIP1 interacts with Rac1 (Kobayashi et
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al., 1998), a Rho GTPase, and both family members are thought to regulate actin
polymerization to shape synapse morphology as part of the WAVE/SCAR complex (Kim
et al., 2006; Pilpel and Segal, 2005; Schenck et al., 2004) We find that a small amount of
CYFIP2 cosediments with polyribosomes in an FMRP-independent manner (Figure
6.7H). Incubation with kcRNA or gqRNA does not alter this distribution.
Nuclear FMRP-interacting protein 1 (NUFIP1) is a nucleocytoplasmic shuttling
protein predominantly found in the nucleus.

However, it has been co-localized with

subsynaptic polyribosomes by electron microscopy (Bardoni et al., 2003b). NUFIP1
interacts with the N-terminal region of FMRP involved in heterodimerization and binds
ribohomopolymers in vitro, specifically poly(G) and poly(U) (Bardoni et al., 1999). In
contrast to the co-localization of NUFIP1 with polyribosomes, we find that NUFIP1 does
not cosediment with polyribosomes in brain lysate from either wild type or FMRP
knockout mice (Figure 6.7I). These findings are not mutually exclusive, as NUFIP1 may
be incorporated in mRNPs that are translationally repressed and in a reserve pool at the
synapse.

Furthermore, unlike Purα, NUFIP1 distribution does not change when

incubated with kcRNA or gqRNA, even though NUFIP1 also binds G-rich RNA
(Bardoni et al., 1999). Perhaps NUFIP1 is part of a translationally silent mRNP that
includes FMRP, and that is important for correct transport and localization of a given
mRNA. Interestingly, NUFIP1 does not interact with FXR1 or FXR2 in a pull-down
assay (Bardoni et al., 1999), and may compete for binding to FMRP.
The coimmunoprecipitation of Y box-binding protein 1 (YB1) with FMRP is
RNA-independent (Ceman et al., 2000). YB1 is both a transcription factor and a core
element of mRNP complexes, specifically a component of both translationally repressed
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and actively translating mRNPs. (Kohno et al., 2003) In the polyribosome gradient
fractionations shown in Figure 6.7J, cytoplasmic YB1 cosediments with small mRNPs; it
does not seem to be associated with polyribosomes.
dFmr1 interacts both genetically and biochemically with PAR complex members
PAR6, dLgl, and aPKCζ (Zarnescu et al., 2005). This relationship is conserved for the
mouse homologs of these proteins. dlgl is an oncogene and encodes a cytoskeletal
protein involved in cellular polarity and cytoplasmic transport that is phosphorylated by
aPKCζ. (Vasioukhin, 2006)

Atypical-PKCζ cosediments primarily with smaller

complexes irrespective of FMRP genotype, although faint bands are visible in fractions
4-7 (Figure 6.7K). Incubation with kcRNA or gqRNA does not alter this distribution.
Thus, mRNAs associated with both FMRP and the PAR/Lgl/aPKCζ complex are likely
to be translationally repressed.
Several groups have identified dAgo2 and the mammalian homolog of dAgo1,
eIF2C2/hAgo2, in complexes that co-purify respectively with dFmr1 and FMRP. (Caudy
et al., 2002; Ishizuka et al., 2002; Jin et al., 2004)

The Argonaute proteins are

components of the RISC complex and bind miRNAs. They are thought to mediate one
mechanism of translational repression through miRNA targeting of mRNAs. (Chen and
Meister, 2005)

Mammalian Ago2 (eIF2C2) has been shown to cosediment with

polyribosomes from cells in culture (Mourelatos et al., 2002). Due to specificity of antimammalian Argonaute antibodies (a kind gift of T. Tuschl) for the human homologs of
these proteins, we could not include mAgo1 and mAgo2 in Figure 6.7. Instead, human
neuroblastoma cells (IMR-32) in culture were lysed and treated with 500nM RNA
(kcRNA, mutant kcRNA or gqRNA) or 30mM EDTA, then analyzed by gradient
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centrifugation and Western blotting. hAgo1, a closely related family member of hAgo2,
is partially associated with polyribosomes, but is not affected by incubation with RNA
ligands for FMRP (Figure 6.8A). hAgo2 exhibits a slightly different distribution, with a
peak in fractions 6-11 which shifts to lighter fractions following treatment with EDTA
(Figure 6.8B). However, like hAgo1, hAgo2 does not shift when incubated with kcRNA
or gqRNA.
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Figure 6.8 Mammalian Argonaute proteins 1 and 2 are not shifted by FMRP RNA
ligands in human IMR32 cells.

Western blots from polyribosome gradient

fractionations in Figure 6.4 were probed for Ago1 (A) and Ago2 (B) (antibodies courtesy
of T. Tuschl). 20-50% sucrose gradient distributions of hAgo1 and hAgo2 do not shift
when incubated with 500nM FMRP RNA ligands.

hAgo2 is associated with

polyribosomes, since the peak in fractions 6-13 (Control, top panel) shifts to the top of
the gradient when treated with 30mM EDTA.
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Protein-protein interactions are not disrupted by kcRNA
While the KH2 domains of FXR1 and FXR2 bind kcRNA directly, and both
FXR1 and FXR2 are competed off polyribosomes by kcRNA in the absence of FMRP, it
is possible that incubation with kcRNA can also disrupt the heterodimerization of these
proteins. In fact, both KH1 and KH2 have been implicated in heterodimerization (Siomi
et al., 1994).

To test this hypothesis, immunoprecipitations from wild type mouse

cerebral cortex lysate for FMRP and an irrelevant antibody to an RNA-binding protein
(anti-Nova) were performed in the presence of 500nM kc2 RNA or mutant kc2 RNA.
FXR2 specifically coprecipitates with FMRP when incubated with either RNA (Figure
6.9). Thus, the KH2:kcRNA interaction does not disrupt heterodimerization of FMRP
and FXR2. To further test this hypothesis, coimmunoprecipitations were carried out in a
mild isotonic buffer under several different conditions, as shown in Figure 6.10. To
control for non-specific interactions, FMRP knockout brain lysate was used with and
without 500nM kcRNA, and FMRP wild type brain lysate was incubated with a control
antibody. Experimental conditions included incubation with 500nM kcRNA, 500nM
gqRNA, 500nM tRNA, 0.1% deoxycholate (DOC), 30mM EDTA, or RNase A. FXR1
coprecipitates with FMRP in all conditions, but shows some background non-specific
precipitation in the immunoprecipitations from FMRP knockout brain and with a control
antibody. FXR2 also coprecipitates with FMRP, but seems to require release from
polyribosomes for efficient capture. It is interesting that FXR1 exhibits an increased
interaction with FMRP in the presence of gqRNA versus kcRNA, while FXR2
coprecipitation with FMRP is greatly reduced by gqRNA compared to kcRNA. MyoVa
is precipitated in all conditions, including the three controls. The only decrease in
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Figure 6.9 Kissing complex RNA does not abrogate heterodimerization of FMRP
with FXR2. Post-mitochondrial supernatant from mouse cerebral cortex (lysed in 1X
brain polyribosome buffer, see Chapter 2) was treated with 500nM kc2 or mutant kc2 and
incubated with protein A-sepharose pre-bound to 7G1-1 or control (rabbit anti-Nova)
antibody for 2 hours at 4°C. IP matrix was washed twice with lysis buffer and extracted
by boiling in 1X Laemmli sample buffer (Bio-Rad). 10% of IP eluate (IP), 1% of pre-IP
lysate (Tot), and 1% of post-IP supernatant (Sup) were analyzed by SDS and Western
blotting for FMRP (1C3) and FXR2 (1G2).
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Figure 6.10 Co-immunoprecipitations of FMRP with interacting proteins
under a variety of treatments. Mouse cerebral cortices from wild type and
FMRP knockout mice were lysed and post-mitochondrial supernatants were
prepared as in Figure 6.9. Lysates were incubated as noted for “IP condition”
with 500nM of the indicated RNA, 0.1% sodium deoxycholate (DOC), 30mM
EDTA, 2ug/ml RNase A (RNase), or buffer (blank). After pre-clearing with
protein A-sepharose for 30 min at 4°C, aliquots were taken for pre-IP total input
samples (T). Lysates were immunoprecipitated with mixture of two monoclonal
antibodies to FMRP (7G1-1 and 2F5) pre-bound to bridging anti-mouse Fcgamma
antibody fragment (Jackson Labs):protein A-sepharose.

Control antibody IP

eliminates both monoclonal antibodies to IP with bridging antibody alone. IP
matrices were incubated for 2 hours at 4°C and washed twice with lysis buffer
before boiling in 1X Laemmli sample buffer. 1% of Input (T), 10% of IP eluate
(IP), and 1% post-IP supernatant (S) are analyzed by Western blotting with
antibodies to FMRP (2F5), FXR1 (830, courtesy of B. Bardoni), FXR2 (1G2),
myosin Va (Sigma), Pur alpha (Abnova), mStaufen (Chemicon), atypical Protein
Kinase C zeta (Sigma), and ribosomal protein P0 (Biodesign). (Of note, signal for
FMRP saturated in some IP conditions, producing low signal “circles” inside
FMRP bands.)
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MyoVa capture occurs when treated with deoxycholate, indicating that stringent washes
may yield a more specific result. Purα shows maximal coprecipitation with FMRP when
both proteins are released from polyribosomal complexes, as seen in the EDTA- and
RNase-treated conditions.

Since the Purα-FMRP interaction has been previously

reported to be RNA-dependent (Ohashi et al., 2002), perhaps this interaction is an artifact
of incomplete RNase digestion. Under these conditions, mStaufen, aPKCζ and ribosomal
protein P0 do not coimmunoprecipitate with FMRP. Thus, KH2:kcRNA interaction does
not disrupt heterodimerization of FXR proteins. Other FMRP-interacting proteins are
more difficult to capture using this method. The effects of kcRNA and gqRNA on these
interactions remain unclear.

RNA decoys: a tool for domain-specific functional inhibition
Since it is evident that the highly conserved KH2 domains of all three FXR family
members bind kissing complex RNA with high affinity, and that only FMRP is able to
bind g-quartet RNA motifs, these RNAs represent possible tools for domain-specific
functional inhibition of these proteins in vivo. However, the in vivo expression of these
RNAs is not trivial. Since they are short, non-translated RNAs with significant doublestranded regions, early attempts to express each high-affinity ligand as an individual 96nt
species resulted in low expression levels and poor export from the nucleus (data not
shown). A scheme for improved expression of these decoy RNAs is based on work by
the Liebhaber and Taira laboratories.

Their studies have shown that the human

tRNA(Val) (Kuwabara et al., 2001) and the adenoviral VA1 RNA (Makeyev et al., 2002)
are expressed at high levels and exported to the cytoplasm. Moreover, RNA sequences of
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interest can be inserted at various locations within these RNAs without disrupting folding
or nuclear export. Both of these RNAs have internal Pol III promoters that should
increase expression by two to three orders of magnitude greater than that from Pol II
promoters.

We have constructed RNA decoys using either the tRNA or the VA1

cassettes, and containing kissing complex or g-quartet RNA motifs. Mfold-predicted
structures for each species are shown in Figure 6.11 (Zuker, 2003). Mutations that
disrupt binding to FMRP are indicated. In vitro transcribed RNA decoys using both
cassettes bind purified FMRP with affinities close to those for FMRP SELEX target
RNAs alone, as shown in Figure 6.12. This is the case when transcribed RNA is gel
purified, denatured and refolded prior to incubation with recombinant FMRP (Figure
6.12A, top two panels). It is also true when in vitro transcribed RNA, after buffer
exchange via G-25 sephacryl, is incubated directly with recombinant FMRP, bypassing
any denaturation and refolding (Figure 6.12A, bottom panel, and B). In addition, FMRP
does not bind tRNA or VA1 RNA alone, and does not bind mutated forms of the RNA
decoys. While recombinant FMRP binds tRNA and VA1 cassettes that include kcRNA
sequences, these RNAs may not function to disrupt FMRP:polyribosome complexes in
mouse cerebral cortical lysate. Indeed, Figure 6.13 shows that while 500nM tRNAkc7
completely disrupts FMRP association with polyribosomes (A), 1uM VA1kc7 has no
effect (B).

For this reason, the VA1 cassette constructs were not used for further

experiments.
To facilitate expression in vivo, tRNA expression constructs were cloned into the
3’LTR of a lentiviral vector developed by the Trono laboratory (Arrighi et al., 2004).
This vector (pLVTHM, diagrammed in Figure 6.14) has the advantage of containing an
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Figure 6.11 Predicted structures of RNA decoy molecules. Mfold-predicted
structures of tRNA (A) and VA1 (B) expression cassettes and RNA decoys
containing kc7 RNA or sc1 RNA sequences. A mutation that abrogates binding
to FMRP is indicated for each. Pink asterisks denote kc7 nucleotides that form
the base-pair “kiss” between loops.
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Figure 6.12 RNA decoys bind recombinant FMRP in vitro. (A) Filter binding assays
for tRNA-based RNA decoys using recombinant FMRP KH2 (for kcRNA constructs,
upper left panel) or C-terminus proteins (for sc1 RNA constructs, upper right panel). kc7
and kc2 are positive controls for protein activity. Upper panels test gel-purified, heatdenatured and refolded RNAs; binding affinities are listed at middle right panel. Middle
left panel tests KH2 binding to co-transcriptionally folded RNA decoys (purified twice
with G-50 sepharose columns, no heat denaturation); binding affinities are listed in figure
legend. (B) Filter binding assays for co-transcriptionally folded VA1-based RNA decoys
as in (A).
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Figure 6.13 In vitro transcribed RNA decoys in polyribosome shift assay. Mouse
cerebral cortex lysates were prepared for polyribosome fractionation and incubated with
the indicated concentrations of in vitro transcribed RNAs before sucrose gradient
centrifugation. Western blots of TCA-precipitated gradient fractions for FMRP indicate
that tRNAkc7 RNA (A) competes FMRP off polyribosomes, whereas VA1kc7 RNA does
not (B).
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Figure 6.14 Lentiviral expression system for RNA decoys. (A) Schematic illustration
of pLVTt adapted from D. Trono and colleagues.

The H1 promoter (red box) of

pLVTHM (D. Trono) in the 3’LTR has been replaced with the tRNA decoy expression
cassette. (B) Northern blot for RNA decoy expression in 293T cells 40 hours postlentiviral transduction with virus encoding empty tRNA cassette (tRNA), tRNAkc7 (tkc),
tRNAmini-sc1 (tgq), or untransduced (UT). 15ug of total nuclear (N) or cytoplasmic (C)
RNA was electrophoresed on a denaturing 8% acrylamide/7M urea gel. After transfer to
positively charged nylon membrane, blot was probed with P32-labeled anti-sense probe
to the tRNA expression cassette. Ladder is single stranded DNA. Band at bottom of blot
represents hybridization to a non-lentiviral sequence, possibly endogenous tRNA.
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GFP reporter and a Tet-operator site adjacent to the RNA decoy cassette.

When

combined with an additional vector that contains a KRAB repressor fused to a Tetrepressor protein, expression of RNA decoys can be induced by doxycycline (Szulc et al.,
2006). Figure 6.14B is a Northern blot from 293T cells transduced with lentivirus
encoding tRNAkc7 (tkc), tRNAminisc1 (tgq) or the tRNA cassette alone. An antisense
probe to the tRNA expression cassette reveals that all three RNAs are transcribed and
exported to the cytoplasm, although export of tRNAminisc1 is much less efficient than
either tRNAkc7 or the tRNA cassette.
In vivo activity of tRNAkc7 and tRNAkc2 was examined by polyribosome
analysis of transduced cells. Briefly, high titer lentivirus was produced in packaging
cells, concentrated, and used to transduce 15cm plates of 293T cells. This method
produced approximately 90% EGFP-positive cells. Forty hours post-transduction, cells
were lysed and layered on 20-50% sucrose gradients.

Western blots from gradient

fractions are shown in Figure 6.15A. FMRP in cells transduced with lentivirus encoding
tRNAkc7, tRNAkc2, tRNAmutkc2, or the tRNA cassette, remains associated with
polyribosomes. Western blots from Figure 6.13A are reproduced here for comparison.
In order to ensure that these RNAs were expressed, RNA was precipitated from aliquots
of nuclear and cytoplasmic fractions of the cells used in Figure 6.15A. Northern blotting
with an antisense tRNA probe (Figure 6.15B) reveals that the tRNA cassette, tRNAkc7
and tRNAkc2 RNAs were expressed and exported to the cytoplasm.
Since tRNA-based RNA decoys are expressed, exported to the cytoplasm, and can
functionally interact with FMRP in a spike-in assay, it is not clear why these RNAs did
not have the same effect in vivo. In order to more precisely quantify the in vivo
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Figure 6.15 tRNAkcRNA does not compete FMRP off polyribosomes in vivo.

(A)

Western blots for FMRP of polyribosomal sucrose gradient centrifugations of 293T cells
40 hours post-lentiviral transduction with the indicated virus. Transduction efficiency
was approximately 90% by GFP expression. Blots from Figure 6.13A are reproduced
here for comparison. (B) RNA precipitated from nuclear and cytoplasmic fractions of
cells in (A) is analyzed by Northern blotting with an antisense probe to the tRNA
expression cassette (UT: untransduced, t: tRNA expression cassette, tk7: tRNAkc7, tk2:
tRNA kc2.)
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concentration of these RNA decoys, the antisense tRNA signal from 10µl pellets of
transduced cells were compared to a known amount of in vitro transcribed tRNAkc7
(Figure 6.16A). In sum, tRNA decoys are present at less than 1nM in transduced cells.
In contrast, there are approximately six picomoles of FMRP in the post-mitochondrial
supernatant from one juvenile (postnatal day 8) mouse cerebral cortex (Figure 6.16B).
The 7G1-1 monoclonal antibody recognizes an epitope in the FMRP-specific variable
loop of KH2 encoded by exon 11. 7G1-1 recognition of the indicated amounts of protein
from wild type or FMRP knockout cerebral cortex were compared to known quantities of
recombinant mouse FMRP KH2 (includes exon 11, but not exon 12.)

A rough

calculation based on the approximate volume of one mouse cerebral cortex (two
hemispheres) yields an approximate concentration of 20nM FMRP in brain.

No

quantitation was done for FXR1 or FXR2, which also bind kcRNA with high affinity.
Thus, it seems that the tRNA-based system of RNA decoy expression is not sufficient for
effective functional inhibition of FXR KH2 domains. This may be due to a combination
of factors, namely, insufficient decoy expression levels, sequestration of RNA decoys by
unknown factors, and/or an increased susceptibility of FMRP to kcRNA binding when
diluted approximately five-fold in brain lysis buffer.

Further work is necessary to

elucidate these requirements. Despite the difficulties in creating a viable system of in
vivo RNA decoys for FXR family members, such an array of tool would be invaluable to
the study of FMRP, FXR1 and FXR2 function in neurons, and could yield insights into
the molecular mechanisms of Fragile-X mental retardation syndrome. Ultimately, a
kissing complex RNA decoy could be used to create a conditional, KH2 domain-specific
dominant negative simultaneously for all three FXR family members.
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Figure 6.16 Quantitations of RNA decoy and endogenous FMRP expression. (A)
Northern blot probed with labeled antisense tRNA expression cassette oligonucleotide of
RNA from 10ul of packed 293 or 293T cells 40 hours post-lentiviral transduction with
LVTt virus encoding tRNAmutkc2 (293) or tRNAkc7 (293T). 10 femtomoles of in vitro
transcribed tRNAkc7 is included for comparison. (B) Western blot for FMRP (7G1-1)
comparing indicated amounts of mouse brain lysate to recombinant mouse KH2 (includes
exon 11 but lacks exon 12).
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Discussion
We find that kissing complex RNA can disrupt the polyribosome association of
FXR1 and FXR2, as well as FMRP. In their tandem KH domains, these family members
share 90% sequence similarity. Our results indicate that these proteins bind to the same
RNA motif, both in vitro and in vivo. Thus it is likely that they share a mechanism of
action and pool of RNA targets in cells where they are co-expressed, i.e. neurons. Yet,
from a common ancestral gene (dfmr1 is representative), FXR family members have
diverged to include C-terminal regions with only 40% sequence identity. In addition,
these domains do not share a target RNA sequence. Therefore, while FXR1 and FXR2
are found in some cell types that do not express FMRP, they may also have differing
roles in neurons. The potential for homodimerization and heterodimerization between
these proteins adds another layer to the complexity of possibilities for functional roles
and RNA targets. We can imagine that a common mechanism is mediated by KH2
binding to kissing complex RNA motifs that results in a polyribosome-associated
complex. However, the identity of the FXR proteins bound to a given mRNA may
determine a different translational fate. Alternatively, additional FMRP-binding sites,
e.g. G-quartets, may specify a subgroup of mRNAs for a unique purpose at the synapse.
Except for the negative data presented by our laboratory and the Mihailescu laboratory
(Zanotti et al., 2006), there is as yet no data on whether the C-terminal domains FXR1
and FXR2 bind sequence specific RNA structural motifs.

Changes in the protein

composition of an mRNP are known to influence various steps in mRNA processing,
transport, and regulation.

These substitutions may accompany spatial changes, for

example, when cytoplasmic PABC replaces nuclear PABPN1 on the poly(A) tail of an
mRNA during export from the nucleus. (Reviewed in (Kuhn and Wahle, 2004)).
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Changes in mRNP composition can also result from upstream signal transduction. For
example, when nutrients are scarce, cells can restrict translational apparatus to only those
transcripts necessary for survival in a quiescent state. This is accomplished using a
general regulator of translation, Target of Rapamycin (mTOR). (Reviewed in (Hay and
Sonenberg, 2004)

Briefly, the presence of nutrients and/or growth factors activates

mTOR, a kinase which phosphorylates eukaryotic translation initiation factor 4E (eIF4E)binding proteins (4E-BPs), as well as other proteins involved in translational regulation.
Phosphorylation of 4E-BP causes its dissociation from eIF4E and allows eIF4G binding
that results in 40S ribosome subunit recruitment to the m7G-cap of an mRNA. Since
eIF4E is required for cap-dependent translation, this is a general mechanism to regulate
translation of most mRNAs. In neurons, cytoplasmic polyadenylation element (CPE)containing mRNAs are bound by CPE-binding protein (CPEB) and maskin for transport
into dendrites. Maskin also binds eIF4E, preventing interaction with eIF4G. When
NMDA receptors are stimulated at synapses, Aurora A kinase is activated and
phosphorylates CPEB, which induces mRNA polyadenylation and likely leads to
dissociation of maskin from eIF4E, resulting translation of the mRNA. (Huang et al.,
2002; Wu et al., 1998) FXR proteins may regulate translation of mRNA cargoes in a
spatial-, temporal- and/or signal-transduction-dependent manner. In Fragile-X patients
and FMRP knockout mice, the most striking morphological phenotypes in neurons are
seen in the dendritic spines. (Comery et al., 1997; Hinton et al., 1991; Wisniewski et al.,
1991)

In addition, since there is a documented increase in group I metabotropic

glutamate receptor (mGluR)-induced long-term depression (LTD) in hippocampal slices
from FMRP knockout mice (Huber et al., 2002), FMRP activity is thought to be focused
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at synaptic areas. It is possible that while FMRP, FXR1 and FXR2 all associate with
polyribosomes via kissing complex RNA motifs, this association could be spatially or
temporally specific for each protein. Indeed, a single kissing complex motif in a given
mRNA could be sequentially bound by different FXR proteins during its lifetime.
Finally, data showing that FMRP may be associated with changes in the quantity of
polyribosomes in synaptoneurosomes in response to treatment with mGluR agonists,
suggests that FMRP may be a downstream target of signal-transduction cascades induced
by synaptic activity (Weiler et al., 2004).
The overlap in RNA sequence and structure specificity of the KH2 domains of
FXR1, FXR2 and FMRP suggests that they may exhibit some functional redundancy in
neurons. Fmr1-null mice have normal levels and subcellular distributions of FXR1 and
FXR2 (Bakker et al., 2000). Yet, Fragile-X patients and Fmr1-null mice exhibit gross
and molecular phenotypes that are apparently uncompensated by normal levels of FXR1
and FXR2.

These abnormalities in dendritic spine development could be due to a

hypomorphic effect of a loss of FMRP; i.e. increased levels of FXR1 and/or FXR2 could
potentially reduce these effects. However, regulation of FXR family protein levels seems
to be tightly regulated for a good reason. Overexpression of dfmr also results in neuronal
structural abnormalities (Pan et al., 2004).

An alternate hypothesis is that the

abnormalities seen with decreased levels of FMRP are due to unique functions of FMRP,
possibly due to loss of the RGG box and its ability to bind G-quartets. This suggests that
any KH2-specific roles of FMRP are fulfilled by FXR1 and/or FXR2 in the absence of
FMRP. The actual molecular differences in neurons that lack FMRP are likely due to
both of the above possibilities, with the additional caveat that while FXR family members
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share a means of association with polyribosomes, that association may result in a
different fate for the mRNA, depending on which family member is bound.
While kcRNA is bound by the FXR protein family with high affinity and
specificity, this does not preclude the possibility that additional proteins could bind
kissing complex motifs. In fact, Purα is shifted off polyribosomes by incubation with
kcRNA. This effect is independent of FMRP. However, it is not specific to kissing
complex RNA, since incubation with G-quartet RNA can produce a more pronounced
shift in Purα distribution. KH domains from several proteins (Nova1, Nova2, hnRNPE1,
hnRNPE2, SF1 and ZBP) do not bind kcRNA in vitro (J. C. Darnell, manuscript in
preparation.)
Further permutations of FXR protein-containing mRNPs can result from the
association of other proteins.

A number of FMRP-interacting proteins have been

identified. Some of these proteins specifically bind FMRP (e.g. CYFIP1), while others
interact with all three family members (e.g. CYFIP2) (Schenck et al., 2001). Moreover,
some of these interacting proteins (e.g. NUFIP1, CYFIP1, and CYFIP2) bind to the same
N-terminal domain that mediates homodimerization and heterodimerization of FXR
family members, potentially competing for this binding site (Bardoni et al., 1999;
Schenck et al., 2001). We find that KH2 binding to kissing complex RNA does not
disrupt heterodimerization between FMRP and FXR1 or FXR2. Thus, the variety of
proteins that interact with FMRP through the N-terminal domain may also be associated
with polyribosomes through FMRP. FXR1 and FXR2 show a nine percent shift from
heavy polyribosomes to small complexes in wild type versus FMRP knockout cerebral
cortex lysate. This suggests that, while FXR1 and FXR2 interact with polyribosomes
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through direct binding of kissing complex motifs, they may also be able to bind
FMRP:polyribosomes by means of protein-protein heterodimerization.
Studies are ongoing on fmr1/fxr2 double knockout animals, and will provide more
data on the functional redundancy of these proteins. However, a homozygous fxr1-null
mutation is lethal at birth. Therefore, other methods are required to study what happens
when all FXR proteins are functionally absent. Since kcRNA specifically binds to and is
able to compete with endogenous targets of the KH2 domains of FMRP, FXR1 and
FXR2, artificially introduced kcRNAs have the potential to abrogate function of these
domains. On the other hand, gqRNA only binds FMRP. Thus the expression of these
RNAs in vivo represents a system by which the specific roles of FXR proteins could be
dissected with respect to the activities of their RNA binding domains, in the context of
wild type proteins. The development of such a system is not trivial, due to difficulty in
achieving sufficiently high levels of RNA decoy expression, since, to our knowledge,
RNAs of this type are not normally produced by cells. However, if these difficulties can
be overcome, an RNA decoy system could yield valuable insights into FXR function in
translational regulation.
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CHAPTER VII: GENERAL DISCUSSION
Nova proteins are partially bound to polyribosomes
In our studies of density gradient distributions of RNA-binding proteins in mouse
brain, we found that approximately 10-25% of cytosolic Nova is shifted by EDTA
treatment, supporting the hypothesis that this population of Nova proteins is associated
with polyribosomes. Microarray comparisons between Nova-1 wild type and knockout
spinal cord polyribosomal mRNAs have identified possible targets of Nova. However,
the differences we observed were small, suggesting that translational regulation is likely
to be a subtle process better studied through analysis of corresponding changes in the
mRNA content of other polyribosome gradient regions such as mRNPs. Furthermore,
none our validated Nova alternative splicing targets (Ule et al., 2003; Ule et al., 2005b)
show a greater than two-fold change between wild type and Nova-1 knockout spinal cord
polyribosomes. These data represent the first biochemical assays showing a possible role
for Nova proteins in translational control. As such these studies provide a foundation for
future evaluation of this role in Nova biology; they provide a general platform of data
from which to launch more specific experiments. While yielding some important results,
these experiments were subject to some limitations. First, the lack of robust changes in
polyribosomal mRNA populations in the absence of Nova-1 emphasizes the need for
improved signal to noise ratios when using gradient density fractionation to isolate
polyribosomes from the central nervous system. In essence, the presence of too many
cell types and parts of cells (e.g. cell body vs. processes) obscures specific conclusions in
this method. Clearer data for mRNA targeting and localization could be obtained by
looking at specific neuronal layers using microdissection techniques. These experiments
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did not eliminate redundant function as a confounding variable: comparing wild type to
Nova-1/Nova-2 double knockout mice would yield maximum differences.

Finally,

further amplification of differences in the mRNA complement of polyribosomes can be
achieved by measuring reciprocal changes in mRNA distribution over polyribosomal
gradient fractionations. One can imagine that these methods could also be used to
analyze activity-dependent changes in mRNA association with polyribosomes in a variety
of paradigms such as seizure induction and glycine- or GABA- receptor blockade.
These proposed experiments could further refine our working model of Nova
function in neurons. As such, we have evidence that Nova proteins bind nascent RNA
transcripts in the nucleus and influence splice site selection for nearby exons (Dredge and
Darnell, 2003; Jensen et al., 2000a; Ule et al., 2003; Ule et al., 2006; Ule et al., 2005b).
It is most likely that cytoplasmic Nova proteins remain associated with previously
alternatively-spliced mRNAs as a component of the exon-exon junction complex during
nuclear export. At some point during cytoplasmic mRNA processing and transport, most
Nova proteins disengage from mRNA complexes and return to the nucleus. However, we
have not excluded a possible role for Nova in mRNA transport and/or localization. The
11-22% of cytoplasmic Nova proteins that are associated with brain polyribosomes may
merely be a remnant of the exon-exon junction complex that has survived until an initial
round of translation in the cytoplasm.

Conversely, polyribosome-bound Nova may

influence translational regulation of its target mRNA, perhaps by sequestering such
mRNAs in a ribosome-loaded but inactive state, in readiness for a local signal that allows
translation to procede.
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A conserved role for Fragile X Mental Retardation Protein and its family members FXR1
and FXR2
We found that FMRP is associated with actively translating ribosomal complexes
in mouse cerebral cortex (Stefani et al., 2004). This is in agreement with previously
published data showing that FMRP co-sediments with polyribosomes in tissue culture
cell lines and rat synaptosomes (Corbin et al., 1997; Eberhart et al., 1996; Feng et al.,
1997a; Feng et al., 1997b; Khandjian et al., 1996). However, our results directly refute
the finding that FMRP does not associate with polyribosomes in mouse brain (Zalfa et al.,
2003).
Our microarray screens of polyribosomal mRNA for differences between FMRP
wild type and knockout mouse cerebral cortex show a remarkable lack of significant
differences between the two genotypes in both mRNA populations (polyribosomal and
total). This result contrasts with previous data identifying 251 mRNAs that show altered
polyribosomal distribution in transformed white blood cells from individuals with fragile
X syndrome compared to non-fragile X individuals, and 144 mRNAs differed in the total
RNA population (31 mRNAs were present in both data sets) (Brown et al., 2001). Of the
few genes that show subtle changes (between 1.27- and 1.42-fold) between wild type and
FMRP knockout polyribosomes in our data, only one, proteolipid protein (Plp), has been
previously identified as a target for FMRP (Wang et al., 2004). Our results imply that this
method for evaluation of FMRP control of translational status for target mRNAs may be
limited by an insensitivity to small differences in polyribosomal distribution, that may be
visible only with measurement of reciprocal changes between mRNA populations (i.e.
between lighter and heavier fractions of the sucrose gradient). In order to continue to use
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this method for FMRP mRNA target identification, it is necessary to increase the signal
to noise ratio by measuring these reciprocal changes or by using an animal model with a
more severe phenotype (i.e. FMRP/FXR2 double knockout mice) to validate the subtle
changes in mRNA-polyribosome association that we have identified in FMRP single
knockout mice. Finally, activity-dependent changes in the functional interaction between
FMRP and the translational apparatus have been proposed by a number of groups
(Greenough et al., 2001; Hou et al., 2006; Huber et al., 2002; Weiler et al., 2004). A
polyribosome-associated, transcriptome-wide analysis of the effect of FMRP combined
with synaptic activity in the form of metabotropic glutamate receptor modulation or
seizure induction could provide a more refined view of the activity-dependent actions of
FMRP.
We have discovered that FMRP associates with polyribosomes via binding of
KH2 to kissing complex (loop-loop pseudoknot) RNA motifs (Darnell et al., 2005a).
Competition with exogenous kissing complex RNAs shifts FMRP off polyribosomes.
This interaction is sequence- and structure-specific, as a single point mutation that
disrupts one Watson-Crick base pair between the two loops fails to bind KH2, and fails to
compete FMRP off brain polyribosomes. The binding of the RGG box to G-quartet RNA
does not have an effect on polyribosomal association of FMRP in brain lysate. These
findings support I304N data as a model for Fragile X mental retardation syndrome, and
suggest that new mRNA targets of FMRP KH2 require identification. In addition, these
data pose new questions of how, where and why the KH2 and RGG box RNA-binding
domains interact with their unique target sequences. Do they identify separate classes of
mRNAs, or populations that contain both types of motifs? Do they bind sequentially;
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perhaps one domain facilitates helicase activity that unwinds one RNA structure, thereby
allowing the binding of the other domain? Do they bring together RNA motifs in trans to
effect translational regulation of via elongation or another as yet unidentified
mechanism? These are all questions that can be addressed in further detail using Gquartet and kissing complex RNA sequences as tools to dissect the interactions of these
domains.
Our experiments demonstrated that KH2:kissing complex RNA interaction is
conserved in the FXR protein family. Both FXR1 and FXR2 bind kissing complex
RNAs through KH2, and like FMRP, are effectively competed off polyribosomes by a
similar concentration of exogenous RNA ligand. For FXR1 and FXR2 individually,
approximately nine percent each appear to be associated with polyribosomes through
FMRP, as they show a subtle shift in polyribosomal distribution in FMRP knockout mice.
However, even in the absence of FMRP, FXR1 and FXR2 do bind polyribosomes via
KH2 interaction with kissing complex RNA. We demonstrated that this relationship is
specific to FXR family proteins, since the polyribosomal distributions of other RNAbinding proteins and FMRP-interacting proteins are unaffected by kissing complex RNA.
RNA binding by KH2 does not abrogate heterodimerization of FMRP with FXR1 and
FXR2.

The high degree of sequence and functional conservation between the KH

domains of the three Fragile X-related proteins is a clue to possible overlapping functions
among these proteins and underscores the critical nature of this role.
An argument can be made that the cellular, behavioral and cognitive phenotypes
of fragile X mental retardation syndrome are due to a loss of FMRP RGG domain RNAbinding activity alone, since FXR1 and FXR2 are present at normal levels in individuals
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with fragile X syndrome. However, the existence of a severely affected fragile X patient
with a point mutation in KH2 contradicts this hypothesis (De Boulle et al., 1993). I304N
FMRP is able to bind G-quartet RNA through the RGG-box domain with wild type
affinity (Darnell et al., 2001). Thus, even though the KH domains of FMRP, FXR1 and
FXR2 may share similar roles in translational regulation, the loss-of-function of FMRP
that occurs in fragile X syndrome likely includes roles for both the KH and RGG box
domains. This warrants further investigation of the physiological roles of FXR family
KH domains in translational regulation in vivo. In order to elucidate these roles, it will be
important to develop domain-specific loss-of-function mouse models, such as an FMRP
knock-in allele lacking the RGG box. Mice lacking both FMRP and FXR2 have been
generated and show increased neurological phenotypes (Spencer et al., 2006). The I304N
mutation, while representing a valuable model for fragile X syndrome, does not serve as a
robust dominant negative for all three FMRP family members, since the majority of
FXR1 and FXR2 proteins are associated with polyribosomes in the absence of proteinprotein interactions with FMRP. Our attempts to create a KH2-specific triple functional
knockdown system for FMRP, FXR1 and FXR2 by expression of kissing complex RNA
decoys in vivo have been unsuccessful to date, due to difficulty expressing RNA decoys
at a sufficient level. However, this type of methodology represents a unique strategy to
achieve a more insightful analysis of what appears to be a highly conserved role for FXRfamily proteins in translational control.
Our data suggest a new model for FMRP function in neurons. FMRP, as a
nucleocytoplasmic shuttling protein, binds mRNAs either co-transcriptionally in the
nucleus, during nuclear export, or once the mRNA has reached the cytoplasm. We find

149

that FMRP-bound mRNAs cosediment with the heaviest fractions of the polyribosomal
distribution in a sucrose gradient. FMRP associates with polyribosomes via interaction
between the KH2 domain and a kissing-complex RNA motif. The RGG domain of
FMRP may add additional specificity to this protein-mRNA interaction through a G
quartet motif in the same mRNA. Alternatively, it may bind a G quartet in a separate
RNA moiety, be that microRNA, ribosomal RNA, structural non-coding RNA, or another
mRNA. Since FXR1 and FXR2 also associate with polyribosomes via interaction with
kcRNA motifs, we can envision a pool of mRNAs marked, and perhaps sequestered by
their interactions with FMRP family members. These mRNAs are likely to be loaded
with many ribosomes, in a state of translational repression that can be lifted on receipt of
a local synaptic signal indicating a need for the protein products of these mRNAs. Such a
signal could involve phosphorylation of FMRP family members and/or a conformational
change that unwinds these mRNP complexes and allows translation to restart.
The Nova and Fragile X-related protein families share homology as RNA-binding
proteins through their KH domains. Their diversity in displaying different polyribosomal
associations, subcellular distributions, and likely different roles in post-synaptic
translational regulation, demonstrate the important nature of RNA-binding proteins in
human neurologic function and disease. Their pathophysiologic role is not necessarily
limited to that in the diseases in which they were discovered. For example, FXR1 has
been described as an autoantigen in a case of scleroderma (Bolivar et al., 1998). Of note,
this is just one such example of how RNA-binding proteins are implicated in autoimmune
neurological diseases.

In regard to the biology of these protein families, persistent

pursuit at the bench will not be lost in translation to the clinic.

150

REFERENCES

Abitbol, M., Menini, C., Delezoide, A. L., Rhyner, T., Vekemans, M., and
Mallet, J. (1993). Nucleus basalis magnocellularis and hippocampus are the
major sites of FMR-1 expression in the human fetal brain. Nat Genet 4, 147153.
Adinolfi, S., Ramos, A., Martin, S. R., Dal Piaz, F., Pucci, P., Bardoni, B.,
Mandel, J. L., and Pastore, A. (2003). The N-terminus of the fragile X
mental retardation protein contains a novel domain involved in dimerization
and RNA binding. Biochemistry 42, 10437-10444.
Akamatsu, W., Fujihara, H., Mitsuhashi, T., Yano, M., Shibata, S.,
Hayakawa, Y., Okano, H. J., Sakakibara, S., Takano, H., Takano, T., et al.
(2005). The RNA-binding protein HuD regulates neuronal cell identity and
maturation. Proc Natl Acad Sci U S A 102, 4625-4630.
Akamatsu, W., Okano, H. J., Osumi, N., Inoue, T., Nakamura, S.,
Sakakibara, S., Miura, M., Matsuo, N., Darnell, R. B., and Okano, H.
(1999). Mammalian ELAV-like neuronal RNA-binding proteins HuB and
HuC promote neuronal development in both the central and the peripheral
nervous systems. Proc Natl Acad Sci U S A 96, 9885-9890.
Albert, M. L., Austin, L. M., and Darnell, R. B. (2000). Detection and
treatment of activated T cells in the cerebrospinal fluid of patients with
paraneoplastic cerebellar degeneration. Ann Neurol 47, 9-17.
Albert, M. L., Darnell, J. C., Bender, A., Francisco, L. M., Bhardwaj, N.,
and Darnell, R. B. (1998). Tumor-specific killer cells in paraneoplastic
cerebellar degeneration. Nat Med 4, 1321-1324.
Albert, M. L., and Darnell, R. B. (2004). Paraneoplastic neurological
degenerations: keys to tumour immunity. Nat Rev Cancer 4, 36-44.
Antic, D., and Keene, J. D. (1997). Embryonic lethal abnormal visual RNAbinding proteins involved in growth, differentiation, and posttranscriptional
gene expression. Am J Hum Genet 61, 273-278.
Antic, D., and Keene, J. D. (1998). Messenger ribonucleoprotein complexes
containing human ELAV proteins: interactions with cytoskeleton and
translational apparatus. J Cell Sci 111, 183-197.
151

Antic, D., Lu, N., and Keene, J. D. (1999). ELAV tumor antigen, Hel-N1,
increases translation of neurofilament M mRNA and induces formation of
neurites in human teratocarcinoma cells. Genes Dev 13, 449-461.
Arava, Y., Wang, Y., Storey, J. D., Liu, C. L., Brown, P. O., and Herschlag,
D. (2003). Genome-wide analysis of mRNA translation profiles in
Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 100, 3889-3894.
Argaman, L., and Altuvia, S. (2000). fhlA repression by OxyS RNA: kissing
complex formation at two sites results in a stable antisense-target RNA
complex. J Mol Biol 300, 1101-1112.
Arning, S., Gruter, P., Bilbe, G., and Kramer, A. (1996). Mammalian
splicing factor SF1 is encoded by variant cDNAs and binds to RNA. Rna 2,
794-810.
Arrighi, J. F., Pion, M., Wiznerowicz, M., Geijtenbeek, T. B., Garcia, E.,
Abraham, S., Leuba, F., Dutoit, V., Ducrey-Rundquist, O., van Kooyk, Y., et
al. (2004). Lentivirus-mediated RNA interference of DC-SIGN expression
inhibits human immunodeficiency virus transmission from dendritic cells to
T cells. J Virol 78, 10848-10855.
Ashley, C. T., Jr., Wilkinson, K. D., Reines, D., and Warren, S. T. (1993).
FMR1 protein: conserved RNP family domains and selective RNA binding.
Science 262, 563-566.
Bagni, C., Mannucci, L., Dotti, C. G., and Amaldi, F. (2000). Chemical
stimulation of synaptosomes modulates alpha -Ca2+/calmodulin-dependent
protein kinase II mRNA association to polysomes. J Neurosci 20, RC76.
Bailey, C. H., Bartsch, D., and Kandel, E. R. (1996). Toward a molecular
definition of long-term memory storage. Proc Natl Acad Sci U S A 93,
13445-13452.
Bakker, C. E., de Diego Otero, Y., Bontekoe, C., Raghoe, P., Luteijn, T.,
Hoogeveen, A. T., Oostra, B. A., and Willemsen, R. (2000).
Immunocytochemical and biochemical characterization of FMRP, FXR1P,
and FXR2P in the mouse. Exp Cell Res 258, 162-170.
Bardoni, B., Castets, M., Huot, M. E., Schenck, A., Adinolfi, S., Corbin, F.,
Pastore, A., Khandjian, E. W., and Mandel, J. L. (2003a). 82-FIP, a novel

152

FMRP (fragile X mental retardation protein) interacting protein, shows a cell
cycle-dependent intracellular localization. Hum Mol Genet 12, 1689-1698.
Bardoni, B., Schenck, A., and Mandel, J. L. (1999). A novel RNA-binding
nuclear protein that interacts with the fragile X mental retardation (FMR1)
protein. Hum Mol Genet 8, 2557-2566.
Bardoni, B., Willemsen, R., Weiler, I. J., Schenck, A., Severijnen, L. A.,
Hindelang, C., Lalli, E., and Mandel, J. L. (2003b). NUFIP1 (nuclear FMRP
interacting protein 1) is a nucleocytoplasmic shuttling protein associated
with active synaptoneurosomes. Exp Cell Res 289, 95-107.
Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and
function. Cell 116, 281-297.
Becker, Y., Penman, S., and Darnell, J. E. (1963). A Cytoplasmic Particulate
Involved In Poliovirus Synthesis. Virology 21, 274-276.
Behm-Ansmant, I., Rehwinkel, J., Doerks, T., Stark, A., Bork, P., and
Izaurralde, E. (2006). mRNA degradation by miRNAs and GW182 requires
both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes.
Genes Dev 20, 1885-1898.
Bolivar, J., Guelman, S., Iglesias, C., Ortiz, M., and Valdivia, M. M. (1998).
The fragile-X-related gene FXR1 is a human autoantigen processed during
apoptosis. J Biol Chem 273, 17122-17127.
Bontekoe, C. J., McIlwain, K. L., Nieuwenhuizen, I. M., Yuva-Paylor, L. A.,
Nellis, A., Willemsen, R., Fang, Z., Kirkpatrick, L., Bakker, C. E.,
McAninch, R., et al. (2002). Knockout mouse model for Fxr2: a model for
mental retardation. Hum Mol Genet 11, 487-498.
Braat, A. K., Yan, N., Arn, E., Harrison, D., and Macdonald, P. M. (2004).
Localization-dependent oskar protein accumulation; control after the
initiation of translation. Dev Cell 7, 125-131.
Brosius, J., and Tiedge, H. (2001). Neuronal BC1 RNA: intracellular
transport and activity-dependent modulation. Results Probl Cell Differ 34,
129-138.
Brown, V., Jin, P., Ceman, S., Darnell, J. C., O'Donnell, W. T., Tenenbaum,
S. A., Jin, X., Feng, Y., Wilkinson, K. D., Keene, J. D., et al. (2001).
153

Microarray identification of FMRP-associated brain mRNAs and altered
mRNA translational profiles in fragile X syndrome. Cell 107, 477-487.
Brown, V., Small, K., Lakkis, L., Feng, Y., Gunter, C., Wilkinson, K. D.,
and Warren, S. T. (1998). Purified recombinant Fmrp exhibits selective
RNA binding as an intrinsic property of the fragile X mental retardation
protein. J Biol Chem 273, 15521-15527.
Buckanovich, R. J., Posner, J. B., and Darnell, R. B. (1993). Nova, the
paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is
specifically expressed in the developing motor system. Neuron 11, 657-672.
Buckanovich, R. J., Yang, Y. Y., and Darnell, R. B. (1996). The onconeural
antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of
which is inhibited by paraneoplastic antibodies. J Neurosci 16, 1114-1122.
Bushell, M., Poncet, D., Marissen, W. E., Flotow, H., Lloyd, R. E., Clemens,
M. J., and Morley, S. J. (2000). Cleavage of polypeptide chain initiation
factor eIF4GI during apoptosis in lymphoma cells: characterisation of an
internal fragment generated by caspase-3-mediated cleavage. Cell Death
Differ 7, 628-636.
Caudy, A. A., Ketting, R. F., Hammond, S. M., Denli, A. M., Bathoorn, A.
M., Tops, B. B., Silva, J. M., Myers, M. M., Hannon, G. J., and Plasterk, R.
H. (2003). A micrococcal nuclease homologue in RNAi effector complexes.
Nature 425, 411-414.
Caudy, A. A., Myers, M., Hannon, G. J., and Hammond, S. M. (2002).
Fragile X-related protein and VIG associate with the RNA interference
machinery. Genes Dev 16, 2491-2496.
Ceman, S., Brown, V., and Warren, S. T. (1999). Isolation of an FMRPassociated messenger ribonucleoprotein particle and identification of
nucleolin and the fragile X-related proteins as components of the complex.
Mol Cell Biol 19, 7925-7932.
Ceman, S., Nelson, R., and Warren, S. T. (2000). Identification of mouse
YB1/p50 as a component of the FMRP-associated mRNP particle. Biochem
Biophys Res Commun 279, 904-908.

154

Ceman, S., O'Donnell, W. T., Reed, M., Patton, S., Pohl, J., and Warren, S.
T. (2003). Phosphorylation influences the translation state of FMRPassociated polyribosomes. Hum Mol Genet 12, 3295-3305.
Chapman, R. E., and Walter, P. (1997). Translational attenuation mediated
by an mRNA intron. Curr Biol 7, 850-859.
Chen, L., Yun, S. W., Seto, J., Liu, W., and Toth, M. (2003). The fragile X
mental retardation protein binds and regulates a novel class of mRNAs
containing U rich target sequences. Neuroscience 120, 1005-1017.
Chen, P. Y., and Meister, G. (2005). microRNA-guided posttranscriptional
gene regulation. Biol Chem 386, 1205-1218.
Chicurel, M. E., Terrian, D. M., and Potter, H. (1993). mRNA at the
synapse: analysis of a synaptosomal preparation enriched in hippocampal
dendritic spines. J Neurosci 13, 4054-4063.
Clark, I. E., Wyckoff, D., and Gavis, E. R. (2000). Synthesis of the posterior
determinant Nanos is spatially restricted by a novel cotranslational
regulatory mechanism. Curr Biol 10, 1311-1314.
Coffee, B., Zhang, F., Warren, S. T., and Reines, D. (1999). Acetylated
histones are associated with FMR1 in normal but not fragile X-syndrome
cells. Nat Genet 22, 98-101.
Comery, T. A., Harris, J. B., Willems, P. J., Oostra, B. A., Irwin, S. A.,
Weiler, I. J., and Greenough, W. T. (1997). Abnormal dendritic spines in
fragile X knockout mice: maturation and pruning deficits. Proc Natl Acad
Sci U S A 94, 5401-5404.
Corbin, F., Bouillon, M., Fortin, A., Morin, S., Rousseau, F., and Khandjian,
E. W. (1997). The fragile X mental retardation protein is associated with
poly(A)+ mRNA in actively translating polyribosomes. Hum Mol Genet 6,
1465-1472.
Crino, P. B., and Eberwine, J. (1996). Molecular characterization of the
dendritic growth cone: regulated mRNA transport and local protein
synthesis. Neuron 17, 1173-1187.

155

D'Agata, V., Warren, S. T., Zhao, W., Torre, E. R., Alkon, D. L., and
Cavallaro, S. (2002). Gene expression profiles in a transgenic animal model
of fragile X syndrome. Neurobiol Dis 10, 211-218.
Darnell, J. C., Fraser, C. E., Mostovetsky, O., Stefani, G., Jones, T. A.,
Eddy, S. R., and Darnell, R. B. (2005a). Kissing complex RNAs mediate
interaction between the Fragile-X mental retardation protein KH2 domain
and brain polyribosomes. Genes Dev 19, 903-918.
Darnell, J. C., Jensen, K. B., Jin, P., Brown, V., Warren, S. T., and Darnell,
R. B. (2001). Fragile X mental retardation protein targets G quartet mRNAs
important for neuronal function. Cell 107, 489-499.
Darnell, J. C., Mostovetsky, O., and Darnell, R. B. (2005b). FMRP RNA
targets: identification and validation. Genes Brain Behav 4, 341-349.
Darnell, R. B. (1996). Onconeural antigens and the paraneoplastic
neurologic disorders: at the intersection of cancer, immunity, and the brain.
Proc Natl Acad Sci U S A 93, 4529-4536.
Darnell, R. B., and Posner, J. B. (2003). Paraneoplastic syndromes involving
the nervous system. N Engl J Med 349, 1543-1554.
Darnell, R. B., and Posner, J. B. (2006). Paraneoplastic syndromes affecting
the nervous system. Semin Oncol 33, 270-298.
Davidovic, L., Bechara, E., Gravel, M., Jaglin, X. H., Tremblay, S., Sik, A.,
Bardoni, B., and Khandjian, E. W. (2006). The nuclear MicroSpherule
protein 58 is a novel RNA-binding protein that interacts with fragile X
mental retardation protein in polyribosomal mRNPs from neurons. Hum Mol
Genet 15, 1525-1538.
Davis, B. D., Tai, P. C., and Wallace, B. J. (1974). Complex interactions of
antibiotics with the ribosome. In Ribosomes, A. T. M. Nomura, and P.
Lengyel, eds. (Cold Spring Harbor, NY, Cold Spring Harbor), pp. 771-789.
De Boulle, K., Verkerk, A. J., Reyniers, E., Vits, L., Hendrickx, J., Van Roy,
B., Van den Bos, F., de Graaff, E., Oostra, B. A., and Willems, P. J. (1993).
A point mutation in the FMR-1 gene associated with fragile X mental
retardation. Nat Genet 3, 31-35.

156

De Diego Otero, Y., Severijnen, L. A., van Cappellen, G., Schrier, M.,
Oostra, B., and Willemsen, R. (2002). Transport of fragile X mental
retardation protein via granules in neurites of PC12 cells. Mol Cell Biol 22,
8332-8341.
Denman, R. B., and Sung, Y. J. (2002). Species-specific and isoformspecific RNA binding of human and mouse fragile X mental retardation
proteins. Biochem Biophys Res Commun 292, 1063-1069.
Devys, D., Lutz, Y., Rouyer, N., Bellocq, J. P., and Mandel, J. L. (1993).
The FMR-1 protein is cytoplasmic, most abundant in neurons and appears
normal in carriers of a fragile X premutation. Nat Genet 4, 335-340.
Dockendorff, T. C., Su, H. S., McBride, S. M., Yang, Z., Choi, C. H.,
Siwicki, K. K., Sehgal, A., and Jongens, T. A. (2002). Drosophila lacking
dfmr1 activity show defects in circadian output and fail to maintain
courtship interest. Neuron 34, 973-984.
Dolzhanskaya, N., Sung, Y. J., Conti, J., Currie, J. R., and Denman, R. B.
(2003). The fragile X mental retardation protein interacts with U-rich RNAs
in a yeast three-hybrid system. Biochem Biophys Res Commun 305, 434441.
Dredge, B. K., and Darnell, R. B. (2003). Nova regulates GABA(A) receptor
gamma2 alternative splicing via a distal downstream UCAU-rich intronic
splicing enhancer. Mol Cell Biol 23, 4687-4700.
Dredge, B. K., Stefani, G., Engelhard, C. C., and Darnell, R. B. (2005).
Nova autoregulation reveals dual functions in neuronal splicing. Embo J 24,
1608-1620.
Eberhart, D. E., Malter, H. E., Feng, Y., and Warren, S. T. (1996). The
fragile X mental retardation protein is a ribonucleoprotein containing both
nuclear localization and nuclear export signals. Hum Mol Genet 5, 10831091.
Eberwine, J. (1996). Amplification of mRNA populations using aRNA
generated from immobilized oligo(dT)-T7 primed cDNA. Biotechniques 20,
584-591.
Eberwine, J., Belt, B., Kacharmina, J. E., and Miyashiro, K. (2002).
Analysis of subcellularly localized mRNAs using in situ hybridization,
157

mRNA amplification, and expression profiling. Neurochem Res 27, 10651077.
Eberwine, J., Miyashiro, K., Kacharmina, J. E., and Job, C. (2001). Local
translation of classes of mRNAs that are targeted to neuronal dendrites. Proc
Natl Acad Sci U S A 98, 7080-7085.
Eichler, E. E., Richards, S., Gibbs, R. A., and Nelson, D. L. (1993). Fine
structure of the human FMR1 gene. Hum Mol Genet 2, 1147-1153.
Eom, T., Antar, L. N., Singer, R. H., and Bassell, G. J. (2003). Localization
of a beta-actin messenger ribonucleoprotein complex with zipcode-binding
protein modulates the density of dendritic filopodia and filopodial synapses.
J Neurosci 23, 10433-10444.
Evans, L. L., Lee, A. J., Bridgman, P. C., and Mooseker, M. S. (1998).
Vesicle-associated brain myosin-V can be activated to catalyze actin-based
transport. J Cell Sci 111 (Pt 14), 2055-2066.
Expert-Bezancon, A., Le Caer, J. P., and Marie, J. (2002). Heterogeneous
nuclear ribonucleoprotein (hnRNP) K is a component of an intronic splicing
enhancer complex that activates the splicing of the alternative exon 6A from
chicken beta-tropomyosin pre-mRNA. J Biol Chem 277, 16614-16623.
Eystathioy, T., Chan, E. K., Tenenbaum, S. A., Keene, J. D., Griffith, K.,
and Fritzler, M. J. (2002). A phosphorylated cytoplasmic autoantigen,
GW182, associates with a unique population of human mRNAs within novel
cytoplasmic speckles. Mol Biol Cell 13, 1338-1351.
Farina, K. L., Huttelmaier, S., Musunuru, K., Darnell, R., and Singer, R. H.
(2003). Two ZBP1 KH domains facilitate beta-actin mRNA localization,
granule formation, and cytoskeletal attachment. J Cell Biol 160, 77-87.
Feng, Y., Absher, D., Eberhart, D. E., Brown, V., Malter, H. E., and Warren,
S. T. (1997a). FMRP associates with polyribosomes as an mRNP, and the
I304N mutation of severe fragile X syndrome abolishes this association. Mol
Cell 1, 109-118.
Feng, Y., Gutekunst, C. A., Eberhart, D. E., Yi, H., Warren, S. T., and
Hersch, S. M. (1997b). Fragile X mental retardation protein:
nucleocytoplasmic shuttling and association with somatodendritic
ribosomes. J Neurosci 17, 1539-1547.
158

Ferrandon, D., Koch, I., Westhof, E., and Nusslein-Volhard, C. (1997).
RNA-RNA interaction is required for the formation of specific bicoid
mRNA 3' UTR-STAUFEN ribonucleoprotein particles. Embo J 16, 17511758.
Fridell, R. A., Benson, R. E., Hua, J., Bogerd, H. P., and Cullen, B. R.
(1996). A nuclear role for the Fragile X mental retardation protein. Embo J
15, 5408-5414.
Fu, Y. H., Kuhl, D. P., Pizzuti, A., Pieretti, M., Sutcliffe, J. S., Richards, S.,
Verkerk, A. J., Holden, J. J., Fenwick, R. G., Jr., Warren, S. T., and et al.
(1991). Variation of the CGG repeat at the fragile X site results in genetic
instability: resolution of the Sherman paradox. Cell 67, 1047-1058.
Gabus, C., Mazroui, R., Tremblay, S., Khandjian, E. W., and Darlix, J. L.
(2004). The fragile X mental retardation protein has nucleic acid chaperone
properties. Nucleic Acids Res 32, 2129-2137.
Gagne, J. P., Bonicalzi, M. E., Gagne, P., Ouellet, M. E., Hendzel, M. J., and
Poirier, G. G. (2005). Poly(ADP-ribose) glycohydrolase is a component of
the FMRP-associated messenger ribonucleoparticles. Biochem J 392, 499509.
Galban, S., Fan, J., Martindale, J. L., Cheadle, C., Hoffman, B., Woods, M.
P., Temeles, G., Brieger, J., Decker, J., and Gorospe, M. (2003). von HippelLindau Protein-Mediated Repression of Tumor Necrosis Factor Alpha
Translation Revealed through Use of cDNA Arrays. Mol Cell Biol 23, 23162328.
Gallia, G. L., Johnson, E. M., and Khalili, K. (2000). Puralpha: a
multifunctional single-stranded DNA- and RNA-binding protein. Nucleic
Acids Res 28, 3197-3205.
Gallouzi, I. E., Brennan, C. M., Stenberg, M. G., Swanson, M. S., Eversole,
A., Maizels, N., and Steitz, J. A. (2000). HuR binding to cytoplasmic mRNA
is perturbed by heat shock. Proc Natl Acad Sci U S A 97, 3073-3078.
Gardiol, A., Racca, C., and Triller, A. (1999). Dendritic and postsynaptic
protein synthetic machinery. J Neurosci 19, 168-179.

159

Gardiol, A., Racca, C., and Triller, A. (2001). RNA transport and local
protein synthesis in the dendritic compartment. Results Probl Cell Differ 34,
105-128.
Gebauer, F., and Hentze, M. W. (2004). Molecular mechanisms of
translational control. Nat Rev Mol Cell Biol 5, 827-835.
Gierer, A. (1963). Function of aggregated reticulocyte ribosomes in protein
synthesis. J Mol Biol 6, 148-157.
Gingras, A. C., Raught, B., and Sonenberg, N. (1999). eIF4 initiation
factors: effectors of mRNA recruitment to ribosomes and regulators of
translation. Annu Rev Biochem 68, 913-963.
Gould, E. L., Loesch, D. Z., Martin, M. J., Hagerman, R. J., Armstrong, S.
M., and Huggins, R. M. (2000). Melatonin profiles and sleep characteristics
in boys with fragile X syndrome: a preliminary study. Am J Med Genet 95,
307-315.
Govindarajan, A., Kelleher, R. J., and Tonegawa, S. (2006). A clustered
plasticity model of long-term memory engrams. Nat Rev Neurosci 7, 575583.
Gray, N. K., and Hentze, M. W. (1994). Iron regulatory protein prevents
binding of the 43S translation pre-initiation complex to ferritin and eALAS
mRNAs. Embo J 13, 3882-3891.
Greenough, W. T., Klintsova, A. Y., Irwin, S. A., Galvez, R., Bates, K. E.,
and Weiler, I. J. (2001). Synaptic regulation of protein synthesis and the
fragile X protein. Proc Natl Acad Sci U S A 98, 7101-7106.
Grolleau, A., Bowman, J., Pradet-Balade, B., Puravs, E., Hanash, S., GarciaSanz, J. A., and Beretta, L. (2002). Global and Specific Translational
Control by Rapamycin in T Cells Uncovered by Microarrays and
Proteomics. J Biol Chem %R 101074/jbcM202014200 277, 22175-22184.
Hay, N., and Sonenberg, N. (2004). Upstream and downstream of mTOR.
Genes Dev %R 101101/gad1212704 18, 1926-1945.
Hergersberg, M., Matsuo, K., Gassmann, M., Schaffner, W., Luscher, B.,
Rulicke, T., and Aguzzi, A. (1995). Tissue-specific expression of a

160

FMR1/beta-galactosidase fusion gene in transgenic mice. Hum Mol Genet 4,
359-366.
Hinds, H. L., Ashley, C. T., Sutcliffe, J. S., Nelson, D. L., Warren, S. T.,
Housman, D. E., and Schalling, M. (1993). Tissue specific expression of
FMR-1 provides evidence for a functional role in fragile X syndrome [see
comments] [published erratum appears in Nat Genet 1993 Nov;5(3):312].
Nat Genet 3, 36-43.
Hinton, V. J., Brown, W. T., Wisniewski, K., and Rudelli, R. D. (1991).
Analysis of neocortex in three males with the fragile X syndrome. Am J
Med Genet 41, 289-294.
Hirst, M., Grewal, P., Flannery, A., Slatter, R., Maher, E., Barton, D., Fryns,
J. P., and Davies, K. (1995). Two new cases of FMR1 deletion associated
with mental impairment. Am J Hum Genet 56, 67-74.
Holland, E. C., Sonenberg, N., Pandolfi, P. P., and Thomas, G. (2004).
Signaling control of mRNA translation in cancer pathogenesis. Oncogene
23, 3138-3144.
Hornstra, I. K., Nelson, D. L., Warren, S. T., and Yang, T. P. (1993). High
resolution methylation analysis of the FMR1 gene trinucleotide repeat region
in fragile X syndrome. Hum Mol Genet 2, 1659-1665.
Hou, L., Antion, M. D., Hu, D., Spencer, C. M., Paylor, R., and Klann, E.
(2006). Dynamic Translational and Proteasomal Regulation of Fragile X
Mental Retardation Protein Controls mGluR-Dependent Long-Term
Depression. Neuron 51, 441-454.
Huang, Y. S., Jung, M. Y., Sarkissian, M., and Richter, J. D. (2002). Nmethyl-D-aspartate receptor signaling results in Aurora kinase-catalyzed
CPEB phosphorylation and alpha CaMKII mRNA polyadenylation at
synapses. Embo J 21, 2139-2148.
Huber, K. M., Gallagher, S. M., Warren, S. T., and Bear, M. F. (2002).
Altered synaptic plasticity in a mouse model of fragile X mental retardation.
Proc Natl Acad Sci U S A 99, 7746-7750.
Huttelmaier, S., Zenklusen, D., Lederer, M., Dictenberg, J., Lorenz, M.,
Meng, X., Bassell, G. J., Condeelis, J., and Singer, R. H. (2005). Spatial

161

regulation of beta-actin translation by Src-dependent phosphorylation of
ZBP1. Nature 438, 512-515.
Hutvagner, G., and Zamore, P. D. (2002). A microRNA in a multipleturnover RNAi enzyme complex. Science 297, 2056-2060.
Iguchi, N., Tobias, J. W., and Hecht, N. B. (2006). Expression profiling
reveals meiotic male germ cell mRNAs that are translationally up- and
down-regulated. PNAS %R 101073/pnas0510999103 103, 7712-7717.
Inoue, S., Shimoda, M., Nishinokubi, I., Siomi, M. C., Okamura, M.,
Nakamura, A., Kobayashi, S., Ishida, N., and Siomi, H. (2002). A role for
the Drosophila fragile X-related gene in circadian output. Curr Biol 12,
1331-1335.
Irizarry, R. A., Hobbs, B., Collin, F., Beazer-Barclay, Y. D., Antonellis, K.
J., Scherf, U., and Speed, T. P. (2003). Exploration, normalization, and
summaries of high density oligonucleotide array probe level data.
Biostatistics 4, 249-264.
Irwin, S. A., Galvez, R., and Greenough, W. T. (2000). Dendritic spine
structural anomalies in fragile-X mental retardation syndrome. Cereb Cortex
10, 1038-1044.
Ishizuka, A., Siomi, M. C., and Siomi, H. (2002). A Drosophila fragile X
protein interacts with components of RNAi and ribosomal proteins. Genes
Dev 16, 2497-2508.
Jakymiw, A., Lian, S., Eystathioy, T., Li, S., Satoh, M., Hamel, J. C.,
Fritzler, M. J., and Chan, E. K. (2005). Disruption of GW bodies impairs
mammalian RNA interference. Nat Cell Biol 7, 1267-1274.
Jensen, K. B., Dredge, B. K., Stefani, G., Zhong, R., Buckanovich, R. J.,
Okano, H. J., Yang, Y. Y., and Darnell, R. B. (2000a). Nova-1 regulates
neuron-specific alternative splicing and is essential for neuronal viability.
Neuron 25, 359-371.
Jensen, K. B., Musunuru, K., Lewis, H. A., Burley, S. K., and Darnell, R. B.
(2000b). The tetranucleotide UCAY directs the specific recognition of RNA
by the Nova K-homology 3 domain. Proc Natl Acad Sci U S A 97, 57405745.

162

Jin, P., and Warren, S. T. (2003). New insights into fragile X syndrome:
from molecules to neurobehaviors. Trends Biochem Sci 28, 152-158.
Jin, P., Zarnescu, D. C., Ceman, S., Nakamoto, M., Mowrey, J., Jongens, T.
A., Nelson, D. L., Moses, K., and Warren, S. T. (2004). Biochemical and
genetic interaction between the fragile X mental retardation protein and the
microRNA pathway. Nat Neurosci 7, 113-117.
Johannes, G., Carter, M. S., Eisen, M. B., Brown, P. O., and Sarnow, P.
(1999). Identification of eukaryotic mRNAs that are translated at reduced
cap binding complex eIF4F concentrations using a cDNA microarray. PNAS
%R 101073/pnas962313118 96, 13118-13123.
Kang, H., and Schuman, E. M. (1996). A requirement for local protein
synthesis in neurotrophin-induced hippocampal synaptic plasticity. Science
273, 1402-1406.
Kawaguchi, R., and Bailey-Serres, J. (2005). mRNA sequence features that
contribute to translational regulation in Arabidopsis. Nucl Acids Res %R
101093/nar/gki240 33, 955-965.
Kelleher, R. J., 3rd, Govindarajan, A., Jung, H. Y., Kang, H., and Tonegawa,
S. (2004a). Translational control by MAPK signaling in long-term synaptic
plasticity and memory. Cell 116, 467-479.
Kelleher, R. J., 3rd, Govindarajan, A., and Tonegawa, S. (2004b).
Translational regulatory mechanisms in persistent forms of synaptic
plasticity. Neuron 44, 59-73.
Khalili, K., Del Valle, L., Muralidharan, V., Gault, W. J., Darbinian, N.,
Otte, J., Meier, E., Johnson, E. M., Daniel, D. C., Kinoshita, Y., et al.
(2003). Puralpha is essential for postnatal brain development and
developmentally coupled cellular proliferation as revealed by genetic
inactivation in the mouse. Mol Cell Biol 23, 6857-6875.
Khandjian, E. W., Corbin, F., Woerly, S., and Rousseau, F. (1996). The
fragile X mental retardation protein is associated with ribosomes. Nat Genet
12, 91-93.
Khandjian, E. W., Fortin, A., Thibodeau, A., Tremblay, S., Cote, F., Devys,
D., Mandel, J. L., and Rousseau, F. (1995). A heterogeneous set of FMR1

163

proteins is widely distributed in mouse tissues and is modulated in cell
culture. Hum Mol Genet 4, 783-789.
Khandjian, E. W., Huot, M.-E., Tremblay, S., Davidovic, L., Mazroui, R.,
and Bardoni, B. (2004). Biochemical evidence for the association of fragile
X mental retardation protein with brain polyribosomal ribonucleoparticles.
PNAS %R 101073/pnas0405398101 101, 13357-13362.
Kiledjian, M., Wang, X., and Liebhaber, S. A. (1995). Identification of two
KH domain proteins in the alpha-globin mRNP stability complex. Embo J
14, 4357-4364.
Kim, S. H., Suddath, F. L., Quigley, G. J., McPherson, A., Sussman, J. L.,
Wang, A. H., Seeman, N. C., and Rich, A. (1974). Three-dimensional
tertiary structure of yeast phenylalanine transfer RNA. Science 185, 435440.
Kim, Y., Sung, J. Y., Ceglia, I., Lee, K. W., Ahn, J. H., Halford, J. M., Kim,
A. M., Kwak, S. P., Park, J. B., Ho Ryu, S., et al. (2006). Phosphorylation of
WAVE1 regulates actin polymerization and dendritic spine morphology.
Nature 442, 814-817.
Kindler, S., Wang, H., Richter, D., and Tiedge, H. (2005). RNA transport
and local control of translation. Annu Rev Cell Dev Biol 21, 223-245.
Kobayashi, K., Kuroda, S., Fukata, M., Nakamura, T., Nagase, T., Nomura,
N., Matsuura, Y., Yoshida-Kubomura, N., Iwamatsu, A., and Kaibuchi, K.
(1998). p140Sra-1 (specifically Rac1-associated protein) is a novel specific
target for Rac1 small GTPase. J Biol Chem 273, 291-295.
Kobayashi, S., Agui, K., Kamo, S., Li, Y., and Anzai, K. (2000). Neural
BC1 RNA associates with pur alpha, a single-stranded DNA and RNA
binding protein, which is involved in the transcription of the BC1 RNA
gene. Biochem Biophys Res Commun 277, 341-347.
Kohno, K., Izumi, H., Uchiumi, T., Ashizuka, M., and Kuwano, M. (2003).
The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 25,
691-698.
Kolb, F. A., Malmgren, C., Westhof, E., Ehresmann, C., Ehresmann, B.,
Wagner, E. G., and Romby, P. (2000). An unusual structure formed by

164

antisense-target RNA binding involves an extended kissing complex with a
four-way junction and a side-by-side helical alignment. Rna 6, 311-324.
Krichevsky, A. M., and Kosik, K. S. (2001). Neuronal RNA granules: a link
between RNA localization and stimulation-dependent translation. Neuron
32, 683-696.
Kuhn, U., and Wahle, E. (2004). Structure and function of poly(A) binding
proteins. Biochim Biophys Acta 1678, 67-84.
Kuwabara, T., Warashina, M., Sano, M., Tang, H., Wong-Staal, F.,
Munekata, E., and Taira, K. (2001). Recognition of engineered tRNAs with
an extended 3' end by Exportin-t (Xpo-t) and transport of tRNA-attached
ribozymes to the cytoplasm in somatic cells. Biomacromolecules 2, 12291242.
Laggerbauer, B., Ostareck, D., Keidel, E. M., Ostareck-Lederer, A., and
Fischer, U. (2001). Evidence that fragile X mental retardation protein is a
negative regulator of translation. Hum Mol Genet 10, 329-338.
Lai, D., Sakkas, D., and Huang, Y. (2006). The fragile X mental retardation
protein interacts with a distinct mRNA nuclear export factor NXF2. Rna 12,
1446-1449.
Lee, S. M., Dunnavant, F. D., Jang, H., Zunt, J., and Levin, M. C. (2006).
Autoantibodies that recognize functional domains of hnRNPA1 implicate
molecular mimicry in the pathogenesis of neurological disease. Neurosci
Lett 401, 188-193.
Levin, M. C., Lee, S. M., Kalume, F., Morcos, Y., Dohan, F. C., Jr., Hasty,
K. A., Callaway, J. C., Zunt, J., Desiderio, D., and Stuart, J. M. (2002).
Autoimmunity due to molecular mimicry as a cause of neurological disease.
Nat Med 8, 509-513.
Levine, T. D., Gao, F., King, P. H., Andrews, L. G., and Keene, J. D. (1993).
Hel-N1: an autoimmune RNA-binding protein with specificity for 3'
uridylate-rich untranslated regions of growth factor mRNAs. Mol Cell Biol
13, 3494-3504.
Lewis, H. A., Musunuru, K., Jensen, K. B., Edo, C., Chen, H., Darnell, R.
B., and Burley, S. K. (2000). Sequence-specific RNA binding by a Nova KH

165

domain: implications for paraneoplastic disease and the fragile X syndrome.
Cell 100, 323-332.
Li, Y., Chin, L.-S., Weigel, C., and Li, L. (2001a). Spring, a Novel RING
Finger Protein That Regulates Synaptic Vesicle Exocytosis. J Biol Chem
%R 101074/jbcM106141200 276, 40824-40833.
Li, Z., Zhang, Y., Ku, L., Wilkinson, K. D., Warren, S. T., and Feng, Y.
(2001b). The fragile X mental retardation protein inhibits translation via
interacting with mRNA. Nucleic Acids Res 29, 2276-2283.
Liu, J., Rivas, F. V., Wohlschlegel, J., Yates, J. R., 3rd, Parker, R., and
Hannon, G. J. (2005). A role for the P-body component GW182 in
microRNA function. Nat Cell Biol 7, 1261-1266.
Lu, R., Wang, H., Liang, Z., Ku, L., O'Donnell W, T., Li, W., Warren, S. T.,
and Feng, Y. (2004). The fragile X protein controls microtubule-associated
protein 1B translation and microtubule stability in brain neuron
development. Proc Natl Acad Sci U S A 101, 15201-15206.
Lugenbeel, K. A., Peier, A. M., Carson, N. L., Chudley, A. E., and Nelson,
D. L. (1995). Intragenic loss of function mutations demonstrate the primary
role of FMR1 in fragile X syndrome. Nat Genet 10, 483-485.
Makeyev, A. V., Eastmond, D. L., and Liebhaber, S. A. (2002). Targeting a
KH-domain protein with RNA decoys. Rna 8, 1160-1173.
Marissen, W. E., Triyoso, D., Younan, P., and Lloyd, R. E. (2004).
Degradation of poly(A)-binding protein in apoptotic cells and linkage to
translation regulation. Apoptosis 9, 67-75.
Marks, P. A., Burka, E. R., and Schlessinger, D. (1962). Protein Synthesis In
Erythroid Cells, I. Reticulocyte Ribosomes Active In Stimulating Amino
Acid Incorporation. Proc Natl Acad Sci U S A 48, 2163-2171.
Mayford, M., Bach, M. E., Huang, Y. Y., Wang, L., Hawkins, R. D., and
Kandel, E. R. (1996). Control of memory formation through regulated
expression of a CaMKII transgene. Science 274, 1678-1683.
Mazroui, R., Huot, M. E., Tremblay, S., Boilard, N., Labelle, Y., and
Khandjian, E. W. (2003). Fragile X Mental Retardation protein determinants

166

required for its association with polyribosomal mRNPs. Hum Mol Genet 12,
3087-3096.
Mazroui, R., Huot, M. E., Tremblay, S., Filion, C., Labelle, Y., and
Khandjian, E. W. (2002). Trapping of messenger RNA by Fragile X Mental
Retardation protein into cytoplasmic granules induces translation repression.
Hum Mol Genet 11, 3007-3017.
Mazumder, B., Sampath, P., Seshadri, V., Maitra, R. K., DiCorleto, P. E.,
and Fox, P. L. (2003). Regulated release of L13a from the 60S ribosomal
subunit as a mechanism of transcript-specific translational control. Cell 115,
187-198.
Meijer, H., de Graaff, E., Merckx, D. M., Jongbloed, R. J., de Die-Smulders,
C. E., Engelen, J. J., Fryns, J. P., Curfs, P. M., and Oostra, B. A. (1994). A
deletion of 1.6 kb proximal to the CGG repeat of the FMR1 gene causes the
clinical phenotype of the fragile X syndrome. Hum Mol Genet 3, 615-620.
Mendez, R., and Richter, J. D. (2001). Translational control by CPEB: a
means to the end. Nat Rev Mol Cell Biol 2, 521-529.
Menon, R. P., Gibson, T. J., and Pastore, A. (2004). The C terminus of
fragile X mental retardation protein interacts with the multi-domain Ranbinding protein in the microtubule-organising centre. J Mol Biol 343, 43-53.
Meyuhas, O. (2000). Synthesis of the translational apparatus is regulated at
the translational level. Eur J Biochem 267, 6321-6330.
Michael, W. M., Eder, P. S., and Dreyfuss, G. (1997). The K nuclear
shuttling domain: a novel signal for nuclear import and nuclear export in the
hnRNP K protein. Embo J 16, 3587-3598.
Michel, C. I., Kraft, R., and Restifo, L. L. (2004). Defective neuronal
development in the mushroom bodies of Drosophila fragile X mental
retardation 1 mutants. J Neurosci 24, 5798-5809.
Mientjes, E. J., Willemsen, R., Kirkpatrick, L. L., Nieuwenhuizen, I. M.,
Hoogeveen-Westerveld, M., Verweij, M., Reis, S., Bardoni, B., Hoogeveen,
A. T., Oostra, B. A., and Nelson, D. L. (2004). Fxr1 knockout mice show a
striated muscle phenotype: implications for Fxr1p function in vivo. Hum
Mol Genet 13, 1291-1302.

167

Mili, S., and Steitz, J. A. (2004). Evidence for reassociation of RNA-binding
proteins after cell lysis: implications for the interpretation of
immunoprecipitation analyses. Rna 10, 1692-1694.
Miyashiro, K., Dichter, M., and Eberwine, J. (1994). On the nature and
differential distribution of mRNAs in hippocampal neurites: implications for
neuronal functioning [see comments]. Proc Natl Acad Sci U S A 91, 1080010804.
Miyashiro, K. Y., Beckel-Mitchener, A., Purk, T. P., Becker, K. G., Barret,
T., Liu, L., Carbonetto, S., Weiler, I. J., Greenough, W. T., and Eberwine, J.
(2003). RNA cargoes associating with FMRP reveal deficits in cellular
functioning in Fmr1 null mice. Neuron 37, 417-431.
Moore, M. J. (2005). From birth to death: the complex lives of eukaryotic
mRNAs. Science 309, 1514-1518.
Morales, J., Hiesinger, P. R., Schroeder, A. J., Kume, K., Verstreken, P.,
Jackson, F. R., Nelson, D. L., and Hassan, B. A. (2002). Drosophila fragile
X protein, DFXR, regulates neuronal morphology and function in the brain.
Neuron 34, 961-972.
Moras, D., Comarmond, M. B., Fischer, J., Weiss, R., Thierry, J. C., Ebel, J.
P., and Giege, R. (1980). Crystal structure of yeast tRNAAsp. Nature 288,
669-674.
Mourelatos, Z., Dostie, J., Paushkin, S., Sharma, A., Charroux, B., Abel, L.,
Rappsilber, J., Mann, M., and Dreyfuss, G. (2002). miRNPs: a novel class of
ribonucleoproteins containing numerous microRNAs. Genes Dev 16, 720728.
Muckenthaler, M., Gray, N. K., and Hentze, M. W. (1998). IRP-1 binding to
ferritin mRNA prevents the recruitment of the small ribosomal subunit by
the cap-binding complex eIF4F. Mol Cell 2, 383-388.
Musco, G., Stier, G., Joseph, C., Castiglione Morelli, M. A., Nilges, M.,
Gibson, T. J., and Pastore, A. (1996). Three-dimensional structure and
stability of the KH domain: molecular insights into the fragile X syndrome.
Cell 85, 237-245.
Musumeci, S. A., Bosco, P., Calabrese, G., Bakker, C., De Sarro, G. B.,
Elia, M., Ferri, R., and Oostra, B. A. (2000). Audiogenic seizures
168

susceptibility in transgenic mice with fragile X syndrome. Epilepsia 41, 1923.
Musunuru, K., and Darnell, R. B. (2001). Paraneoplastic neurologic disease
antigens: RNA-binding proteins and signaling proteins in neuronal
degeneration. Annu Rev Neurosci 24, 239-262.
Musunuru, K., and Darnell, R. B. (2004). Determination and augmentation
of RNA sequence specificity of the Nova K-homology domains. Nucleic
Acids Res 32, 4852-4861.
Nakamura, A., Sato, K., and Hanyu-Nakamura, K. (2004). Drosophila cup is
an eIF4E binding protein that associates with Bruno and regulates oskar
mRNA translation in oogenesis. Dev Cell 6, 69-78.
Nelson, M. R., Leidal, A. M., and Smibert, C. A. (2004). Drosophila Cup is
an eIF4E-binding protein that functions in Smaug-mediated translational
repression. Embo J 23, 150-159.
Nguyen, P. V., and Kandel, E. R. (1996). A macromolecular synthesisdependent late phase of long-term potentiation requiring cAMP in the
medial perforant pathway of rat hippocampal slices. J Neurosci 16, 31893198.
Niessing, D., Blanke, S., and Jackle, H. (2002). Bicoid associates with the
5'-cap-bound complex of caudal mRNA and represses translation. Genes
Dev 16, 2576-2582.
Nimchinsky, E. A., Oberlander, A. M., and Svoboda, K. (2001). Abnormal
development of dendritic spines in FMR1 knock-out mice. J Neurosci 21,
5139-5146.
O'Donnell, W. T., and Warren, S. T. (2002). A decade of molecular studies
of fragile X syndrome. Annu Rev Neurosci 25, 315-338.
Oberle, I., Heilig, R., Moisan, J. P., Kloepfer, C., Mattei, G. M., Mattei, J.
F., Boue, J., Froster-Iskenius, U., Jacobs, P. A., Lathrop, G. M., and et al.
(1986). Genetic analysis of the fragile-X mental retardation syndrome with
two flanking polymorphic DNA markers. Proc Natl Acad Sci U S A 83,
1016-1020.

169

Oberle, I., Rousseau, F., Heitz, D., Kretz, C., Devys, D., Hanauer, A., Boue,
J., Bertheas, M. F., and Mandel, J. L. (1991). Instability of a 550-base pair
DNA segment and abnormal methylation in fragile X syndrome. Science
252, 1097-1102.
Ohashi, S., Kobayashi, S., Omori, A., Ohara, S., Omae, A., Muramatsu, T.,
Li, Y., and Anzai, K. (2000). The single-stranded DNA- and RNA-binding
proteins pur alpha and pur beta link BC1 RNA to microtubules through
binding to the dendrite-targeting RNA motifs. J Neurochem 75, 1781-1790.
Ohashi, S., Koike, K., Omori, A., Ichinose, S., Ohara, S., Kobayashi, S.,
Sato, T. A., and Anzai, K. (2002). Identification of mRNA/protein (mRNP)
complexes containing Puralpha, mStaufen, fragile X protein, and myosin Va
and their association with rough endoplasmic reticulum equipped with a
kinesin motor. J Biol Chem 277, 37804-37810.
Okano, H. J., and Darnell, R. B. (1997). A hierarchy of Hu RNA binding
proteins in developing and adult neurons. J Neurosci 17, 3024-3037.
Oleynikov, Y., and Singer, R. H. (2003). Real-time visualization of ZBP1
association with beta-actin mRNA during transcription and localization.
Curr Biol 13, 199-207.
Olsen, P. H., and Ambros, V. (1999). The lin-4 regulatory RNA controls
developmental timing in Caenorhabditis elegans by blocking LIN-14 protein
synthesis after the initiation of translation. Dev Biol 216, 671-680.
Oostra, B. A., Willems, P. J., and Consortium, D.-B. F. X. (1994). Fmr1
knockout mice: a model to study fragile X mental retardation. The DutchBelgian Fragile X Consortium. Cell 78, 23-33.
Ostareck, D. H., Ostareck-Lederer, A., Shatsky, I. N., and Hentze, M. W.
(2001). Lipoxygenase mRNA silencing in erythroid differentiation: The
3'UTR regulatory complex controls 60S ribosomal subunit joining. Cell 104,
281-290.
Ostareck, D. H., Ostareck-Lederer, A., Wilm, M., Thiele, B. J., Mann, M.,
and Hentze, M. W. (1997). mRNA silencing in erythroid differentiation:
hnRNP K and hnRNP E1 regulate 15-lipoxygenase translation from the 3'
end. Cell 89, 597-606.

170

Ostareck-Lederer, A., and Ostareck, D. H. (2004). Control of mRNA
translation and stability in haematopoietic cells: the function of hnRNPs K
and E1/E2. Biol Cell 96, 407-411.
Ostroff, L. E., Fiala, J. C., Allwardt, B., and Harris, K. M. (2002).
Polyribosomes redistribute from dendritic shafts into spines with enlarged
synapses during LTP in developing rat hippocampal slices. Neuron 35, 535545.
Paillart, J. C., Skripkin, E., Ehresmann, B., Ehresmann, C., and Marquet, R.
(1996). A loop-loop "kissing" complex is the essential part of the dimer
linkage of genomic HIV-1 RNA. Proc Natl Acad Sci U S A 93, 5572-5577.
Pan, L., Zhang, Y. Q., Woodruff, E., and Broadie, K. (2004). The
Drosophila fragile X gene negatively regulates neuronal elaboration and
synaptic differentiation. Curr Biol 14, 1863-1870.
Pause, A., Belsham, G. J., Gingras, A. C., Donze, O., Lin, T. A., Lawrence,
J. C., Jr., and Sonenberg, N. (1994). Insulin-dependent stimulation of protein
synthesis by phosphorylation of a regulator of 5'-cap function. Nature 371,
762-767.
Peier, A. M., McIlwain, K. L., Kenneson, A., Warren, S. T., Paylor, R., and
Nelson, D. L. (2000). (Over)correction of FMR1 deficiency with YAC
transgenics: behavioral and physical features. Hum Mol Genet 9, 1145-1159.
Penman, S., Scherrer, K., Becker, Y., and Darnell, J. E. (1963).
Polyribosomes In Normal And Poliovirus-Infected Hela Cells And Their
Relationship To Messenger-Rna. Proc Natl Acad Sci U S A 49, 654-662.
Pieretti, M., Zhang, F. P., Fu, Y. H., Warren, S. T., Oostra, B. A., Caskey, C.
T., and Nelson, D. L. (1991). Absence of expression of the FMR-1 gene in
fragile X syndrome. Cell 66, 817-822.
Pilpel, Y., and Segal, M. (2005). Rapid WAVE dynamics in dendritic spines
of cultured hippocampal neurons is mediated by actin polymerization. J
Neurochem 95, 1401-1410.
Preiss, T., Baron-Benhamou, J., Ansorge, W., and Hentze, M. W. (2003).
Homodirectional changes in transcriptome composition and mRNA
translation induced by rapamycin and heat shock. Nat Struct Biol 10, 10391047.
171

Racca, C., Gardiol, A., Darnell, R. B., and Triller, A. (submitted). Nova-1
and glycine receptor alpha subunit mRNAs form dendritic and subsynaptic
ribonucleoparticles.
Rajasekhar, V. K., and Holland, E. C. (2004). Postgenomic global analysis
of translational control induced by oncogenic signaling. Oncogene 23, 32483264.
Ramos, A., Hollingworth, D., and Pastore, A. (2003a). G-quartet-dependent
recognition between the FMRP RGG box and RNA. Rna 9, 1198-1207.
Ramos, A., Hollingworth, D., and Pastore, A. (2003b). The role of a
clinically important mutation in the fold and RNA-binding properties of KH
motifs. RNA %R 101261/rna2168503 9, 293-298.
Rao, A., and Steward, O. (1991). Evidence that protein constituents of
postsynaptic membrane specializations are locally synthesized: analysis of
proteins synthesized within synaptosomes. J Neurosci 11, 2881-2895.
Raught, B., Gingras, A. C., Gygi, S. P., Imataka, H., Morino, S., Gradi, A.,
Aebersold, R., and Sonenberg, N. (2000). Serum-stimulated, rapamycinsensitive phosphorylation sites in the eukaryotic translation initiation factor
4GI. Embo J 19, 434-444.
Rich, A., Penman, S., Becker, Y., Darnell, J., and Hall, C. (1963).
Polyribosomes: Size In Normal And Polio- Infected Hela Cells. Science 142,
1658-1663.
Richter, J. D., and Lorenz, L. J. (2002). Selective translation of mRNAs at
synapses. Curr Opin Neurobiol 12, 300-304.
Risebrough, R. W., Tissieres, A., and Watson, J. D. (1962). Messenger-RNA
attachment to active ribosomes. Proc Natl Acad Sci U S A 48, 430-436.
Rudelli, R. D., Brown, W. T., Wisniewski, K., Jenkins, E. C., LaureKamionowska, M., Connell, F., and Wisniewski, H. M. (1985). Adult fragile
X syndrome. Clinico-neuropathologic findings. Acta Neuropathol (Berl) 67,
289-295.
Ruegsegger, U., Leber, J. H., and Walter, P. (2001). Block of HAC1 mRNA
translation by long-range base pairing is released by cytoplasmic splicing
upon induction of the unfolded protein response. Cell 107, 103-114.
172

Ruggero, D., and Sonenberg, N. (2005). The Akt of translational control.
Oncogene 24, 7426-7434.
Schaeffer, C., Bardoni, B., Mandel, J. L., Ehresmann, B., Ehresmann, C.,
and Moine, H. (2001). The fragile X mental retardation protein binds
specifically to its mRNA via a purine quartet motif. Embo J 20, 4803-4813.
Scheetz, A. J., Nairn, A. C., and Constantine-Paton, M. (1997). N-methyl-Daspartate receptor activation and visual activity induce elongation factor-2
phosphorylation in amphibian tecta: a role for N-methyl-D-aspartate
receptors in controlling protein synthesis. Proc Natl Acad Sci U S A 94,
14770-14775.
Scheetz, A. J., Nairn, A. C., and Constantine-Paton, M. (2000). NMDA
receptor-mediated control of protein synthesis at developing synapses. Nat
Neurosci 3, 211-216.
Schenck, A., Bardoni, B., Langmann, C., Harden, N., Mandel, J. L., and
Giangrande, A. (2003). CYFIP/Sra-1 controls neuronal connectivity in
Drosophila and links the Rac1 GTPase pathway to the fragile X protein.
Neuron 38, 887-898.
Schenck, A., Bardoni, B., Moro, A., Bagni, C., and Mandel, J. L. (2001). A
highly conserved protein family interacting with the fragile X mental
retardation protein (FMRP) and displaying selective interactions with
FMRP-related proteins FXR1P and FXR2P. Proc Natl Acad Sci U S A 98,
8844-8849.
Schenck, A., Qurashi, A., Carrera, P., Bardoni, B., Diebold, C., Schejter, E.,
Mandel, J. L., and Giangrande, A. (2004). WAVE/SCAR, a multifunctional
complex coordinating different aspects of neuronal connectivity. Dev Biol
274, 260-270.
Scherrer, K., Latham, H., and Darnell, J. E. (1963). Demonstration of an
unstable RNA and of a precursor to ribosomal RNA in HeLa cells. Proc Natl
Acad Sci U S A 49, 240-248.
Schratt, G. M., Nigh, E. A., Chen, W. G., Hu, L., and Greenberg, M. E.
(2004). BDNF Regulates the Translation of a Select Group of mRNAs by a
Mammalian Target of Rapamycin-Phosphatidylinositol 3-Kinase-Dependent
Pathway during Neuronal Development. J Neurosci %R
101523/JNEUROSCI1739-042004 24, 7366-7377.
173

Schuman, E. M., Dynes, J. L., and Steward, O. (2006). Synaptic regulation
of translation of dendritic mRNAs. J Neurosci 26, 7143-7146.
Seggerson, K., Tang, L., and Moss, E. G. (2002). Two genetic circuits
repress the Caenorhabditis elegans heterochronic gene lin-28 after
translation initiation. Dev Biol 243, 215-225.
Sheflin, L. G., Zhang, W., and Spaulding, S. W. (2001). Androgen regulates
the level and subcellular distribution of the AU-rich ribonucleic acid-binding
protein HuR both in vitro and in vivo. Endocrinology 142, 2361-2368.
Short, K. M., and Cox, T. C. (2006). Subclassification of the RBCC/TRIM
Superfamily Reveals a Novel Motif Necessary for Microtubule Binding. J
Biol Chem %R 101074/jbcM512755200 281, 8970-8980.
Siomi, H., Choi, M., Siomi, M. C., Nussbaum, R. L., and Dreyfuss, G.
(1994). Essential role for KH domains in RNA binding: impaired RNA
binding by a mutation in the KH domain of FMR1 that causes fragile X
syndrome. Cell 77, 33-39.
Siomi, H., Siomi, M. C., Nussbaum, R. L., and Dreyfuss, G. (1993). The
protein product of the fragile X gene, FMR1, has characteristics of an RNAbinding protein. Cell 74, 291-298.
Siomi, M. C., Higashijima, K., Ishizuka, A., and Siomi, H. (2002). Casein
kinase II phosphorylates the fragile X mental retardation protein and
modulates its biological properties. Mol Cell Biol 22, 8438-8447.
Siomi, M. C., Siomi, H., Sauer, W. H., Srinivasan, S., Nussbaum, R. L., and
Dreyfuss, G. (1995). FXR1, an autosomal homolog of the fragile X mental
retardation gene. Embo J 14, 2401-2408.
Siomi, M. C., Zhang, Y., Siomi, H., and Dreyfuss, G. (1996). Specific
sequences in the fragile X syndrome protein FMR1 and the FXR proteins
mediate their binding to 60S ribosomal subunits and the interactions among
them. Mol Cell Biol 16, 3825-3832.
Sittler, A., Devys, D., Weber, C., and Mandel, J. L. (1996). Alternative
splicing of exon 14 determines nuclear or cytoplasmic localisation of fmr1
protein isoforms. Hum Mol Genet 5, 95-102.

174

Slayter, H. S., Warner, J. R., Rich, A., and Hall, C. E. (1963). The
Visualization Of Polyribosomal Structure. J Mol Biol 17, 652-657.
Spencer, C. M., Serysheva, E., Yuva-Paylor, L. A., Oostra, B. A., Nelson, D.
L., and Paylor, R. (2006). Exaggerated behavioral phenotypes in Fmr1/Fxr2
double knockout mice reveal a functional genetic interaction between
Fragile X-related proteins. Hum Mol Genet 15, 1984-1994.
Spyrides, G. J., and Lipmann, F. (1962). Polypeptide synthesis with sucrose
gradient fractions of E. coli ribosomes. Proc Natl Acad Sci U S A 48, 19771983.
Staehelin, T., Brinton, C. C., Wettstein, F. O., and Noll, H. (1963a).
Structure And Function Of E. Coli Ergosomes. Nature 199, 865-870.
Staehelin, T., Wettstein, F. O., and Noll, H. (1963b). Breakdown of rat-liver
ergosomes in vivo after actinomycin inhibition of messenger RNA synthesis.
Science 140, 180-183.
Stefani, G., Fraser, C. E., Darnell, J. C., and Darnell, R. B. (2004). Fragile X
mental retardation protein is associated with translating polyribosomes in
neuronal cells. J Neurosci 24, 7272-7276.
Steward, O. (1983). Polyribosomes at the base of dendritic spines of central
nervous system neurons--their possible role in synapse construction and
modification. Cold Spring Harb Symp Quant Biol 48 Pt 2, 745-759.
Steward, O., and Fass, B. (1983). Polyribosomes associated with dendritic
spines in the denervated dentate gyrus: evidence for local regulation of
protein synthesis during reinnervation. Prog Brain Res 58, 131-136.
Steward, O., and Levy, W. B. (1982). Preferential localization of
polyribosomes under the base of dendritic spines in granule cells of the
dentate gyrus. J Neurosci 2, 284-291.
Steward, O., and Schuman, E. M. (2003). Compartmentalized synthesis and
degradation of proteins in neurons. Neuron 40, 347-359.
Sung, Y. J., Dolzhanskaya, N., Nolin, S. L., Brown, T., Currie, J. R., and
Denman, R. B. (2003). The fragile X mental retardation protein FMRP binds
elongation factor 1A mRNA and negatively regulates its translation in vivo.
J Biol Chem 278, 15669-15678.
175

Sutcliffe, J. S., Nelson, D. L., Zhang, F., Pieretti, M., Caskey, C. T., Saxe,
D., and Warren, S. T. (1992). DNA methylation represses FMR-1
transcription in fragile X syndrome. Hum Mol Genet 1, 397-400.
Sutton, M. A., and Schuman, E. M. (2005). Local translational control in
dendrites and its role in long-term synaptic plasticity. J Neurobiol 64, 116131.
Szulc, J., Wiznerowicz, M., Sauvain, M. O., Trono, D., and Aebischer, P.
(2006). A versatile tool for conditional gene expression and knockdown. Nat
Methods 3, 109-116.
Tamanini, F., Bontekoe, C., Bakker, C. E., van Unen, L., Anar, B.,
Willemsen, R., Yoshida, M., Galjaard, H., Oostra, B. A., and Hoogeveen, A.
T. (1999). Different targets for the fragile X-related proteins revealed by
their distinct nuclear localizations. Hum Mol Genet 8, 863-869.
Tiruchinapalli, D. M., Oleynikov, Y., Kelic, S., Shenoy, S. M., Hartley, A.,
Stanton, P. K., Singer, R. H., and Bassell, G. J. (2003). Activity-dependent
trafficking and dynamic localization of zipcode binding protein 1 and betaactin mRNA in dendrites and spines of hippocampal neurons. J Neurosci 23,
3251-3261.
Todd, P. K., Mack, K. J., and Malter, J. S. (2003). The fragile X mental
retardation protein is required for type-I metabotropic glutamate receptordependent translation of PSD-95. Proc Natl Acad Sci U S A 100, 1437414378.
Treisman, R. (1996). Regulation of transcription by MAP kinase cascades.
Curr Opin Cell Biol 8, 205-215.
Ule, J., Jensen, K., Mele, A., and Darnell, R. B. (2005a). CLIP: a method for
identifying protein-RNA interaction sites in living cells. Methods 37, 376386.
Ule, J., Jensen, K. B., Ruggiu, M., Mele, A., Ule, A., and Darnell, R. B.
(2003). CLIP identifies Nova-regulated RNA networks in the brain. Science
302, 1212-1215.
Ule, J., Stefani, G., Mele, A., Ruggiu, M., Wang, X., Taneri, B.,
Gaasterland, T., Blencowe, B. J., and Darnell, R. B. (2006). An RNA map
predicting Nova-dependent splicing regulation. Nature 444, 580-586.
176

Ule, J., Ule, A., Spencer, J., Williams, A., Hu, J. S., Cline, M., Wang, H.,
Clark, T., Fraser, C., Ruggiu, M., et al. (2005b). Nova regulates brainspecific splicing to shape the synapse. Nat Genet 37, 844-852.
Vasioukhin, V. (2006). Lethal giant puzzle of Lgl. Dev Neurosci 28, 13-24.
Verheij, C., Bakker, C. E., de Graaff, E., Keulemans, J., Willemsen, R.,
Verkerk, A. J., Galjaard, H., Reuser, A. J., Hoogeveen, A. T., and Oostra, B.
A. (1993). Characterization and localization of the FMR-1 gene product
associated with fragile X syndrome. Nature 363, 722-724.
Verheij, C., de Graaff, E., Bakker, C. E., Willemsen, R., Willems, P. J.,
Meijer, N., Galjaard, H., Reuser, A. J., Oostra, B. A., and Hoogeveen, A. T.
(1995). Characterization of FMR1 proteins isolated from different tissues.
Hum Mol Genet 4, 895-901.
Verkerk, A. J., Pieretti, M., Sutcliffe, J. S., Fu, Y. H., Kuhl, D. P., Pizzuti,
A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F. P., and et al. (1991).
Identification of a gene (FMR-1) containing a CGG repeat coincident with a
breakpoint cluster region exhibiting length variation in fragile X syndrome.
Cell 65, 905-914.
Villace, P., Marion, R. M., and Ortin, J. (2004). The composition of Staufencontaining RNA granules from human cells indicates their role in the
regulated transport and translation of messenger RNAs. Nucleic Acids Res
32, 2411-2420.
Wang, H., Iacoangeli, A., Lin, D., Williams, K., Denman, R. B., Hellen, C.
U., and Tiedge, H. (2005). Dendritic BC1 RNA in translational control
mechanisms. J Cell Biol 171, 811-821.
Wang, H., Ku, L., Osterhout, D. J., Li, W., Ahmadian, A., Liang, Z., and
Feng, Y. (2004). Developmentally-programmed FMRP expression in
oligodendrocytes: a potential role of FMRP in regulating translation in
oligodendroglia progenitors. Hum Mol Genet 13, 79-89.
Wang, H., and Tiedge, H. (2004). Translational control at the synapse.
Neuroscientist 10, 456-466.
Warner, J., Madden, M. J., and Darnell, J. E. (1963a). The interaction of
poliovirus RNA with Escherichia coli ribosomes. Virology 19, 393-399.

177

Warner, J. R., and Knopf, P. M. (2002). The discovery of polyribosomes.
Trends Biochem Sci 27, 376-380.
Warner, J. R., Knopf, P. M., and Rich, A. (1963b). A multiple ribosomal
structure in protein synthesis. Proc Natl Acad Sci U S A 49, 122-129.
Weiler, I. J., Spangler, C. C., Klintsova, A. Y., Grossman, A. W., Kim, S.
H., Bertaina-Anglade, V., Khaliq, H., de Vries, F. E., Lambers, F. A., Hatia,
F., et al. (2004). Fragile X mental retardation protein is necessary for
neurotransmitter-activated protein translation at synapses. Proc Natl Acad
Sci U S A 101, 17504-17509.
Wettstein, F. O., Staehelin, T., and Noll, H. (1963). Ribosomal aggregate
engaged in protein synthesis: characterization of the ergosome. Nature 197,
430-435.
Willemsen, R., Oostra, B. A., Bassell, G. J., and Dictenberg, J. (2004). The
fragile X syndrome: from molecular genetics to neurobiology. Ment Retard
Dev Disabil Res Rev 10, 60-67.
Wisniewski, K. E., Segan, S. M., Miezejeski, C. M., Sersen, E. A., and
Rudelli, R. D. (1991). The Fra(X) syndrome: neurological,
electrophysiological, and neuropathological abnormalities. Am J Med Genet
38, 476-480.
Wu, L., Wells, D., Tay, J., Mendis, D., Abbott, M. A., Barnitt, A., Quinlan,
E., Heynen, A., Fallon, J. R., and Richter, J. D. (1998). CPEB-mediated
cytoplasmic polyadenylation and the regulation of experience-dependent
translation of alpha-CaMKII mRNA at synapses. Neuron 21, 1129-1139.
Yang, Y. Y., Yin, G. L., and Darnell, R. B. (1998). The neuronal RNAbinding protein Nova-2 is implicated as the autoantigen targeted in POMA
patients with dementia. Proc Natl Acad Sci U S A 95, 13254-13259.
Zalfa, F., Giorgi, M., Primerano, B., Moro, A., Di Penta, A., Reis, S.,
Oostra, B., and Bagni, C. (2003). The fragile X syndrome protein FMRP
associates with BC1 RNA and regulates the translation of specific mRNAs
at synapses. Cell 112, 317-327.
Zanotti, K. J., Lackey, P. E., Evans, G. L., and Mihailescu, M. R. (2006).
Thermodynamics of the fragile X mental retardation protein RGG box
interactions with G quartet forming RNA. Biochemistry 45, 8319-8330.
178

Zarnescu, D. C., Jin, P., Betschinger, J., Nakamoto, M., Wang, Y.,
Dockendorff, T. C., Feng, Y., Jongens, T. A., Sisson, J. C., Knoblich, J. A.,
et al. (2005). Fragile X protein functions with lgl and the par complex in
flies and mice. Dev Cell 8, 43-52.
Zhang, Q., Pedigo, N., Shenoy, S., Khalili, K., and Kaetzel, D. M. (2005).
Puralpha activates PDGF-A gene transcription via interactions with a G-rich,
single-stranded region of the promoter. Gene 348, 25-32.
Zhang, Y., O'Connor, J. P., Siomi, M. C., Srinivasan, S., Dutra, A.,
Nussbaum, R. L., and Dreyfuss, G. (1995). The fragile X mental retardation
syndrome protein interacts with novel homologs FXR1 and FXR2. Embo J
14, 5358-5366.
Zhang, Y. Q., Bailey, A. M., Matthies, H. J., Renden, R. B., Smith, M. A.,
Speese, S. D., Rubin, G. M., and Broadie, K. (2001). Drosophila fragile Xrelated gene regulates the MAP1B homolog Futsch to control synaptic
structure and function. Cell 107, 591-603.
Zong, Q., Schummer, M., Hood, L., and Morris, D. R. (1999). Messenger
RNA translation state: the second dimension of high-throughput expression
screening. Proc Natl Acad Sci U S A 96, 10632-10636.
Zuker, M. (2003). Mfold web server for nucleic acid folding and
hybridization prediction. Nucleic Acids Res 31, 3406-3415.

179

